• Genomics of lethal prostate cancer at diagnosis and castration-resistance.
    • Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, Miranda S, Nava Rodrigues D, Gurel B, Clarke M, Atkin M, Chandler R, Messina C, Sumanasuriya S, Bianchini D, Barrero M, Petremolo A, Zafeiriou Z, Fontes MS, Perez-Lopez R, Tunariu N, Fulton BA, Jones R, McGovern UB, Ralph C, Varughese M, Parikh O, Jain S, Elliott T, Sandhu S, Porta N, Hall E, Yuan W, Carreira S, de Bono JS.
    • J Clin Invest. 2019 Dec 24. pii: 132031. doi: 10.1172/JCI132031. [Epub ahead of print]
    • Colocalization of BRCA1 with Tau Aggregates in Human Tauopathies.
    • Kurihara M, Mano T, Saito Y, Murayama S, Toda T, Iwata A.
    • Brain Sci. 2019 Dec 20;10(1). pii: E7. doi: 10.3390/brainsci10010007.
    • Next-Generation Sequencing Identifies BRCA1 and/or BRCA2 Mutations in Women at High Hereditary Risk for Breast Cancer with Shorter Telomere Length.
    • Peker Eyüboğlu İ, Yenmiş G, Bingöl EN, Yüksel Ş, Tokat F, Özbek P, Güllü Amuran G, Yakıcıer C, Akkiprik M.
    • OMICS. 2019 Dec 17. doi: 10.1089/omi.2019.0103. [Epub ahead of print]
    • Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.
    • Whitehair R, Peres LC, Mills AM.
    • Int J Gynecol Pathol. 2019 Dec 16. doi: 10.1097/PGP.0000000000000657. [Epub ahead of print]
    • Systemic investigations into the molecular features of bilateral breast cancer for diagnostic purposes.
    • Imyanitov EN, Ekatherina K.
    • Expert Rev Mol Diagn. 2019 Dec 13. doi: 10.1080/14737159.2020.1705157. [Epub ahead of print]
    • Review
    • Spliceogenic analysis of BRCA1 c.439T>C (rs794727800) variant by High Resolution Melting Analysis.
    • Minucci A, Mazzuccato G, D'Indinosante M, Di Nardo L, Concolino P, De Bonis M, Urbani A, Scambia G, Fagotti A, Capoluongo E.
    • Mol Biol Rep. 2019 Dec 12. doi: 10.1007/s11033-019-05199-3. [Epub ahead of print]
    • BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.
    • Stefansson OA, Hilmarsdottir H, Olafsdottir K, Tryggvadottir L, Sverrisdottir A, Johannsson OT, Jonasson JG, Eyfjord JE, Sigurdsson S.
    • JNCI Cancer Spectr. 2019 Dec 11;4(2):pkz100. doi: 10.1093/jncics/pkz100. eCollection 2020 Apr.
    • BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance.
    • Wang Y, Bernhardy AJ, Nacson J, Krais JJ, Tan YF, Nicolas E, Radke MR, Handorf E, Llop-Guevara A, Balmaña J, Swisher EM, Serra V, Peri S, Johnson N.
    • Nat Commun. 2019 Dec 11;10(1):5661. doi: 10.1038/s41467-019-13530-6.
    • Histone proteomics reveals novel post-translational modifications in breast cancer.
    • Perri AM, Agosti V, Olivo E, Concolino A, Angelis M, Tammè L, Fiumara CV, Cuda G, Scumaci D.
    • Aging (Albany NY). 2019 Dec 8;11. doi: 10.18632/aging.102577. [Epub ahead of print]
    • Mechanisms of PARP inhibitor resistance in ovarian cancer.
    • Kubalanza K, Konecny GE.
    • Curr Opin Obstet Gynecol. 2019 Dec 6. doi: 10.1097/GCO.0000000000000600. [Epub ahead of print]
    • Review
    • Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer.
    • Cardenas H, Jiang G, Thomes Pepin J, Parker JB, Condello S, Nephew KP, Nakshatri H, Chakravarti D, Liu Y, Matei D.
    • NPJ Precis Oncol. 2019 Dec 6;3:32. doi: 10.1038/s41698-019-0103-4. eCollection 2019.
    • Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.
    • Telli ML, Chu C, Badve SS, Vinayak S, Silver DP, Isakoff SJ, Kaklamani V, Gradishar W, Stearns V, Connolly RM, Ford JM, Gruber JJ, Adams S, Garber J, Tung N, Neff C, Bernhisel R, Timms KM, Richardson AL.
    • Clin Cancer Res. 2019 Dec 3. pii: clincanres.0664.2019. doi: 10.1158/1078-0432.CCR-19-0664. [Epub ahead of print]
    • BRCA2 genemutation, c.2808_2811delACAA (p.Ala938Profs), in malebreastcancer - clinicopathologicalanalysisbased on a case report.
    • Huszno J, Fiszer-Kierzkowska A, Piglowski W, Mazur M.
    • Prz Menopauzalny. 2019 Dec;18(4):227-229. doi: 10.5114/pm.2019.93120. Epub 2020 Jan 15.
    • Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response.
    • Franzese E, Centonze S, Diana A, Lombardi A, Carlino F, Guerrera LP, De Vita F, Caraglia M, Pignata S, Ciardiello F, Orditura M.
    • Front Oncol. 2019 Nov 29;9:1289. doi: 10.3389/fonc.2019.01289. eCollection 2019.
    • Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients.
    • Sugino K, Tamura R, Nakaoka H, Yachida N, Yamaguchi M, Mori Y, Yamawaki K, Suda K, Ishiguro T, Adachi S, Isobe M, Yamaguchi M, Kashima K, Motoyama T, Inoue I, Yoshihara K, Enomoto T.
    • Sci Rep. 2019 Nov 28;9(1):17808. doi: 10.1038/s41598-019-54116-y.
    • Assessment of ovarian reserve and reproductive outcomes in BRCA1 or BRCA2 mutation carriers.
    • Ponce J, Fernandez-Gonzalez S, Calvo I, Climent M, Peñafiel J, Feliubadaló L, Teulé A, Lázaro C, Brunet JM, Candás-Estébanez B, Durán Retamal M.
    • Int J Gynecol Cancer. 2019 Nov 27. pii: ijgc-2019-000626. doi: 10.1136/ijgc-2019-000626. [Epub ahead of print]
    • BRCA1 mutation influences progesterone response in human benign mammary organoids.
    • Davaadelger B, Choi MR, Singhal H, Clare SE, Khan SA, Kim JJ.
    • Breast Cancer Res. 2019 Nov 26;21(1):124. doi: 10.1186/s13058-019-1214-0.
    • The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
    • van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, Bergman AM, van Oort IM, de Wit R, Voest EE, Steeghs N, Yamaguchi TN, Livingstone J, Boutros PC, Martens JWM, Sleijfer S, Cuppen E, Zwart W, van de Werken HJG, Mehra N, Lolkema MP.
    • Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7.
    • Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status.
    • Abdel-Sater F, Najar M, Fayyad-Kazan H.
    • J Cell Physiol. 2019 Nov 17. doi: 10.1002/jcp.29398. [Epub ahead of print]
    • Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents.
    • Póti Á, Gyergyák H, Németh E, Rusz O, Tóth S, Kovácsházi C, Chen D, Szikriszt B, Spisák S, Takeda S, Szakács G, Szallasi Z, Richardson AL, Szüts D.
    • Genome Biol. 2019 Nov 14;20(1):240. doi: 10.1186/s13059-019-1867-0.
    • Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.
    • Teixeira LA, Candido Dos Reis FJ.
    • J Clin Pathol. 2019 Nov 12. pii: jclinpath-2019-206276. doi: 10.1136/jclinpath-2019-206276. [Epub ahead of print]
    • Review
    • Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.
    • Farolfi A, Lorusso D, Pignata S, De Giorgi U.
    • J Clin Oncol. 2019 Nov 7:JCO1902055. doi: 10.1200/JCO.19.02055. [Epub ahead of print]

    Related:

    Original research:

    Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

    • Molecular Profiles of BRCA1-Associated Ovarian Cancer Treated by Platinum-Based Therapy: Analysis of Primary, Residual and Relapsed Tumours.
    • Sokolenko AP, Bizin IV, Preobrazhenskaya EV, Gorodnova TV, Ivantsov AO, Iyevleva AG, Savonevich EL, Kotiv KB, Kuligina ES, Imyanitov EN.
    • Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32776. [Epub ahead of print]
    • The BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability.
    • Arason A, Agnarsson BA, Johannesdottir G, Johannsson OT, Hilmarsdottir B, Reynisdottir I, Barkardottir RB.
    • Genes (Basel). 2019 Nov 1;10(11). pii: E882. doi: 10.3390/genes10110882.
    • Differences in cysteine peptidases-like activity in sera of patients with breast cancer.
    • Kilar E, Siewiński M, Hirnle L, Skiba T, Goła B K, Gburek J, Murawski M, Janocha A.
    • Cancer Biomark. 2019 Oct 25. doi: 10.3233/CBM-190327. [Epub ahead of print]
    • BRCA1 mislocalization leads to aberrant DNA damage response in heterozygous ABRAXAS1 mutation carrier cells.
    • Bose M, Sachsenweger J, Laurila N, Parplys AC, Willmann J, Jungwirth J, Groth M, Rapakko K, Nieminen P, Friedl TWP, Heiserich L, Meyer F, Tuppurainen H, Peltoketo H, Nevanlinna H, Pylkäs K, Borgmann K, Wiesmüller L, Winqvist R, Pospiech H.
    • Hum Mol Genet. 2019 Oct 20. pii: ddz252. doi: 10.1093/hmg/ddz252. [Epub ahead of print]
    • RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
    • Haynes B, Gajan A, Nangia-Makker P, Shekhar MP.
    • Biochim Biophys Acta Mol Basis Dis. 2019 Oct 19:165561. doi: 10.1016/j.bbadis.2019.165561. [Epub ahead of print]
    • BRCA1 Deficiency Upregulates NNMT Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
    • Kanakkanthara A, Kurmi K, Ekstrom TL, Hou X, Purfeerst ER, Heinzen EP, Correia C, Huntoon CJ, O'Brien D, Wahner Hendrickson AE, Dowdy SC, Li H, Oberg AL, Hitosugi T, Kaufmann SH, Weroha SJ, Karnitz LM.
    • Cancer Res. 2019 Oct 16. pii: canres.1405.2019. doi: 10.1158/0008-5472.CAN-19-1405. [Epub ahead of print]
    • A CD146 FACS Protocol Enriches for Luminal Keratin 14/19 Double Positive Human Breast Progenitors.
    • Gerdur Ísberg Ó, Kim J, Fridriksdottir AJ, Morsing M, Timmermans-Wielenga V, Rønnov-Jessen L, Petersen OW, Villadsen R.
    • Sci Rep. 2019 Oct 16;9(1):14843. doi: 10.1038/s41598-019-50903-9.
    • Salivary Gland Function, Antioxidant Defence and Oxidative Damage in the Saliva of Patients with Breast Cancer: Does the BRCA1 Mutation Disturb the Salivary Redox Profile?
    • Sawczuk B, Maciejczyk M, Sawczuk-Siemieniuk M, Posmyk R, Zalewska A, Car H.
    • Cancers (Basel). 2019 Oct 8;11(10). pii: E1501. doi: 10.3390/cancers11101501.
    • ADP-ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers.
    • Conrad LB, Lin KY, Nandu T, Gibson BA, Lea JS, Kraus WL.
    • Mol Cancer Ther. 2019 Oct 8. pii: molcanther.0569.2019. doi: 10.1158/1535-7163.MCT-19-0569. [Epub ahead of print]
    • Distinct Alterations in Tricarboxylic Acid Cycle Metabolites Associate with Cancer and Autism Phenotypes in Cowden Syndrome and Bannayan-Riley-Ruvalcaba Syndrome.
    • Yehia L, Ni Y, Feng F, Seyfi M, Sadler T, Frazier TW, Eng C.
    • Am J Hum Genet. 2019 Oct 3;105(4):813-821. doi: 10.1016/j.ajhg.2019.09.004. Epub 2019 Sep 26.
    • Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
    • S SK, Swamy SN, Premalatha CS, Pallavi VR, Gawari R.
    • Asian Pac J Cancer Prev. 2019 Oct 1;20(10):3001-3005. doi: 10.31557/APJCP.2019.20.10.3001.
    • Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course.
    • Lee JM, Botesteanu DA, Tomita Y, Yuno A, Lee MJ, Kohn EC, Annunziata CM, Matulonis U, MacDonald LA, Nair JR, Macneill KM, Trepel JB.
    • Oncol Lett. 2019 Oct;18(4):3914-3924. doi: 10.3892/ol.2019.10731. Epub 2019 Aug 7.
    • The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
    • Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S.
    • Cancer Immunol Immunother. 2019 Sep 23. doi: 10.1007/s00262-019-02393-x. [Epub ahead of print]
    • ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2-/- ovarian cancer cells.
    • Liu L, Cai S, Han C, Banerjee A, Wu D, Cui T, Xie G, Zhang J, Zhang X, McLaughlin E, Yin M, Backes FJ, Chakravarti A, Zheng Y, Wang QE.
    • Mol Cancer Ther. 2019 Sep 18. pii: molcanther.0242.2019. doi: 10.1158/1535-7163.MCT-19-0242. [Epub ahead of print]
    • Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.
    • Yadav S, Hart SN, Hu C, Hillman D, Lee KY, Gnanaolivu R, Na J, Polley EC, Couch FJ, Kohli M.
    • JCO Precis Oncol. 2019 Sep 17;3:PO.19.00067. doi: 10.1200/PO.19.00067.
    • Mouse mammary tumor virus (MMTV) - like exogenous sequences are associated with sporadic but not hereditary human breast carcinoma.
    • Naccarato AG, Lessi F, Zavaglia K, Scatena C, Al Hamad MA, Aretini P, Menicagli M, Roncella M, Ghilli M, Caligo MA, Mazzanti CM, Bevilacqua G.
    • Aging (Albany NY). 2019 Sep 13;11. doi: 10.18632/aging.102252. [Epub ahead of print]
    • Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ.
    • Ding L, Su Y, Fassl A, Hinohara K, Qiu X, Harper NW, Huh SJ, Bloushtain-Qimron N, Jovanović B, Ekram M, Zi X, Hines WC, Alečković M, Gil Del Alcazar C, Caulfield RJ, Bonal DM, Nguyen QD, Merino VF, Choudhury S, Ethington G, Panos L, Grant M, Herlihy W, Au A, Rosson GD, Argani P, Richardson AL, Dillon D, Allred DC, Babski K, Kim EMH, McDonnell CH 3rd, Wagner J, Rowberry R, Bobolis K, Kleer CG, Hwang ES, Blum JL, Cristea S, Sicinski P, Fan R, Long HW, Sukumar S, Yeon Park S, Garber JE, Bissell M, Yao J, Polyak K.
    • Nat Commun. 2019 Sep 13;10(1):4182. doi: 10.1038/s41467-019-12125-5.
    • Germline BRCA-associated Endometrial Carcinoma is a Distinct Clinicopathologic Entity.
    • de Jonge MM, Ritterhouse LL, de Kroon CD, Vreeswijk MPG, Segal JP, Puranik R, Study H, Hollema H, Rookus MA, van Asperen CJ, Van Leeuwen FE, Smit VTHBM, Howitt BE, Bosse T.
    • Clin Cancer Res. 2019 Sep 6. pii: clincanres.0848.2019. doi: 10.1158/1078-0432.CCR-19-0848. [Epub ahead of print]
    • The Expression Level of BRCA2 and Its Changes during Chemotherapy in Patients with Different Pathological Types of Mammary Cancer.
    • Huang Y, Luo M, Huang J, Huang S, Wei L, Zhang Y, Zhang Z.
    • Iran J Public Health. 2019 Sep;48(9):1654-1662.
    • Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
    • Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, Jones K, Kohaar I, Ali A, Ravindranath L, Young D, Cullen J, Dorsey TH, Sesterhenn IA, Brassell SA, Rosner IL, Ross D, Dahut W, Ambs S, Figg WD, Srivastava S, Dean M.
    • Prostate Cancer Prostatic Dis. 2019 Sep;22(3):406-410. doi: 10.1038/s41391-018-0114-1. Epub 2018 Dec 12.
    • Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
    • Li W, Shao D, Li L, Wu M, Ma S, Tan X, Zhong S, Guo F, Wang Z, Ye M.
    • J Ovarian Res. 2019 Aug 31;12(1):80. doi: 10.1186/s13048-019-0560-y.
    • IMMUNODETECTION AND QUANTIFICATION OF ENZYMATIC MARKERS IN THECA CELLS: THE EARLY PROCESS OF OVARIAN STEROIDOGENESIS.
    • Asiabi P, Leonel ECR, Marbaix E, Dolmans MM, Amorim CA.
    • Biol Reprod. 2019 Aug 28. pii: ioz167. doi: 10.1093/biolre/ioz167. [Epub ahead of print]
    • Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
    • Fountzilas E, Konstantopoulou I, Vagena A, Apostolou P, Papadimitriou C, Christodoulou C, Tryfonopoulos D5, Manousou K, Delimitsou A, Papamentzelopoulou M, Fountzilas G, Yannoukakos D, Fostira F.
    • Clin Breast Cancer. 2019 Aug 22. pii: S1526-8209(19)30642-1. doi: 10.1016/j.clbc.2019.08.003. [Epub ahead of print]
    • How latent viruses cause breast cancer: An explanation based on the microcompetition model.
    • Polansky H, Schwab H.
    • Bosn J Basic Med Sci. 2019 Aug 20;19(3):221-226. doi: 10.17305/bjbms.2018.3950.
    • Vascular endothelium function among male carriers of BRCA 1&2 germline mutation.
    • Witberg G, Lev E, Ber Y, Tabachnik T, Sela S, Belo I, Leshem-Lev D, Margel D.
    • Oncotarget. 2019 Aug 20;10(49):5041-5051. doi: 10.18632/oncotarget.27118. eCollection 2019 Aug 20.
    • Identification of LCN1 as a Potential Biomarker for Breast Cancer by Bioinformatic Analysis.
    • Yang Y, Li F, Luo X, Jia B, Zhao X, Liu B, Gao R, Yang L, Wei W, He J.
    • DNA Cell Biol. 2019 Aug 19. doi: 10.1089/dna.2019.4843. [Epub ahead of print]
    • Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.
    • Ferreira EN, Brianese RC, de Almeida RVB, Drummond RD, de Souza JE, da Silva IT, de Souza SJ, Carraro DM.
    • Transl Oncol. 2019 Aug 13;12(11):1453-1460. doi: 10.1016/j.tranon.2019.07.016. [Epub ahead of print]
    • BRCA1 and BRCA2 Gene Expression: Diurnal Variability and Influence of Shift Work.
    • Bracci M, Ciarapica V, Zabaleta ME, Tartaglione MF, Pirozzi S, Giuliani L, Piva F, Valentino M, Ledda C, Rapisarda V, Stevens RG, Santarelli L.
    • Cancers (Basel). 2019 Aug 9;11(8). pii: E1146. doi: 10.3390/cancers11081146.
    • Homologous recombination DNA repair defects in PALB2-associated breast cancers.
    • Li A, Geyer FC, Blecua P, Lee JY, Selenica P, Brown DN, Pareja F, Lee SSK, Kumar R, Rivera B, Bi R, Piscuoglio S, Wen HY, Lozada JR, Gularte-Mérida R, Cavallone L; kConFab Investigators, Rezoug Z, Nguyen-Dumont T, Peterlongo P, Tondini C, Terkelsen T, Rønlund K, Boonen SE, Mannerma A, Winqvist R, Janatova M, Rajadurai P, Xia B, Norton L, Robson ME, Ng PS, Looi LM, Southey MC, Weigelt B, Soo-Hwang T, Tischkowitz M, Foulkes WD, Reis-Filho JS.
    • NPJ Breast Cancer. 2019 Aug 8;5:23. doi: 10.1038/s41523-019-0115-9. eCollection 2019.
    • Functional analysis of clinical BARD1 germline variants.
    • Toh MR, Chong ST, Chan SH, Low CE, Ishak NDB, Lim JQ, Courtney E, Ngeow J.
    • Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4). pii: a004093. doi: 10.1101/mcs.a004093. Print 2019 Aug.
    • Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.
    • Yousif HMA, Mohammed RAA.
    • Curr Probl Cancer. 2019 Aug;43(4):377-385. doi: 10.1016/j.currproblcancer.2018.10.003. Epub 2018 Nov 6.
    • Molecular characteristics of breast cancer according to clinicopathological factors.
    • Huszno J, Kolosza Z.
    • Mol Clin Oncol. 2019 Aug;11(2):192-200. doi: 10.3892/mco.2019.1869. Epub 2019 May 28.
    • Multi-omics analysis reveals the BRCA1 mutation and mismatch repair gene signatures associated with survival, protein expression, and copy number alterations in prostate cancer.
    • Hsiao TH, Chiu YC, Shao YJ.
    • Transl Cancer Res. 2019 Aug;8(4):1279-1288. doi: 10.21037/tcr.2019.07.05.
    • Chromosomal radiosensitivity of triple negative breast cancer patients.
    • Francies FZ, Herd O, Cairns A, Nietz S, Murdoch M, Slabbert J, Claes KB, Vral A, Baeyens A.
    • Int J Radiat Biol. 2019 Jul 26:1-30. doi: 10.1080/09553002.2019.1649502. [Epub ahead of print]
    • CpG promoter hypo-methylation and up-regulation of microRNA-190b in hormone receptor-positive breast cancer.
    • Frick E, Gudjonsson T, Eyfjord J, Jonasson J, Tryggvadóttir L, Stefansson O, Sigurdsson S.
    • Oncotarget. 2019 Jul 23;10(45):4664-4678. doi: 10.18632/oncotarget.27083. eCollection 2019 Jul 23.
    • Abrupt involution induces inflammation, estrogenic signaling, and hyperplasia linking lack of breastfeeding with increased risk of breast cancer.
    • Basree MM, Shinde N, Koivisto C, Cuitino M, Kladney R, Zhang J, Stephens J, Palettas M, Zhang A, Kim HK, Acero-Bedoya S, Trimboli A, Stover DG, Ludwig T, Ganju R, Weng D, Shields P, Freudenheim J, Leone GW, Sizemore GM, Majumder S, Ramaswamy B.
    • Breast Cancer Res. 2019 Jul 17;21(1):80. doi: 10.1186/s13058-019-1163-7.
    • Somatic variants of potential clinical significance in the tumors of BRCA phenocopies.
    • Buckingham L, Mitchell R, Maienschein-Cline M, Green S, Hu VH, Cobleigh M, Rotmensch J, Burgess K, Usha L.
    • Hered Cancer Clin Pract. 2019 Jul 16;17:21. doi: 10.1186/s13053-019-0117-5. eCollection 2019.
    • Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
    • Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS.
    • J Clin Invest. 2019 Jul 16;130. pii: 127613. doi: 10.1172/JCI127613.
    • Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
    • Danzinger S, Tan YY, Rudas M, Kastner MT, Weingartshofer S, Muhr D, Singer CF.
    • BMC Cancer. 2019 Jul 15;19(1):695. doi: 10.1186/s12885-019-5908-6.
    • Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
    • Brandão RD, Mensaert K, López-Perolio I, Tserpelis D, Xenakis M, Lattimore V, Walker LC, Kvist A, Vega A, Gutiérrez-Enríquez S, Díez O; KConFaB Investigators, de la Hoya M, Spurdle AB, De Meyer T, Blok MJ.
    • Int J Cancer. 2019 Jul 15;145(2):401-414. doi: 10.1002/ijc.32114. Epub 2019 Feb 7.
    • Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
    • Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, Dolling D, Welti JC, Neeb A, Sumanasuriya S, Rescigno , Bianchini D, Tunariu N, Carreira S, Sharp A, Oyen W, de Bono JS.
    • Eur Urol. 2019 Jul 13. pii: S0302-2838(19)30520-2. doi: 10.1016/j.eururo.2019.06.030. [Epub ahead of print]
    • Tumour lineage shapes BRCA-mediated phenotypes.
    • Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS.
    • Nature. 2019 Jul 10. doi: 10.1038/s41586-019-1382-1. [Epub ahead of print]
    • Isomerization of BRCA1-BARD1 promotes replication fork protection.
    • Daza-Martin M, Starowicz K, Jamshad M, Tye S, Ronson GE, MacKay HL, Chauhan AS, Walker AK, Stone HR, Beesley JFJ, Coles JL, Garvin AJ, Stewart GS, McCorvie TJ, Zhang X, Densham RM, Morris JR.
    • Nature. 2019 Jul 3. doi: 10.1038/s41586-019-1363-4. [Epub ahead of print]
    • Night Shift Work, DNA Methylation and Telomere Length: An Investigation on Hospital Female Nurses.
    • Carugno M, Maggioni C, Crespi E, Bonzini M, Cuocina S, Dioni L, Tarantini L, Consonni D, Ferrari L, Pesatori AC.
    • Int J Environ Res Public Health. 2019 Jun 28;16(13). pii: E2292. doi: 10.3390/ijerph16132292.
    • Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
    • Kim B, Won D, Lee ST, Choi JR.
    • PLoS One. 2019 Jun 26;14(6):e0217521. doi: 10.1371/journal.pone.0217521. eCollection 2019.
    • A Provocative Molecular Link between Mammographic Density and BRCA1-loss associated TNBC.
    • Xu J, Olusola G, Footman A, Hansen N, Cheriyan AM, Koganti K, Reddy V, Yezdani S, Eddy V, De'smond H, Bakinde N, Okoli J, Oprea G, Gundry K, Reddy ESP, Rao VN.
    • Int J Hum Genet Genet Disord. 2019;1(1):1-8. doi: 10.18689/ijhg-1000101. Epub 2019 Jun 21.
    • Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity.
    • Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Solé A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monsó MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.
    • Cancer Res. 2019 Jun 18. pii: canres.3835.2018. doi: 10.1158/0008-5472.CAN-18-3835. [Epub ahead of print]
    • Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations.
    • Lal A, Ramazzotti D, Weng Z, Liu K, Ford JM, Sidow A.
    • BMC Med Genomics. 2019 Jun 10;12(1):84. doi: 10.1186/s12920-019-0545-0.
    • Clinical Impact of RANK Signalling in Ovarian Cancer.
    • Wieser V, Sprung S, Tsibulak I, Haybaeck J, Hackl H, Fiegl H, Marth C, Zeimet AG.
    • Cancers (Basel). 2019 Jun 8;11(6). pii: E791. doi: 10.3390/cancers11060791.
    • High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients.
    • Chen J, Haanpää MK, Gruber JJ, Jäger N, Ford JM, Snyder MP.
    • Clin Cancer Res. 2019 Jun 7. pii: clincanres.2423.2018. doi: 10.1158/1078-0432.CCR-18-2423. [Epub ahead of print]
    • Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria.
    • Wang S, Pitt JJ, Zheng Y, Yoshimatsu TF, Gao G, Sanni A, Oluwasola O, Ajani M, Fitzgerald D, Odetunde A, Khramtsova G, Hurley I, Popoola A, Falusi A, Ogundiran T, Obafunwa J, Ojengbede O, Ibrahim N, Barretina J, White KP, Huo D, Olopade O.
    • Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32498. [Epub ahead of print]
    • Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis.
    • Pascual T, Gonzalez-Farre B, Teixidó C, Oleaga L, Oses G, Ganau S, Chic N, Riu G, Adamo B, Galván P, Vidal M, Soy D, Urbano Á, Muñoz M, Prat A.
    • JCO Precis Oncol. 2019 Dec [2019 Jun 7];3:1-6. doi: 10.1200/PO.19.00012.
    • Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients.
    • Fernandes GC, Felicio PS, Michelli RAD, Coelho AS, Scapulatempo-Neto C, Palmero EI.
    • Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1655-1660. doi: 10.31557/APJCP.2019.20.6.1655.
    • Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.
    • Meier A, Veeraraghavan H, Nougaret S, Lakhman Y, Sosa R, Soslow RA, Sutton EJ, Hricak H, Sala E, Vargas HA.
    • Abdom Radiol (NY). 2019 Jun;44(6):2040-2047. doi: 10.1007/s00261-018-1840-5.
    • Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing.
    • Slavin TP, Coffee B, Bernhisel R, Logan J, Cox HC, Marcucci G, Weitzel J, Neuhausen SL, Mancini-DiNardo D.
    • Cancer Genet. 2019 Jun;235-236:31-38. doi: 10.1016/j.cancergen.2019.04.005. Epub 2019 Apr 13.
    • Endometrial cancers in BRCA1 or BRCA2 germline mutations carriers.
    • Smith E, Paula ADC, Mandelker D, Weigelt B.
    • Gynecol Oncol. 2019 Jun;153(3):e8-e9. doi: 10.1016/j.ygyno.2019.03.125.
    • Conference abstract
    • The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers.
    • Mandelker D, Kumar R, Pei X, Selenica P, Setton J, Arunachalam S, Ceyhan-Birsoy O, Brown DN, Norton L, Robson ME, Wen HY, Powell S, Riaz N, Weigelt B, Reis-Filho JS.
    • JNCI Cancer Spectr. 2019 Apr 27;3(2):pkz027. doi: 10.1093/jncics/pkz027. eCollection 2019 Jun.
    • Molecular comparison of interval and screen-detected breast cancers.
    • Cheasley D, Li N, Rowley SM, Elder K, Mann GB, Loi S, Savas P, Goode DL, Kader T, Zethoven M, Semple T, Fox SB, Pang JM, Byrne D, Devereux L, Nickson C, Procopio P, Lee G, Hughes S, Saunders H, Fujihara KM, Kuykhoven K, Connaughton J, James PA, Gorringe KL, Campbell IG.
    • J Pathol. 2019 Jun;248(2):243-252. doi: 10.1002/path.5251. Epub 2019 Mar 8.
    • Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort.
    • André S, Pereira T, Silva F, Machado P, Vaz F, Aparício M, Silva GL, Pinto AE.
    • Mol Clin Oncol. 2019 Jun;10(6):644-654. doi: 10.3892/mco.2019.1841. Epub 2019 Apr 8.
    • BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.
    • Solinas C, Marcoux D, Garaud S, Vitória JR, Van den Eynden G, de Wind A, De Silva P, Boisson A, Craciun L, Larsimont D, Piccart-Gebhart M, Detours V, t'Kint de Roodenbeke D, Willard-Gallo K.
    • Cancer Lett. 2019 May 28;450:88-97. doi: 10.1016/j.canlet.2019.02.027. Epub 2019 Feb 22.
    • BRCA1 Attenuates Progesterone Effects on Proliferation and NFκB Activation in Normal Human Mammary Epithelial Cells.
    • Hilton HN, Patterson McDonald LJ, Santucci N, van der Bent FR, Silvestri A, Graham JD, Clarke CL.
    • J Mammary Gland Biol Neoplasia. 2019 May 18. doi: 10.1007/s10911-019-09431-5. [Epub ahead of print]
    • Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
    • Nones K, Johnson J, Newell F, Patch AM, Thorne H, Kazakoff SH, de Luca XM, Parsons MT, Ferguson K, Reid L, Reed AEM, Srihari S, Lakis V, Davidson AL, Mukhopadhyay P, Holmes O, Xu Q, Wood S, Leonard C; Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab); Australian Breast Cancer Tissue Bank (ABCTB); Brisbane Breast Bank (BBB), Beesley J, Harris J, Barnes D, Degasperi A, Ragan MA, Spurdle AB, Khanna KK, Lakhani SR, Pearson JV, Nik-Zainal S, Chenevix-Trench G, Waddell N, Simpson PT.
    • Ann Oncol. 2019 May 15. pii: mdz132. doi: 10.1093/annonc/mdz132. [Epub ahead of print]

    Related:

    Editorial:

    Journey's End: the quest for BRCA-like hereditary breast cancer genes is nearly over.

    • A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases.
    • Tyran M, Carbuccia N, Garnier S, Guille A, Adelaïde J, Finetti P, Toulzian J, Viens P, Tallet A, Goncalves A, Metellus P, Birnbaum D, Chaffanet M, Bertucci F.
    • Cancers (Basel). 2019 May 13;11(5):665. doi: 10.3390/cancers11050665.
    • FANCM, RAD1, CHEK1 and TP53I3 act as BRCA-like tumor suppressors and are mutated in hereditary ovarian cancer.
    • Lopes JL, Chaudhry S, Lopes GS, Levin NK, Tainsky MA.
    • Cancer Genet. 2019 May 8. pii: S2210-7762(19)30037-7. doi: 10.1016/j.cancergen.2019.04.061. [Epub ahead of print]
    • Alterations in DNA damage repair genes in primary liver cancer.
    • Lin J, Shi J, Guo H, Yang X, Jiang Y, Long J, Bai Y, Wang D, Yang X, Wan X, Zhang L, Pan J, Hu K, Guan M, Huo L, Sang X, Wang K, Zhao H.
    • Clin Cancer Res. 2019 May 8. pii: clincanres.0127.2019. doi: 10.1158/1078-0432.CCR-19-0127. [Epub ahead of print]
    • Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    • da Costa AABA, do Canto LM, Larsen SJ, Ribeiro ARG, Stecca CE, Petersen AH, Aagaard MM, de Brot L, Baumbach J, Baiocchi G, Achatz MI, Rogatto SR.
    • BMC Cancer. 2019 May 6;19(1):422. doi: 10.1186/s12885-019-5622-4.
    • WIP1 Contributes to the Adaptation of Fanconi Anemia Cells to DNA Damage as Determined by the Regulatory Network of the Fanconi Anemia and Checkpoint Recovery Pathways.
    • Rodríguez A, Naveja JJ, Torres L, García de Teresa B, Juárez-Figueroa U, Ayala-Zambrano C, Azpeitia E, Mendoza L, Frías S.
    • Front Genet. 2019 May 3;10:411. doi: 10.3389/fgene.2019.00411. eCollection 2019.
    • Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
    • Morse CB, Toukatly MN, Kilgore MR, Agnew KJ, Bernards SS, Norquist BM, Pennington KP, Garcia RL, Liao JB, Swisher EM.
    • Gynecol Oncol. 2019 May;153(2):217-222. doi: 10.1016/j.ygyno.2019.02.011. Epub 2019 Feb 23.

    Related:

    Editorial:

    Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?

    • ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    • Mesquita KA, Alabdullah M, Griffin M, Toss MS, Fatah TMAA, Alblihy A, Moseley P, Chan SYT, Rakha EA, Madhusudan S.
    • Gynecol Oncol. 2019 May;153(2):416-424. doi: 10.1016/j.ygyno.2019.02.014. Epub 2019 Feb 20.
    • A common SNP in the UNG gene decreases ovarian cancer risk in BRCA2 mutation carriers.
    • Baquero JM, Benítez-Buelga C, Fernández V, Urioste M, García-Giménez JL, Perona R; CIMBA Consortium, Benítez J, Osorio A.
    • Mol Oncol. 2019 May;13(5):1110-1120. doi: 10.1002/1878-0261.12470. Epub 2019 Mar 1.
    • The influence of BRCA2 mutation on localized prostate cancer.
    • Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, Risbridger GP.
    • Nat Rev Urol. 2019 May;16(5):281-290. doi: 10.1038/s41585-019-0164-8.
    • Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics - the Cohort study of TP53 carrier early onset breast cancer (COPE study).
    • Packwood K, Martland G, Sommerlad M, Shaw E, Moutasim K, Thomas G, Bateman A, Jones L, Haywood L, Evans DG, Birch JM, Alsalmi OA, Henderson A, Poplawski N, Eccles DM.
    • J Pathol Clin Res. 2019 Apr 30. doi: 10.1002/cjp2.133. [Epub ahead of print]
    • EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy.
    • Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips EH, Severson T, van de Ven M, Brambillasca CS, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler RK, Linn SC, Jonkers J.
    • Clin Cancer Res. 2019 Apr 29. pii: clincanres.4024.2018. doi: 10.1158/1078-0432.CCR-18-4024. [Epub ahead of print]
    • Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.
    • Macedo GS, Alemar B, Ashton-Prolla P.
    • Genet Mol Biol. 2019 Apr 29. pii: S1415-47572019005015101. doi: 10.1590/1678-4685-GMB-2018-0104. [Epub ahead of print]
    • Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
    • Wen WX, Leong CO.
    • PLoS One. 2019 Apr 25;14(4):e0215381. doi: 10.1371/journal.pone.0215381. eCollection 2019.
    • An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.
    • Perrone ME, Reder NP, Agoff SN, Garcia RL, Agnew KJ, Norquist BM, Pennington KP, Swisher EM, Kilgore MR.
    • Int J Gynecol Pathol. 2019 Apr 24. doi: 10.1097/PGP.0000000000000604. [Epub ahead of print]
    • Insights into BRCA Cancer Predisposition from Integrated Germline and Somatic Analyses in 7632 Cancers.
    • Yost S, Ruark E, Alexandrov LB, Rahman N.
    • JNCI Cancer Spectr. 2019 Apr 19;3(2):pkz028. doi: 10.1093/jncics/pkz028. eCollection 2019 Jun.
    • BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells.
    • Zhang X, Wang Y, Chiang HC, Hsieh YP, Lu C, Park BH, Jatoi I, Jin VX, Hu Y, Li R.
    • Breast Cancer Res. 2019 Apr 17;21(1):51. doi: 10.1186/s13058-019-1132-1.
    • Hyaline fibrous involution of breast lobules: a histologic finding associated with germline BRCA mutation.
    • Lee HE, Arshad M, Brahmbhatt RD, Hoskin TL, Winham SJ, Frost MH, Radisky DC, Denison LA, Degnim AC, Visscher DW.
    • Mod Pathol. 2019 Apr 17. doi: 10.1038/s41379-019-0217-9. [Epub ahead of print]
    • BRCA1-No Matter How You Splice It.
    • Li D, Harlan-Williams LM, Kumaraswamy E, Jensen RA.
    • Cancer Res. 2019 Apr 16. doi: 10.1158/0008-5472.CAN-18-3190. [Epub ahead of print]
    • Review
    • Dual TGFβ/BMP pathway inhibition enables expansion and characterization of multiple epithelial cell types of the normal and cancerous breast.
    • Prasad M, Kumar B, Bhat-Nakshatri P, Anjanappa M, Sandusky G, Miller KD, Storniolo AM, Nakshatri H.
    • Mol Cancer Res. 2019 Apr 16. pii: molcanres.0165.2019. doi: 10.1158/1541-7786.MCR-19-0165. [Epub ahead of print]
    • Detecting the mutational signature of homologous recombination deficiency in clinical samples.
    • Gulhan DC, Lee JJ, Melloni GEM, Cortés-Ciriano I, Park PJ.
    • Nat Genet. 2019 Apr 15. doi: 10.1038/s41588-019-0390-2. [Epub ahead of print]
    • Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
    • Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S, Heimbach A, Marmé F, Schmidt S, Prieske K, Gevensleben H, Burges A, Borde J, De Gregorio N, Nürnberg P, El-Balat A, Thiele H, Hilpert F, Altmüller J, Meier W, Dietrich D, Kimmig R, Schoemig-Markiefka B, Kast K, Braicu E, Baumann K, Jackisch C, Park-Simon TW, Ernst C, Hanker L, Pfisterer J, Schnelzer A, du Bois A, Schmutzler RK, Harter P.
    • J Med Genet. 2019 Apr 12. pii: jmedgenet-2018-105930. doi: 10.1136/jmedgenet-2018-105930. [Epub ahead of print]
    • Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma.
    • Yan T, Cui H, Zhou Y, Yang B, Kong P, Zhang Y, Liu Y, Wang B, Cheng Y, Li J, Guo S, Xu E, Liu H, Cheng C, Zhang L, Chen L, Zhuang X, Qian Y, Yang J, Ma Y, Li H, Wang F, Liu J, Liu X, Su D, Wang Y, Sun R, Guo S, Li Y, Cheng X, Liu Z, Zhan Q, Cui Y.
    • Nat Commun. 2019 Apr 11;10(1):1670. doi: 10.1038/s41467-019-09255-1.
    • Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients.
    • Deng H, Chen M, Guo X, Heng J, Xu X, Peng L, Jiang H, Li G, Day JX, Li J, Shan D, Li Y, Zhou Y, Liu B, Dai L, Wang X, Wang J.
    • Mol Genet Genomic Med. 2019 Apr 10:e672. doi: 10.1002/mgg3.672. [Epub ahead of print]
    • N6-methylation of adenosine (m6A) of FZD10 mRNA contributes to PARP inhibitor resistance.
    • Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, Zhang R.
    • Cancer Res. 2019 Apr 9. pii: canres.3592.2018. doi: 10.1158/0008-5472.CAN-18-3592. [Epub ahead of print]
    • β-hCG induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.
    • Sengodan SK, Hemalatha SK, Nadhan R, Somanathan T, Mathew AP, Chil A, Kopczynski J, Nair RS, Kumar JM, Srinivas P.
    • Carcinogenesis. 2019 Apr 9. pii: bgz070. doi: 10.1093/carcin/bgz070. [Epub ahead of print]
    • Beyond Trophic Factors: Exploiting the Intrinsic Regenerative Properties of Adult Neurons.
    • Duraikannu A, Krishnan A, Chandrasekhar A, Zochodne DW.
    • Front Cell Neurosci. 2019 Apr 5;13:128. doi: 10.3389/fncel.2019.00128. eCollection 2019.
    • Epigenetic modulation of BRCA-1 and MGMT genes, and histones H4 and H3 are associated with breast tumors.
    • Paydar P, Asadikaram G, Nejad HZ, Akbari H, Abolhassani M, Moazed V, Nematollahi MH, Ebrahimi G, Fallah H.
    • J Cell Biochem. 2019 Apr 2. doi: 10.1002/jcb.28645. [Epub ahead of print]
    • Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
    • Han Y, Li CW, Hsu JM, Hsu JL, Chan LC, Tan X, He GJ.
    • Am J Cancer Res. 2019 Apr 1;9(4):800-815. eCollection 2019.
    • Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis.
    • Thibodeau ML, Zhao EY, Reisle C, Ch'ng C, Wong HL, Shen Y, Jones MR, Lim HJ, Young S, Cremin C, Pleasance E, Zhang W, Holt R, Eirew P, Karasinska J, Kalloger SE, Taylor G, Majounie E, Bonakdar M, Zong Z, Bleile D, Chiu R, Birol I, Gelmon K, Lohrisch C, Mungall KL, Mungall AJ, Moore R, Ma YP, Fok A, Yip S, Karsan A, Huntsman D, Schaeffer DF, Laskin J, Marra MA, Renouf DJ, Jones SJM, Schrader KA.
    • Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003681. doi: 10.1101/mcs.a003681. Print 2019 Apr.
    • Clinical findings and outcomes of MRI staging of breast cancer in a diverse population.
    • Raghavendra A, Wecsler J, Ji L, Sheth P, Ricker C, Church T, Sposto R, Lang J, Sener S, Larsen L, Tripathy D.
    • Breast Cancer Res Treat. 2019 Apr;174(2):315-324. doi: 10.1007/s10549-018-05084-w. Epub 2018 Dec 12.
    • Review
    • ASSESSMENT OF THE VALUE OF METHYLATION FEATURES IN DIFFERENT TISSUES FOR PREOPERATIVE IDENTIFICATION OF HIGH-RISK BREAST TUMORS.
    • Kankava K, Kvaratskhelia E, Burkadze G, Tsikhiseli G, Azanishvili T, Tkemaladze T, Abzianidze E.
    • Georgian Med News. 2019 Apr;(289):143-151.
    • Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer.
    • Feng L, Jin F.
    • Oncol Lett. 2019 Apr;17(4):3687-3700. doi: 10.3892/ol.2019.10046. Epub 2019 Feb 18.
    • BRCA1/2 mutation spectrum in Chinese early-onset breast cancer.
    • Shen M, Yang L, Lei T, Xiao L, Li L, Zhang P, Feng W, Ye F, Bu H.
    • Transl Cancer Res. 2019 Apr;8(2):483-490. doi: 10.21037/tcr.2019.03.02.
    • County poverty levels influence genome-wide DNA methylation profiles in African American and European American women.
    • Hsu PC, Kadlubar S, Su LJ, Acheampong D, Rogers LJ, Runnells G, McElfish PA, Schootman M.
    • Transl Cancer Res. 2019 Apr;8(2):683-692. doi: 10.21037/tcr.2019.02.07.
    • Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    • Zaman T, Sun P, Narod SA, Salmena L, Kotsopoulos J.
    • Oncotarget. 2019 Mar 29;10(25):2475-2483. doi: 10.18632/oncotarget.26810. eCollection 2019 Mar 29.
    • Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer.
    • Kraya AA, Maxwell KN, Wubbenhorst B, Wenz BM, Pluta J, Rech AJ, Dorfman LM, Lunceford N, Barrett A, Mitra N, Morrissette JJ, Feldman M, Nayak A, Domchek SM, Vonderheide RH, Nathanson KL.
    • Clin Cancer Res. 2019 Mar 26. pii: clincanres.0468.2018. doi: 10.1158/1078-0432.CCR-18-0468. [Epub ahead of print]
    • Integrating Germline and Somatic Mutation Information for the Discovery of Biomarkers in Triple-Negative Breast Cancer.
    • Wu J, Mamidi TKK, Zhang L, Hicks C.
    • Int J Environ Res Public Health. 2019 Mar 23;16(6). pii: E1055. doi: 10.3390/ijerph16061055.
    • Beyond DNA repair: the novel immunological potential of PARP inhibitors.
    • Chabanon RM, Soria JC, Lord CJ, Postel-Vinay S.
    • Mol Cell Oncol. 2019 Mar 13;6(2):1585170. doi: 10.1080/23723556.2019.1585170. eCollection 2019.
    • Direct Ex Vivo Observation of Homologous Recombination Defect Reversal After DNA-Damaging Chemotherapy in Patients With Metastatic Breast Cancer.
    • Meijer TG, Verkaik NS, van Deurzen CHM, Dubbink HJ, den Toom TD, Sleddens HFBM, De Hoop EO, Dinjens WNM, Kanaar R, van Gent DC, Jager A.
    • JCO Precis Oncol. 2019 Dec [2019 Mar 11];3:1-12. doi: 10.1200/PO.18.00268.
    • DHA Oral Supplementation Modulates Serum Epoxydocosapentaenoic Acid (EDP) Levels in Breast Cancer Patients.
    • Molfino A, Amabile MI, Lionetto L, Spagnoli A, Ramaccini C, De Luca A, Simmaco M, Monti M, Muscaritoli M.
    • Oxid Med Cell Longev. 2019 Mar 5;2019:1280987. doi: 10.1155/2019/1280987. eCollection 2019.
    • BRCA1 represses DNA replication initiation through antagonizing estrogen signaling and maintains genome stability in parallel with WEE1-MCM2 signaling during pregnancy.
    • Xu X, Chen E, Mo L, Zhang L, Shao F, Miao K, Liu J, Su SM, Valecha M, In Chan U, Zheng H, Chen M, Chen W, Chen Q, Fu H, Aladjem MI, He Y, Deng CX.
    • Hum Mol Genet. 2019 Mar 1;28(5):842-857. doi: 10.1093/hmg/ddy398.
    • Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
    • Sønderstrup IMH, Jensen MB, Ejlertsen B, Eriksen JO, Gerdes AM, Kruse TA, Larsen MJ, Thomassen M, Laenkholm AV.
    • Acta Oncol. 2019 Mar;58(3):363-370. doi: 10.1080/0284186X.2018.1539239. Epub 2019 Jan 7.
    • Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways.
    • Qi F, Qin WX, Zang YS.
    • Oncol Lett. 2019 Mar;17(3):2905-2914. doi: 10.3892/ol.2019.9884. Epub 2019 Jan 3.
    • CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression.
    • Zhao R, Kaakati R, Liu X, Xu L, Lee AK, Bachelder R, Li CY, Hollenbeck ST.
    • Plast Reconstr Surg. 2019 Mar;143(3):747-756. doi: 10.1097/PRS.0000000000005316.

    Related:

    Research news:

    Discussion: CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression.

    • The Tumor Suppressor PALB2: Inside Out.
    • Ducy M, Sesma-Sanz L, Guitton-Sert L, Lashgari A, Gao Y, Brahiti N, Rodrigue A, Margaillan G, Caron MC, Côté J, Simard J, Masson JY.
    • Trends Biochem Sci. 2019 Mar;44(3):226-240. doi: 10.1016/j.tibs.2018.10.008. Epub 2019 Jan 10.
    • Tumor suppressor MCPH1 regulates gene expression profiles related to malignant conversion and chromosomal assembly.
    • Tervasmäki A, Mantere T, Eshraghi L, Laurila N, Tuppurainen H, Ronkainen VP, Koivuluoma S, Devarajan R, Peltoketo H, Pylkäs K.
    • Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32234. [Epub ahead of print]
    • AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer.
    • Kubli SP, Bassi C, Roux C, Wakeham A, Göbl C, Zhou W, Jafari SM, Snow B, Jones L, Palomero L, Thu KL, Cassetta L, Soong D, Berger T, Ramachandran P, Baniasadi SP, Duncan G, Lindzen M, Yarden Y, Herranz C, Lazaro C, Chu MF, Haight J, Tinto P, Silvester J, Cescon DW, Petit A, Pettersson S, Pollard JW, Mak TW, Pujana MA, Cappello P, Gorrini C.
    • Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3604-3613. doi: 10.1073/pnas.1815126116. Epub 2019 Feb 7.
    • Distinct Histologic, Immunohistochemical and Clinical Features Associated With Serous Endometrial Intraepithelial Carcinoma Involving Polyps.
    • Trinh VQ, Pelletier MP, Echelard P, Warkus T, Sauthier P, Gougeon F, Mès-Masson AM, Provencher DM, Rahimi K.
    • Int J Gynecol Pathol. 2019 Feb 14. doi: 10.1097/PGP.0000000000000591. [Epub ahead of print]
    • Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report.
    • Suda K, Nakaoka H, Hata C, Yahata N, Isobe M, Kameyama H, Wakai T, Motoyama T, Inoue I, Yoshihara K, Enomoto T.
    • Diagn Pathol. 2019 Feb 11;14(1):17. doi: 10.1186/s13000-019-0795-3.
    • Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency.
    • Yoshino Y, Endo S, Chen Z, Qi H, Watanabe G, Chiba N.
    • Sci Rep. 2019 Feb 7;9(1):1644. doi: 10.1038/s41598-018-38311-x.
    • Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
    • Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.
    • Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.
    • Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.
    • Omari A, Nastały P, Stoupiec S, Bałabas A, Dąbrowska M, Bielińska B, Huss S, Pantel K, Semjonow A, Eltze E, Brandt B, Bednarz-Knoll N.
    • Int J Cancer. 2019 Feb 1;144(3):607-614. doi: 10.1002/ijc.31905. Epub 2018 Oct 22.
    • Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA1-/2- carriers.
    • Ponandai-Srinivasan S, Lalitkumar PG, Garcia L, Varghese SJ, Carlson JW, Gemzell-Danielsson K, Floter Radestad A.
    • Acta Obstet Gynecol Scand. 2019 Feb;98(2):250-261. doi: 10.1111/aogs.13485. Epub 2018 Nov 15.
    • Oestrogen receptor status and survival in women with BRCA2-associated breast cancer.
    • Metcalfe K, Lynch HT, Foulkes WD, Tung N, Olopade OI, Eisen A, Lerner-Ellis J, Snyder C, Kim SJ, Sun P, Narod SA.
    • Br J Cancer. 2019 Feb;120(4):398-403. doi: 10.1038/s41416-019-0376-y. Epub 2019 Feb 6.
    • BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
    • Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM.
    • Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13.
    • Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.
    • Kotoula V, Lakis S, Tikas I, Giannoulatou E, Lazaridis G, Papadopoulou K, Manoussou K, Efstratiou I, Papanikolaou A, Fostira F, Vlachos I, Tarlatzis B, Fountzilas G.
    • Gynecol Oncol. 2019 Feb;152(2):375-386. doi: 10.1016/j.ygyno.2018.11.016. Epub 2018 Nov 14.
    • Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    • Tian T, Shan L, Yang W, Zhou X, Shui R.
    • Hum Pathol. 2019 Feb;84:231-238. doi: 10.1016/j.humpath.2018.10.004. Epub 2018 Oct 16.
    • Genetic variation and radiation quality impact cancer promoting cellular phenotypes in response to HZE exposure.
    • Sridharan DM, Enerio S, Wang C, LaBarge MA, Stampfer MR, Pluth JM.
    • Life Sci Space Res (Amst). 2019 Feb;20:101-112. doi: 10.1016/j.lssr.2018.10.002. Epub 2018 Oct 21.
    • Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico-pathological and molecular (next generation sequencing) study of 22 cases.
    • Hájková N, Tichá I, Hojný J, Němejcová K, Bártů M, Michálková R, Zikán M, Cibula D, Laco J, Geryk T, Méhes G, Dundr P.
    • Oncol Lett. 2019 Feb;17(2):2207-2214. doi: 10.3892/ol.2018.9855. Epub 2018 Dec 20.
    • Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer.
    • Veneris JT, Huang L, Churpek JE, Conzen SD, Fleming GF.
    • Int J Gynecol Cancer. 2019 Jan 25. pii: ijgc-2018-000101. doi: 10.1136/ijgc-2018-000101. [Epub ahead of print]
    • Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
    • Annunziato S, de Ruiter JR, Henneman L, Brambillasca CS, Lutz C, Vaillant F, Ferrante F, Drenth AP, van der Burg E, Siteur B, van Gerwen B, de Bruijn R, van Miltenburg MH, Huijbers IJ, van de Ven M, Visvader JE, Lindeman GJ, Wessels LFA, Jonkers J.
    • Nat Commun. 2019 Jan 23;10(1):397. doi: 10.1038/s41467-019-08301-2.
    • BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers.
    • Semmler L, Reiter-Brennan C, Klein A.
    • J Breast Cancer. 2019 Jan 22;22(1):1-14. doi: 10.4048/jbc.2019.22.e6. eCollection 2019 Mar.
    • Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
    • Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD.
    • Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):619-624. doi: 10.1073/pnas.1814027116. Epub 2018 Dec 24.
    • Relationship between Background Parenchymal Enhancement on High-risk Screening MRI and Future Breast Cancer Risk.
    • Grimm LJ, Saha A, Ghate SV, Kim C, Soo MS, Yoon SC, Mazurowski MA.
    • Acad Radiol. 2019 Jan;26(1):69-75. doi: 10.1016/j.acra.2018.03.013. Epub 2018 Mar 27.
    • Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation.
    • El Tannouri R, Albuisson E, Jonveaux P, Luporsi E.
    • Fam Cancer. 2019 Jan;18(1):1-8. doi: 10.1007/s10689-018-0079-1.
    • Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
    • Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui JL, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson ML, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Nowak JA, Wolpin BM.
    • Genet Med. 2019 Jan;21(1):213-223. doi: 10.1038/s41436-018-0009-5. Epub 2018 Jul 2.
    • The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    • Hjortkjær M, Malik Aagaard Jørgensen M, Waldstrøm M, Ørnskov D, Søgaard-Andersen E, Jakobsen A, Dahl-Steffensen K.
    • Int J Gynecol Cancer. 2019 Jan;29(1):166-173. doi: 10.1136/ijgc-2018-000017.
    • Transcriptome mining of non-BRCA1/A2 and BRCA1/A2 familial breast cancer.
    • Akbari V, Kallhor M, Akbari MT.
    • J Cell Biochem. 2019 Jan;120(1):575-583. doi: 10.1002/jcb.27413. Epub 2018 Aug 20.
    • G2 Chromosomal Radiosensitivity Assay for Testing Individual Radiation Sensitivity.
    • Haskins JS, Kato TA.
    • Methods Mol Biol. 2019;1984:39-45. doi: 10.1007/978-1-4939-9432-8_5.
    • Book, Review
    • Association Between Impairment of DNA Double Strand Break Repair and Decreased Ovarian Reserve in Patients With Endometriosis.
    • Choi YS, Park JH, Lee JH, Yoon JK, Yun BH, Park JH, Seo SK, Sung HJ, Kim HS, Cho S, Lee BS.
    • Front Endocrinol (Lausanne). 2018 Dec 21;9:772. doi: 10.3389/fendo.2018.00772. eCollection 2018.
    • USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
    • Lim KS, Li H, Roberts EA, Gaudiano EF, Clairmont C, Sambel LA, Ponnienselvan K, Liu JC, Yang C, Kozono D, Parmar K, Yusufzai T, Zheng N, D'Andrea AD.
    • Mol Cell. 2018 Dec 20;72(6):925-941.e4. doi: 10.1016/j.molcel.2018.10.045.
    • Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects.
    • Meijer TG, Verkaik NS, Sieuwerts AM, van Riet J, Naipal KAT, van Deurzen CHM, den Bakker MA, Sleddens HFBM, Dubbink HJ, den Toom TD, Dinjens WNM, Lips E, Nederlof PM, Smid M, van de Werken HJG, Kanaar R, Martens JWM, Jager A, van Gent DC.
    • Clin Cancer Res. 2018 Dec 15;24(24):6277-6287. doi: 10.1158/1078-0432.CCR-18-0063. Epub 2018 Aug 23.
    • Complete pathological response following neoadjuvant FOLFOX chemotherapy in BRCA2-mutant locally advanced rectal cancer: a case report.
    • Lin Z, Liu J, Peng L, Zhang D, Jin M, Wang J, Xue J, Liu H, Zhang T.
    • BMC Cancer. 2018 Dec 14;18(1):1253. doi: 10.1186/s12885-018-5182-z.
    • Histopathological patterns of primary malignant ovarian neoplasms in different age groups in Almadinah Almunawwarah region, KSA.
    • Yousif HM, Mohammed RA, Missawi HM, Elsawaf ZM, Albasri AM.
    • J Taibah Univ Med Sci. 2018 Dec 11;14(1):73-78. doi: 10.1016/j.jtumed.2018.11.005. eCollection 2019 Feb.
    • Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress.
    • Bayard Q, Meunier L, Peneau C, Renault V, Shinde J, Nault JC, Mami I, Couchy G, Amaddeo G, Tubacher E, Bacq D, Meyer V, La Bella T, Debaillon-Vesque A, Bioulac-Sage P, Seror O, Blanc JF, Calderaro J, Deleuze JF, Imbeaud S, Zucman-Rossi J, Letouzé E.
    • Nat Commun. 2018 Dec 7;9(1):5235. doi: 10.1038/s41467-018-07552-9.
    • Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways.
    • Austria T, Marion C, Yu V, Widschwendter M, Hinton DR, Dubeau L.
    • Int J Cancer. 2018 Dec 1;143(11):2932-2942. doi: 10.1002/ijc.31659. Epub 2018 Oct 3.
    • A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
    • Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dientsmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V.
    • EMBO Mol Med. 2018 Dec;10(12). pii: e9172. doi: 10.15252/emmm.201809172.
    • Genome-wide DNA methylation assessment of 'BRCA1-like' early-onset breast cancer: Data from the Australian Breast Cancer Family Registry.
    • Scott CM, Wong EM, Joo JE, Dugué PA, Jung CH, O'Callaghan N, Dowty J, Giles GG, Hopper JL, Southey MC.
    • Exp Mol Pathol. 2018 Dec;105(3):404-410. doi: 10.1016/j.yexmp.2018.11.006. Epub 2018 Nov 10.
    • Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
    • Wang Z, Zhang J, Zhang Y, Deng Q, Liang H.
    • Int J Mol Med. 2018 Dec;42(6):3542-3550. doi: 10.3892/ijmm.2018.3870. Epub 2018 Sep 11.
    • An Unusual Adenomatoid Tumor of Fimbria with Pronounced Psammoma Bodies in a BRCA Positive Patient as a Pitfall for Carcinoma on Frozen Section.
    • Lee CM, Moh M, Sullivan PS, Moatamed NA.
    • Case Rep Pathol. 2018 Nov 21;2018:8148147. doi: 10.1155/2018/8148147. eCollection 2018.
    • Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition.
    • Santana Dos Santos E, Lallemand F, Burke L, Stoppa-Lyonnet D, Brown M, Caputo SM, Rouleau E.
    • Cancers (Basel). 2018 Nov 16;10(11). pii: E453. doi: 10.3390/cancers10110453.
    • Cell Origins of High-Grade Serous Ovarian Cancer.
    • Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC Jr.
    • Cancers (Basel). 2018 Nov 12;10(11). pii: E433. doi: 10.3390/cancers10110433.
    • Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer.
    • Li J, Ugalde-Morales E, Wen WX, Decker B, Eriksson M, Torstensson A, Christensen HN, Dunning AM, Allen J, Luccarini C, Pooley KA, Simard J, Dorling L, Easton DF, Teo SH, Hall P, Czene K.
    • Cancer Res. 2018 Nov 1;78(21):6329-6338. doi: 10.1158/0008-5472.CAN-18-1018.
    • Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
    • Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM.
    • Cancer Prev Res (Phila). 2018 Nov;11(11):697-706. doi: 10.1158/1940-6207.CAPR-18-0009. Epub 2018 Sep 19.
    • 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
    • Aziz D, Etemadmoghadam D, Caldon CE, Au-Yeung G, Deng N, Hutchinson R; Australian Ovarian Cancer Study Group, Bowtell D, Waring P.
    • Gynecol Oncol. 2018 Nov;151(2):327-336. doi: 10.1016/j.ygyno.2018.08.039. Epub 2018 Sep 9.
    • Poly(ADP-ribose) polymerase-3 overexpression is associated with poor prognosis in patients with breast cancer following chemotherapy.
    • Song Z, Wang Y, Xiao Q, Yu Z, Zhao L, Wu H, Sun M, Chai Z, Hou P, Geng X, Liu W, Wei M.
    • Oncol Lett. 2018 Nov;16(5):5621-5630. doi: 10.3892/ol.2018.9398. Epub 2018 Sep 5.
    • Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.
    • Yang SYC, Lheureux S, Karakasis K, Burnier JV, Bruce JP, Clouthier DL, Danesh A, Quevedo R, Dowar M, Hanna Y, Li T, Lu L, Xu W, Clarke BA, Ohashi PS, Shaw PA, Pugh TJ, Oza AM.
    • Genome Med. 2018 Oct 31;10(1):81. doi: 10.1186/s13073-018-0590-x.
    • BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?
    • Lønning PE, Knappskog S.
    • Clin Epigenetics. 2018 Oct 22;10(1):128. doi: 10.1186/s13148-018-0566-0.

    Related:

    Original research:

    Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters.

    • Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.
    • Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN.
    • J Clin Oncol. 2018 Oct 19:JCO1800328. doi: 10.1200/JCO.18.00328. [Epub ahead of print]
    • Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer.
    • An Y, Bi F, You Y, Liu X, Yang Q.
    • J Cancer. 2018 Oct 18;9(21):4058-4071. doi: 10.7150/jca.25587. eCollection 2018.
    • Inhibition of Estrogen Signaling Reduces the Incidence of BRCA1-associated Mammary Tumor Formation.
    • Baek HJ, Kim SE, Choi EK, Kim JK, Shin DH, Park EJ, Kim TH, Kim JY, Kim KG, Deng CX, Kim SS.
    • Int J Biol Sci. 2018 Oct 3;14(12):1755-1768. doi: 10.7150/ijbs.28142. eCollection 2018.
    • Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.
    • Yap YS, Munusamy P, Lim C, Chan CHT, Prawira A, Loke SY, Lim SH, Ong KW, Yong WS, Ng SBH, Tan IBH, Callen DF, Lim JCT, Thike AA, Tan PH, Lee ASG.
    • Breast Cancer Res Treat. 2018 Oct;171(3):719-735. doi: 10.1007/s10549-018-4851-6. Epub 2018 Jun 21.
    • Germline and Somatic NF1 Alterations Are Linked to Increased HER2 Expression in Breast Cancer.
    • Wang X, Kallionpää RA, Gonzales PR, Chitale DA, Tousignant RN, Crowley JP, Chen Z, Yoder SJ, Blakeley JO, Acosta MT, Korf BR, Messiaen LM, Tainsky MA.
    • Cancer Prev Res (Phila). 2018 Oct;11(10):655-664. doi: 10.1158/1940-6207.CAPR-18-0072. Epub 2018 Aug 13
    • Aberrant promoter methylation of PCDH10 as a potential diagnostic and prognostic biomarker for patients with breast cancer.
    • Liu W, Wu J, Shi G, Yue X, Liu D, Zhang Q.
    • Oncol Lett. 2018 Oct;16(4):4462-4470. doi: 10.3892/ol.2018.9214. Epub 2018 Jul 25.
    • Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
    • Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.
    • Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z.
    • BRCA1 Promoter Methylation and Clinicopathological Characteristics in Sporadic Breast Cancer Patients in Indonesia.
    • Harahap WA, Sudji IR, Nindrea RD.
    • Asian Pac J Cancer Prev. 2018 Sep 26;19(9):2643-2649.
    • Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas.
    • Buckley AR, Ideker T, Carter H, Harismendy O, Schork NJ.
    • Genome Med. 2018 Sep 14;10(1):69. doi: 10.1186/s13073-018-0579-5.
    • Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
    • Li G, Guo X, Chen M, Tang L, Jiang H, Day JX, Xie Y, Peng L, Xu X, Li J, Wang S, Xiao Z, Dai L, Wang J.
    • PLoS One. 2018 Sep 13;13(9):e0203495. doi: 10.1371/journal.pone.0203495. eCollection 2018.
    • MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer.
    • Milevskiy MJG, Sandhu GK, Wronski A, Korbie D, Brewster BL, Shewan A, Edwards SL, French JD, Brown MA.
    • Oncotarget. 2018 Sep 11;9(71):33577-33588. doi: 10.18632/oncotarget.26094. eCollection 2018 Sep 11.

    Related:

    Comment:

    MiRNAs prognostic for basal and BRCA1 breast cancer.

    • Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
    • Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms KM, Neff C, Solimeno C, Pruss D, Eklund AC, Tóth E, Kiss O, Rusz O, Cserni G, Zombori T, Székely B, Kulka J, Tímár J, Csabai I, Szallasi Z.
    • Ann Oncol. 2018 Sep 1;29(9):1948-1954. doi: 10.1093/annonc/mdy216.
    • Association of BRCA2 K3326* With Small Cell Lung Cancer and Squamous Cell Cancer of the Skin.
    • Rafnar T, Sigurjonsdottir GR, Stacey SN, Halldorsson G, Sulem P, Pardo LM, Helgason H, Sigurdsson ST, Gudjonsson T, Tryggvadottir L, Olafsdottir GH, Jonasson JG, Alexiusdottir K, Sigurdsson A, Gudmundsson J, Saemundsdottir J, Sigurdsson JK, Johannsdottir H, Uitterlinden A, Vermeulen SH, Galesloot TE, Allain DC, Lacko M, Sigurgeirsson B, Thorisdottir K, Johannsson OT, Sigurdsson F, Ragnarsson GB, Isaksson H, Hardardottir H, Gudbjartsson T, Gudbjartsson DF, Masson G, Kiemeney LAML, Ewart Toland A, Nijsten T, Peters WHM, Olafsson JH, Jonsson S, Thorsteinsdottir U, Thorleifsson G, Stefansson K.
    • J Natl Cancer Inst. 2018 Sep 1;110(9):967-974. doi: 10.1093/jnci/djy002.

    Related:

    Research News:

    Mixing Mutation Location With Carcinogen Exposure: A Recipe for Tissue Specificity in BRCA2-Associated Cancers?

    • The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.
    • Weigelt B, Bi R, Kumar R, Blecua P, Mandelker DL, Geyer FC, Pareja F, James PA; kConFab Investigators, Couch FJ, Eccles DM, Blows F, Pharoah P, Li A, Selenica P, Lim RS, Jayakumaran G, Waddell N, Shen R, Norton L, Wen HY, Powell SN, Riaz N, Robson ME, Reis-Filho JS, Chenevix-Trench G.
    • J Natl Cancer Inst. 2018 Sep 1;110(9):1030-1034. doi: 10.1093/jnci/djy028.
    • Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women.
    • Sakurada S, Watanabe Y, Tokunaga H, Takahashi F, Yamada H, Takehara K, Yaegashi N.
    • Jpn J Clin Oncol. 2018 Sep 1;48(9):794-798. doi: 10.1093/jjco/hyy095.
    • Comparison of background parenchymal enhancement and fibroglandular density at breast magnetic resonance
    • Grubstein A, Rapson Y, Benzaquen O, Rozenblatt S, Gadiel I, Atar E, Yerushalmi R, Cohen MJ.
    • Clin Imaging. 2018 Sep - Oct;51:347-351. doi: 10.1016/j.clinimag.2018.06.010. Epub 2018 Jun 30.
    • Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
    • Vos S, Elias SG, van der Groep P, Smolders YH, van Gils CH, van Diest PJ.
    • Am J Surg Pathol. 2018 Sep;42(9):1262-1272. doi: 10.1097/PAS.0000000000001115.
    • BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    • Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H, Zeimet AG.
    • Br J Cancer. 2018 Sep;119(6):683-692. doi: 10.1038/s41416-018-0217-4. Epub 2018 Aug 15.
    • Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.
    • Rodríguez-Balada M, Roig B, Melé M, Salvat M, Martorell L, Borràs J, Gumà J.
    • Clin Transl Oncol. 2018 Sep;20(9):1226-1231. doi: 10.1007/s12094-018-1837-0. Epub 2018 Feb 5.
    • Evaluation of Microscopic Changes in Fallopian Tubes of BRCA Mutation Carriers by Morphometric Analysis of Histologic Slides: A Preliminary Pilot Study.
    • Amit A, Sabo E, Zohar Y, Trugman E, Pranovich I, Reiss A, Matanes E, Klorin G.
    • Int J Gynecol Pathol. 2018 Sep;37(5):460-467. doi: 10.1097/PGP.0000000000000440.
    • Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations.
    • Zhu X, Tian T, Ruan M, Rao J, Yang W, Cai X, Sun M, Qin G, Zhao Z, Wu J, Shao Z, Shui R, Hu Z.
    • J Breast Cancer. 2018 Sep;21(3):297-305. doi: 10.4048/jbc.2018.21.e38. Epub 2018 Sep 12.
    • Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.
    • Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK.
    • Oncologist. 2018 Sep;23(9):998-1003. doi: 10.1634/theoncologist.2017-0645. Epub 2018 Apr 5.
    • Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
    • da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz MDPE.
    • Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e450s. doi: 10.6061/clinics/2018/e450s.
    • Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities.
    • Casey AE, Sinha A, Singhania R, Livingstone J, Waterhouse P, Tharmapalan P, Cruickshank J, Shehata M, Drysdale E, Fang H, Kim H, Isserlin R, Bailey S, Medina T, Deblois G, Shiah YJ, Barsyte-Lovejoy D, Hofer S, Bader G, Lupien M, Arrowsmith C, Knapp S, De Carvalho D, Berman H, Boutros PC, Kislinger T, Khokha R.
    • J Cell Biol. 2018 Aug 6;217(8):2951-2974. doi: 10.1083/jcb.201804042. Epub 2018 Jun 19.

    Related:

    Press: Breast Cancer Epigenetics Study Reveals Potential Drug Targets. (Clinical OMICs)

    • Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
    • Hao D, Liu J, Chen M, Li J, Wang L, Li X, Zhao Q, Di LJ.
    • Clin Cancer Res. 2018 Aug 1;24(15):3560-3571. doi: 10.1158/1078-0432.CCR-17-3862. Epub 2018 Apr 16.
    • Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
    • Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Nuti M, Taube ET, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.
    • Br J Cancer. 2018 Aug;119(3):330-338. doi: 10.1038/s41416-018-0157-z. Epub 2018 Jun 29.
    • Molecular correlates of intermediate- and high-risk localized prostate cancer.
    • Ye H, Sowalsky AG.
    • Urol Oncol. 2018 Aug;36(8):368-374. doi: 10.1016/j.urolonc.2017.12.022. Epub 2018 Mar 2.
    • Review
    • Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma.
    • Na K, Lee JY, Sung JY, Kim GM, Koo JS, Kim HS.
    • Virchows Arch. 2018 Aug;473(2):165-175. doi: 10.1007/s00428-018-2390-5. Epub 2018 Jun 20.
    • Methylation Profiles of BRCA1, RASSF1A and GSTP1 in Vietnamese Women with Breast Cancer.
    • Vu TL, Nguyen TT, Doan VTH, Vo LTT.
    • Asian Pac J Cancer Prev. 2018 Jul 27;19(7):1887-1893.
    • Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters.
    • Al-Moghrabi N, Al-Showimi M, Al-Yousef N, Al-Shahrani B, Karakas B, Alghofaili L, Almubarak H, Madkhali S, Al Humaidan H.
    • Clin Epigenetics. 2018 Jul 26;10(1):99. doi: 10.1186/s13148-018-0529-5.

    Related:

    Letter, Commentary:

    BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?

    • Therapeutic landscape in mutational triple negative breast cancer.
    • Shi Y, Jin J, Ji W, Guan X.
    • Mol Cancer. 2018 Jul 14;17(1):99. doi: 10.1186/s12943-018-0850-9.
    • Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer.
    • Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F, Birkbak NJ, Eklund AC, Syed A, Szallasi Z.
    • NPJ Breast Cancer. 2018 Jul 2;4:16. doi: 10.1038/s41523-018-0066-6. eCollection 2018.
    • Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
    • Van Heetvelde M, Van Bockstal M, Poppe B, Lambein K, Rosseel T, Atanesyan L, Deforce D, Van Den Berghe I, De Leeneer K, Van Dorpe J, Vral A, Claes KBM.
    • Cancer Lett. 2018 Jul 1;425:125-133. doi: 10.1016/j.canlet.2018.03.026. Epub 2018 Mar 23.
    • A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
    • Vos S, van Diest PJ, Moelans CB.
    • Crit Rev Oncol Hematol. 2018 Jul;127:29-41. doi: 10.1016/j.critrevonc.2018.05.008. Epub 2018 May 14.
    • Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.
    • Stronach EA, Paul J, Timms KM, Hughes E, Brown K, Neff C, Perry M, Gutin A, El-Bahrawy M, Steel JH, Liu X, Lewsley LA, Siddiqui N, Gabra H, Lanchbury JS, Brown R.
    • Mol Cancer Res. 2018 Jul;16(7):1103-1111. doi: 10.1158/1541-7786.MCR-18-0034. Epub 2018 May 3.
    • BRCA1 Mutation Status and Follicular Fluid Exposure Alters NFκB Signaling and ISGylation in Human Fallopian Tube Epithelial Cells.
    • Hollingsworth J, Lau A, Tone A, Kollara A, Allen L, Colgan TJ, Dube V, Rosen B, Murphy KJ, Greenblatt EM, Feigenberg T, Virtanen C, Brown TJ.
    • Neoplasia. 2018 Jul;20(7):697-709. doi: 10.1016/j.neo.2018.05.005. Epub 2018 May 28.
    • Association of Germline PALB2 Mutation and Response to Platinum-Based Chemotherapy in Metastatic Breast Cancer: A Case Series.
    • Isaac D, Karapetyan L, Tamkus D.
    • JCO Precis Oncol. 2018 Nov [2018 Jun 26];2:1-5. doi: 10.1200/PO.17.00258.
    • Interleukin enhancer binding factor 2 is a prognostic biomarker for breast cancer that also predicts neoadjuvant chemotherapy responses.
    • Jin Z, Xu L, Zhang L, Zhao M, Li D, Ye L, Ma Y, Ren S, Yu H, Wang D, Liang C, Chen B.
    • Am J Transl Res. 2018 Jun 15;10(6):1677-1689. eCollection 2018.
    • Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
    • Afghahi A, Purington N, Han SS, Desai M, Pierson E, Mathur MB, Seto T, Thompson CA, Rigdon J, Telli ML, Badve SS, Curtis CN, West RB, Horst K, Gomez SL, Ford JM, Sledge GW, Kurian AW.
    • Clin Cancer Res. 2018 Jun 15;24(12):2851-2858. doi: 10.1158/1078-0432.CCR-17-1323. Epub 2018 Mar 26.
    • Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
    • Hao D, Liu J, Chen M, Li J, Wang L, Li X, Zhao Q, Di L
    • Clin Cancer Res. 2018 Jun 12. doi: 10.1158/1078-0432.CCR-17-3862. [Epub ahead of print]
    • Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
    • Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie D, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.
    • Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008.
    • Genetic alterations detected by comparative genomic hybridization in BRCAX breast and ovarian cancers of Brazilian population.
    • Felicio PS, Bidinotto LT, Melendez ME, Grasel RS, Campacci N, Galvão HCR, Scapulatempo-Neto C, Dufloth RM, Evangelista AF, Palmero EI.
    • Oncotarget. 2018 Jun 8;9(44):27525-27534. doi: 10.18632/oncotarget.25537. eCollection 2018 Jun 8.
    • Heterochromatin-Encoded Satellite RNAs Induce Breast Cancer.
    • Zhu Q, Hoong N, Aslanian A, Hara T, Benner C, Heinz S, Miga KH, Ke E, Verma S, Soroczynski J, Yates JR 3rd, Hunter T, Verma IM.
    • Mol Cell. 2018 Jun 7;70(5):842-853.e7. doi: 10.1016/j.molcel.2018.04.023. Epub 2018 May 31.
    • Molecular Subtypes of Prostate Cancer.
    • Arora K, Barbieri CE.
    • Curr Oncol Rep. 2018 Jun 1;20(8):58. doi: 10.1007/s11912-018-0707-9.
    • Review
    • Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
    • Hu Z, Shen R, Campbell A, McMichael E, Yu L, Ramaswamy B, London CA, Xu T, Carson WE 3rd.
    • Cancer Immunol Res. 2018 Jun;6(6):671-684. doi: 10.1158/2326-6066.CIR-17-0343. Epub 2018 Apr 5.
    • Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis.
    • Watanabe G, Chiba N, Nomizu T, Furuta A, Sato K, Miyashita M, Tada H, Suzuki A, Ohuchi N, Ishida T.
    • Cancer Sci. 2018 Jun;109(6):2027-2035. doi: 10.1111/cas.13595. Epub 2018 May 15.
    • Glucocorticoid receptor overexpression slightly shifts microRNA expression patterns in triple-negative breast cancer.
    • Buschmann D, González R, Kirchner B, Mazzone C, Pfaffl MW, Schelling G, Steinlein O, Reithmair M.
    • Int J Oncol. 2018 Jun;52(6):1765-1776. doi: 10.3892/ijo.2018.4336. Epub 2018 Mar 27.
    • Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
    • Dai Y, Sun C, Feng Y, Jia Q, Zhu B.
    • J Cell Mol Med. 2018 May 31. doi: 10.1111/jcmm.13678. [Epub ahead of print]
    • Distinct DNA Methylation Profiles in Ovarian Tumors: Opportunities for Novel Biomarkers.
    • Losi L, Fonda S, Saponaro S, Chelbi ST, Lancellotti C, Gozzi G, Alberti L, Fabbiani L, Botticelli L, Benhattar J.
    • Int J Mol Sci. 2018 May 24;19(6). pii: E1559. doi: 10.3390/ijms19061559.
    • Leucocytes telomere length and breast cancer risk/ susceptibility: A case-control study.
    • Pavanello S, Varesco L, Gismondi V, Bruzzi P, Bolognesi C.
    • PLoS One. 2018 May 21;13(5):e0197522. doi: 10.1371/journal.pone.0197522. eCollection 2018.
    • Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1.
    • Seo A, Steinberg-Shemer O, Unal S, Casadei S, Walsh T, Gumruk F, Shalev S, Shimamura A, Akarsu NA, Tamary H3, King MC.
    • Proc Natl Acad Sci U S A. 2018 May 15;115(20):5241-5246. doi: 10.1073/pnas.1801796115. Epub 2018 Apr 30.
    • MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer.
    • Lagendijk M, Sadaatmand S, Koppert LB, Tilanus-Linthorst MMA, de Weerd V, Ramírez-Moreno R, Smid M, Sieuwerts AM, Martens JWM.
    • Oncotarget. 2018 May 11;9(36):24335-24346. doi: 10.18632/oncotarget.25262. eCollection 2018 May 11.
    • Metabolomic profiles in breast cancer:a pilot case-control study in the breast cancer family registry.
    • Dougan MM, Li Y, Chu LW, Haile RW, Whittemore AS, Han SS, Moore SC, Sampson JN, Andrulis IL, John EM, Hsing AW.
    • BMC Cancer. 2018 May 5;18(1):532. doi: 10.1186/s12885-018-4437-z.
    • DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.
    • Gupta R, Somyajit K, Narita T, Maskey E, Stanlie A, Kremer M, Typas D, Lammers M, Mailand N, Nussenzweig A, Lukas J, Choudhary C.
    • Cell. 2018 May 3;173(4):972-988.e23. doi: 10.1016/j.cell.2018.03.050. Epub 2018 Apr 12.
    • RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    • Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.
    • Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.
    • Comparison of BRCA1 Expression between Triple-Negative and Luminal Breast Tumors.
    • Darbeheshti F, Izadi P, Emami Razavi AN, Yekaninejad M, Tavakkoly Bazzaz J.
    • Iran Biomed J. 2018 May 1;22(3):210-4. Epub 2017 Jun 25.
    • A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.
    • Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach RH, Lin LL.
    • J Clin Invest. 2018 May 1;128(5):2116-2126. doi: 10.1172/JCI97992. Epub 2018 Apr 16.

    Related:

    Identifier: NCT02637934: Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT. (ClinicalTrials.gov)

    Commentary:

    The evolving landscape of predictive biomarkers of response to PARP inhibitors.

    • Invasive breast carcinomas with ATM gene variants of uncertain significance share distinct histopathologic features.
    • Abdulrahman AA, Heintzelman RC, Corbman M, Garcia FU.
    • Breast J. 2018 May;24(3):291-297. doi: 10.1111/tbj.12930. Epub 2017 Oct 7.
    • Loss of Heterozygosity in BRCA1 and BRCA2 Genes in Patients with Ovarian Cancer and Probability of Its Use for Clinical Classification of Variations.
    • Kechin AA, Boyarskikh UA, Ermolenko NA, Tyulyandina AS, Lazareva DG, Avdalyan AM, Tyulyandin SA, Kushlinskii NE, Filipenko ML.
    • Bull Exp Biol Med. 2018 May;165(1):94-100. doi: 10.1007/s10517-018-4107-9. Epub 2018 May 24.
    • Molecular analysis of PALB2 associated breast cancers.
    • Lee JEA, Li N, Rowley SM, Cheasley D, Zethoven M, McInerny S, Gorringe KL, James PA, Campbell IG.
    • J Pathol. 2018 May;245(1):53-60. doi: 10.1002/path.5055. Epub 2018 Mar 30.
    • Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report.
    • Sonnenblick A, Zick A, Maoz M, Cohen S, Kadouri L, Peretz T, Hubert A.
    • Mol Clin Oncol. 2018 May;8(5):683-685. doi: 10.3892/mco.2018.1588. Epub 2018 Mar 9.
    • SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    • Xu L, Che X, Wu Y, Song N, Shi S, Wang S, Li C, Zhang L, Zhang X, Qu X, Teng Y.
    • Oncol Rep. 2018 May;39(5):2315-2323. doi: 10.3892/or.2018.6319. Epub 2018 Mar 16.
    • Somatic mutations in early onset luminal breast cancer.
    • Encinas G, Sabelnykova VY, de Lyra EC, Hirata Katayama ML, Maistro S, de Vasconcellos Valle PWM, de Lima Pereira GF, Rodrigues LM, de Menezes Pacheco Serio PA, de Gouvêa ACRC, Geyer FC, Basso RA, Pasini FS, Del Pilar Esteves Diz M, Brentani MM, Guedes Sampaio Góes JC, Chammas R, Boutros PC, Koike Folgueira MAA.
    • Oncotarget. 2018 Apr 27;9(32):22460-22479. doi: 10.18632/oncotarget.25123. eCollection 2018 Apr 27.
    • Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
    • Renault AL, Mebirouk N, Fuhrmann L, Bataillon G, Cavaciuti E, Le Gal D, Girard E, Popova T, La Rosa P, Beauvallet J, Eon-Marchais S, Dondon MG, d'Enghien CD, Laugé A, Chemlali W, Raynal V, Labbé M, Bièche I, Baulande S, Bay JO, Berthet P, Caron O, Buecher B, Faivre L, Fresnay M, Gauthier-Villars M, Gesta P, Janin N, Lejeune S, Maugard C, Moutton S, Venat-Bouvet L, Zattara H, Fricker JP, Gladieff L, Coupier I; CoF-AT; GENESIS; kConFab, Chenevix-Trench G, Hall J, Vincent-Salomon A, Stoppa-Lyonnet D, Andrieu N, Lesueur F.
    • Breast Cancer Res. 2018 Apr 17;20(1):28. doi: 10.1186/s13058-018-0951-9.
    • Gene-specific methylation profiles in BRCA-mutation positive and BRCA-mutation negative male breast cancers.
    • Rizzolo P, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Palli D, Ottini L.
    • Oncotarget. 2018 Apr 13;9(28):19783-19792. doi: 10.18632/oncotarget.24856. eCollection 2018 Apr 13.
    • BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.
    • Wieser V, Gaugg I, Fleischer M, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Zeimet AG, Fiegl H, Marth C.
    • Oncotarget. 2018 Apr 3;9(25):17501-17511. doi: 10.18632/oncotarget.24770. eCollection 2018 Apr 3.
    • Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    • Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart M, Rothe F, Sotiriou C.
    • Ann Oncol. 2018 Apr 1;29(4):895-902. doi: 10.1093/annonc/mdy024.
    • [Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    • Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.
    • Rev Esp Patol. 2018 Apr - Jun;51(2):84-96. doi: 10.1016/j.patol.2017.11.002. Epub 2018 Jan 17.
    • Consensus statement, Review, [Article in Spanish]
    • Down-regulation of microRNA-19b in hormone receptor-positive/HER2-negative breast cancer.
    • Maleki E, Ghaedi K, Shahanipoor K, Karimi Kurdistani Z.
    • APMIS. 2018 Apr;126(4):303-308. doi: 10.1111/apm.12820.
    • Sebaceous carcinoma of the breast in a patient with a pathogenic BRCA2 (886delGT) mutation - focus on histopathologic and immunohistochemical features.
    • Acosta AM, Al Rasheed MRH, Xu H, Salibay C, Pins MR.
    • APMIS. 2018 Apr;126(4):353-356. doi: 10.1111/apm.12826.
    • Case report
    • DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.
    • Ramos JD, Mostaghel EA, Pritchard CC, Yu EY.
    • Clin Genitourin Cancer. 2018 Apr;16(2):106-110. doi: 10.1016/j.clgc.2017.11.009. Epub 2017 Dec 6.
    • Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    • Xiao X, Dong D, He W, Song L, Wang O, Yue J, Xie L.
    • Gynecol Oncol. 2018 Apr;149(1):146-154. doi: 10.1016/j.ygyno.2018.02.009. Epub 2018 Mar 1.
    • Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy.
    • Park KJ, Patel P, Linkov I, Jotwani A, Kauff N, Pike MC.
    • Histopathology. 2018 Apr;72(5):766-776. doi: 10.1111/his.13444. Epub 2018 Jan 29.
    • Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers.
    • Tanaka H, Phipps EA, Wei T, Wu X, Goswami C, Liu Y, Sledge GW Jr, Mina L, Herbert BS.
    • Mol Carcinog. 2018 Apr;57(4):567-575. doi: 10.1002/mc.22773. Epub 2018 Jan 5.
    • Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
    • Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, Antonarakis ES.
    • Prostate. 2018 Apr;78(5):401-407. doi: 10.1002/pros.23484. Epub 2018 Jan 25.
    • Proteomics Analysis to Assess the Role of Mitochondria in BRCA1-Mediated Breast Tumorigenesis.
    • Concolino A, Olivo E, Tammè L, Fiumara CV, De Angelis MT, Quaresima B, Agosti V, Costanzo FS, Cuda G, Scumaci D.
    • Proteomes. 2018 Mar 27;6(2). pii: E16. doi: 10.3390/proteomes6020016.
    • SYK expression level distinguishes control from BRCA1-mutated lymphocytes.
    • Zahavi T, Sonnenblick A, Shimshon Y, Kadouri L, Peretz T, Salmon AY, Salmon-Divon M.
    • Cancer Manag Res. 2018 Mar 26;10:589-598. doi: 10.2147/CMAR.S156359. eCollection 2018.
    • Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging?
    • Ben-Aharon I, Levi M, Margel D, Yerushalmi R, Rizel S, Perry S, Sharon E, Hasky N, Abir R, Fisch B, Tobar A, Shalgi R, Stemmer SM.
    • Oncotarget. 2018 Mar 23;9(22):15931-15941. doi: 10.18632/oncotarget.24638. eCollection 2018 Mar 23.
    • EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.
    • Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor ER, Toretsky JA, Stegmaier K, Lessnick SL, Chen Y, Bishop AJR.
    • Nature. 2018 Mar 15;555(7696):387-391. doi: 10.1038/nature25748. Epub 2018 Mar 7.

    Related:

    Research news:

    Ewing Sarcomas Phenocopy BRCA1-Deficient Tumors.

    • White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.
    • Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans DG, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S.
    • Ann Intern Med. 2018 Mar 6;168(5):326-334. doi: 10.7326/M17-0101. Epub 2018 Jan 16.

    Related:

    Press: Normal-tissue BRCA1 Methylation May Occur Before Birth, Raise Ovarian Cancer Risk. (Medscape/Reuters Health)

    Press: Commentary: Is This 'Provocative Finding' Related to Serous Ovarian Cancer? (Medscape Oncology)

    • White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk: A Perspective.
    • Dobrovic A.
    • Ann Intern Med. 2018 Mar 6;168(5):365-366. doi: 10.7326/M17-3340. Epub 2018 Jan 16.
    • Editorial
    • Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.
    • Martín de la Fuente L, Malander S, Hartman L, Jönsson JM, Ebbesson A, Nilbert M, Måsbäck A, Hedenfalk I.
    • Int J Gynecol Pathol. 2018 Mar;37(2):101-109. doi: 10.1097/PGP.0000000000000394.
    • MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
    • Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubiński J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Głaz A, Chenevix-Trench G, Cazorla A, Brucker SY; Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Høgdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benítez J, Pharoah PDP, Köbel M, Ramus SJ, Goode EL.
    • Mayo Clin Proc. 2018 Mar;93(3):307-320. doi: 10.1016/j.mayocp.2017.10.023.
    • p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.
    • Coates PJ, Nenutil R, Holcakova J, Nekulova M, Podhorec J, Svoboda M, Vojtesek B.
    • Virchows Arch. 2018 Mar;472(3):351-359. doi: 10.1007/s00428-018-2324-2. Epub 2018 Feb 27.
    • A20 Constitutional methylation of BRCA1 gene in breast cancer.
    • Prajzendanc K, Kaczmarek K, Łukomska A, Sukiennicki G, Szwiec M, Huzarski T, Wojdacz TK, Lubiński J, Jakubowska A.
    • Hered Cancer Clin Pract. 2018 Feb 28;16(Suppl 1):A20. Meeting abstracts from Clinical Genetics of Cancer 2017; Szczecin, Poland. 21-22 September 2017. doi: 10.1186/s13053-018-0087-z.
    • Conference abstract
    • Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer - an observational study.
    • Isfoss BL, Holmqvist B, Sand E, Forsell J, Jernström H, Olsson H.
    • BMC Cancer. 2018 Feb 27;18(1):230. doi: 10.1186/s12885-018-4151-x.
    • Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy.
    • Banda K, Swisher EM, Wu D, Pritchard CC, Gadi VK.
    • JCO Precis Oncol. 2018 Nov [2018 Feb 14];2:1-6. doi: 10.1200/PO.17.00044.

    Related:

    Commentary:

    Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum.

    • Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum.
    • Ganesan S.
    • JCO Precis Oncol. 2018 Nov [2018 Feb 14];2:1-4. doi: 10.1200/PO.18.00001.

    Related:

    Case report:

    Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy.

    Case report:

    Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer.

    Original research:

    Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.

    • Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    • Ibrahim M, Yadav S, Ogunleye F, Zakalik D.
    • BMC Cancer. 2018 Feb 13;18(1):179. doi: 10.1186/s12885-018-4098-y.
    • BARD1 is necessary for ubiquitylation of nucleosomal histone H2A and for transcriptional regulation of estrogen metabolism genes.
    • Stewart MD, Zelin E, Dhall A, Walsh T, Upadhyay E, Corn JE, Chatterjee C, King MC, Klevit RE.
    • Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1316-1321. doi: 10.1073/pnas.1715467115. Epub 2018 Jan 24.
    • Negative regulation of BRCA1 by transforming acidic coiled-coil protein 3 (TACC3).
    • Kim JL, Ha GH, Campo L, Breuer EK.
    • Biochem Biophys Res Commun. 2018 Feb 5;496(2):633-640. doi: 10.1016/j.bbrc.2018.01.101. Epub 2018 Jan 19.
    • Genomic Analysis Using Regularized Regression in High-Grade Serous Ovarian Cancer.
    • Natanzon Y, Earp M, Cunningham JM, Kalli KR, Wang C, Armasu SM, Larson MC, Bowtell DD, Garsed DW, Fridley BL, Winham SJ, Goode EL.
    • Cancer Inform. 2018 Feb 1;17:1176935118755341. doi: 10.1177/1176935118755341. eCollection 2018.
    • BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    • Brianese RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, Barros BDF, Ferreira ENE, Formiga MNDC, de Andrade VP, de Lima VCC, Carraro DM.
    • Breast Cancer Res Treat. 2018 Feb;167(3):803-814. doi: 10.1007/s10549-017-4552-6. Epub 2017 Nov 7.
    • Expression of βV-Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia.
    • Mathew D, Wang Y, Van Arsdale A, Horwitz SB, McDaid H.
    • Int J Gynecol Cancer. 2018 Feb;28(2):363-370. doi: 10.1097/IGC.0000000000001160.
    • Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens.
    • Verma D, Agarwal K, Tudu SK.
    • Indian J Pathol Microbiol. 2018 Jan-Mar;61(1):31-38. doi: 10.4103/IJPM.IJPM_393_16.
    • Integrated microRNA and mRNA signatures in peripheral blood lymphocytes of familial epithelial ovarian cancer.
    • Dou YD, Huang T, Wang Q, Shu X, Zhao SG, Li L, Liu T, Lu G, Chan WY, Liu HB.
    • Biochem Biophys Res Commun. 2018 Jan 29;496(1):191-198. doi: 10.1016/j.bbrc.2018.01.023. Epub 2018 Jan 4.
    • DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.
    • Misenko SM, Patel DS, Her J, Bunting SF.
    • Cell Cycle. 2018;17(7):881-891. doi: 10.1080/15384101.2018.1456295. Epub 2018 May 15.
    • Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data.
    • Khiabanian H, Hirshfield KM, Goldfinger M, Bird S, Stein M, Aisner J, Toppmeyer D, Wong S, Chan N, Dhar K, Gheeya J, Vig H, Hadigol M, Pavlick D, Ansari S, Ali S, Xia B, Rodriguez-Rodriguez L, Ganesan S.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00148. Epub 2018 Jan 19.
    • Gene aberration profile of tumors of adolescent and young adult females.
    • Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, Takahashi K, Totsuka H, Ogiwara H, Hirose S, Kono K, Tamura K, Okamoto A, Kinoshita T, Kato T, Kohno T.
    • Oncotarget. 2017 Dec 29;9(5):6228-6237. doi: 10.18632/oncotarget.23765. eCollection 2018 Jan 19.
    • Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1.
    • Norris EJ, Jones WD, Surleac MD, Petrescu AJ, Destephanis D, Zhang Q, Hamadeh I, Kneisl JS, Livasy CA, Ganapathi RN, Tait DL, Ganapathi MK.
    • Gynecol Oncol Rep. 2018 Jan 17;23:41-44. doi: 10.1016/j.gore.2018.01.005. eCollection 2018 Feb.
    • Contralateral breast cancers: Independent cancers or metastases?
    • Begg CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, Ng CKY, Sakr RA, Bernstein JL, Burke KA, King TA, Piscuoglio S, Mauguen A, Orlow I, Weigelt B, Seshan VE, Morrow M, Reis-Filho JS.
    • Int J Cancer. 2018 Jan 15;142(2):347-356. doi: 10.1002/ijc.31051. Epub 2017 Sep 28.
    • A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations: a pilot study.
    • Dey S, Marino N, Bishop K, Dahlgren PN, Shendre A, Storniolo AM, He C, Tanaka H.
    • Oncotarget. 2017 Dec 29;9(3):4214-4222. doi: 10.18632/oncotarget.23767. eCollection 2018 Jan 9.
    • Proteomic Profiling of β-hCG-Induced Spheres in BRCA1 Defective Triple Negative Breast Cancer Cells.
    • Sengodan SK, Rajan A, Hemalatha SK, Nadhan R, Jaleel A, Srinivas P.
    • J Proteome Res. 2018 Jan 5;17(1):276-289. doi: 10.1021/acs.jproteome.7b00562. Epub 2017 Nov 7.
    • Antioxydation And Cell Migration Genes Are Identified as Potential Therapeutic Targets in Basal-Like and BRCA1 Mutated Breast Cancer Cell Lines.
    • Privat M, Rudewicz J, Sonnier N, Tamisier C, Ponelle-Chachuat F, Bignon YJ.
    • Int J Med Sci. 2018 Jan 1;15(1):46-58. doi: 10.7150/ijms.20508. eCollection 2018.
    • Characterization of basal-like subtype in a Danish consecutive primary breast cancer cohort.
    • Kinalis S, Nielsen FC, Talman ML, Ejlertsen B, Rossing M.
    • Acta Oncol. 2018 Jan;57(1):51-57. doi: 10.1080/0284186X.2017.1398837. Epub 2017 Nov 22.
    • Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.
    • Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Cancer Sci. 2018 Jan;109(1):166-173. doi: 10.1111/cas.13426. Epub 2017 Nov 10.
    • Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.
    • Danzinger S, Tan YY, Rudas M, Kastner MT, Weingartshofer S, Muhr D, Singer CF; kConFab Investigators.
    • Cancer Invest. 2018;36(7):378-388. doi: 10.1080/07357907.2018.1499934. Epub 2018 Aug 24.
    • BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
    • Kumar M, Sahu RK, Goyal A, Sharma S, Kaur N, Mehrotra R, Singh UR, Hedau S.
    • Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3293-3299.
    • Genetic variation in the NEIL2 DNA glycosylase gene is associated with oxidative DNA damage in BRCA2 mutation carriers.
    • Benítez-Buelga C, Baquero JM, Vaclova T, Fernández V, Martín P, Inglada-Perez L, Urioste M, Osorio A, Benítez J.
    • Oncotarget. 2017 Nov 23;8(70):114626-114636. doi: 10.18632/oncotarget.22638. eCollection 2017 Dec 29.
    • Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.
    • Roig B, Rodríguez-Balada M, Samino S, Lam EW, Guaita-Esteruelas S, Gomes AR, Correig X, Borràs J, Yanes O, Gumà J.
    • Sci Rep. 2017 Dec 19;7(1):17831. doi: 10.1038/s41598-017-17897-8.
    • Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
    • Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM.
    • Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. doi: 10.1158/1078-0432.CCR-17-1941.
    • Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
    • Gschwantler-Kaulich D, Weingartshofer S, Rappaport-Fürhauser C, Zeilinger R, Pils D, Muhr D, Braicu EI, Kastner MT, Tan YY, Semmler L, Sehouli J, Singer CF.
    • PLoS One. 2017 Dec 15;12(12):e0189641. doi: 10.1371/journal.pone.0189641. eCollection 2017.
    • Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas.
    • Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, Ru Y, Lichtenberg T, Sturtz LA, Shelley CS, Benz CC, Mills GB, Laird PW, Shriver CD, Perou CM, Olopade OI.
    • JAMA Oncol. 2017 Dec 1;3(12):1654-1662. doi: 10.1001/jamaoncol.2017.0595.

    Related:

    Letter, Comment:

    Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening.

    Letter, Reply:

    Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply.

    • Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
    • Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Toloczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf AD, Ryan A, Chudecka-Glaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubinski J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Eilber U, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, deFazio A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido Dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ.
    • JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.
    • Mechanism of tandem duplication formation in BRCA1-mutant cells.
    • Willis NA, Frock RL, Menghi F, Duffey EE, Panday A, Camacho V, Hasty EP, Liu ET, Alt FW, Scully R.
    • Nature. 2017 Nov 30;551(7682):590-595. doi: 10.1038/nature24477. Epub 2017 Nov 22.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. High-Penetrance Breast and/or Gynecologic Cancer Susceptibility Genes. BRCA1 and BRCA2. Pathology of breast cancer.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Adipokines in hereditary breast cancer patients and healthy relatives.
    • Sambiasi D, Summa S, Digennaro M, Pilato B, Paradiso A, Tommasi S.
    • Oncotarget. 2017 Sep 18;8(60):101255-101261. doi: 10.18632/oncotarget.21018. eCollection 2017 Nov 24.
    • Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer.
    • Ratajska M, Koczkowska M, Żuk M, Gorczyński A, Kuźniacka A, Stukan M, Biernat W, Limon J, Wasąg B.
    • Oncotarget. 2017 Sep 8;8(60):101325-101332. doi: 10.18632/oncotarget.20722. eCollection 2017 Nov 24.
    • The roles of pathology in targeted therapy of women with gynecologic cancers.
    • Murali R, Grisham RN, Soslow RA.
    • Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31530-5. doi: 10.1016/j.ygyno.2017.11.020. [Epub ahead of print]
    • Review
    • Increased single-strand annealing rather than non-homologous end-joining predicts hereditary ovarian carcinoma.
    • Deniz M, Romashova T, Kostezka S, Faul A, Gundelach T, Moreno-Villanueva M, Janni W, Friedl TWP, Wiesmüller L.
    • Oncotarget. 2017 Oct 9;8(58):98660-98676. doi: 10.18632/oncotarget.21720. eCollection 2017 Nov 17.
    • Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer.
    • Wang Y, Ung MH, Cantor S, Cheng C.
    • Sci Rep. 2017 Nov 16;7(1):15742. doi: 10.1038/s41598-017-16138-2.
    • VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients.
    • Schirosi L, De Summa S, Tommasi S, Paradiso A, Gasparini G, Popescu O, Simone G, Mangia A.
    • Int J Cancer. 2017 Nov 1;141(9):1901-1911. doi: 10.1002/ijc.30868. Epub 2017 Jul 20.
    • Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    • Vanderstichele A, Busschaert P, Olbrecht S, Lambrechts D, Vergote I.
    • Eur J Cancer. 2017 Nov;86:5-14. doi: 10.1016/j.ejca.2017.08.029. Epub 2017 Sep 23.
    • Combined tumor genomic profiling and exome sequencing in a breast cancer family implicates ATM in tumorigenesis: a proof of principle study.
    • Bubien V, Bonnet F, Dupiot-Chiron J, Barouk-Simonet E, Jones N, de Reynies A, MacGrogan G, Sevenet N, Letouzé E, Longy M.
    • Genes Chromosomes Cancer. 2017 Nov;56(11):788-799. doi: 10.1002/gcc.22482. Epub 2017 Aug 16.
    • Biallelic Deletion of PALB2 Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition.
    • Bhangoo MS, Costantini C, Clifford BT, Chung JH, Schrock AB, Ali SM, Klempner SJ.
    • JCO Precis Oncol. 2017 Nov;1:1-7. doi: 10.1200/PO.17.00043.
    • High grade serous ovarian carcinomas originate in the fallopian tube.
    • Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE.
    • Nat Commun. 2017 Oct 23;8(1):1093. doi: 10.1038/s41467-017-00962-1.
    • Roles of BCCIP deficiency in mammary tumorigenesis.
    • Droz-Rosario R, Lu H, Liu J, Liu NA, Ganesan S, Xia B, Haffty BG, Shen Z.
    • Breast Cancer Res. 2017 Oct 18;19(1):115. doi: 10.1186/s13058-017-0907-5.
    • Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families.
    • Pouliot MC, Kothari C, Joly-Beauparlant C, Labrie Y, Ouellette G, Simard J, Droit A, Durocher F.
    • Oncotarget. 2017 Aug 12;8(45):78691-78712. doi: 10.18632/oncotarget.20219. eCollection 2017 Oct 3.
    • Hypoxia-induced factor-1 alpha, vascular endothelial growth factor expression in BRCA1-related breast cancer: A prospective study in tertiary care hospital.
    • Sharma M, Piplani S, Madan M, Manjari M, Garg S, Kaur K.
    • Indian J Pathol Microbiol. 2017 Oct-Dec;60(4):469-474. doi: 10.4103/IJPM.IJPM_524_16.
    • Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
    • Ha SM, Chae EY, Cha JH, Kim HH, Shin HJ, Choi WJ.
    • AJR Am J Roentgenol. 2017 Oct;209(4):920-928. doi: 10.2214/AJR.16.16957. Epub 2017 Aug 10.
    • BRCA related breast cancer and sporadic tumors: same prognosis or survivorship bias?
    • Ballatore Z, Bracci R, Bianchi F, Maccaroni E, Belvederesi L, Brugiati C, Murrone A, Pagliaretta S, Pistelli M, Berardi R.
    • Ann Oncol. 2017 Oct;28 Suppl 6:vi28. doi: 10.1093/annonc/mdx424.011.
    • BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
    • Tacconi EM, Lai X, Folio C, Porru M, Zonderland G, Badie S, Michl J, Sechi I, Rogier M, Matía García V, Batra AS, Rueda OM, Bouwman P, Jonkers J, Ryan A, Reina-San-Martin B, Hui J, Tang N, Bruna A, Biroccio A, Tarsounas M.
    • EMBO Mol Med. 2017 Oct;9(10):1398-1414. doi: 10.15252/emmm.201607446.

    Related:

    Research report, Commentary:

    Thwarting endogenous stress: BRCA protects against aldehyde toxicity.

    • Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis.
    • Kobayashi H, Ogawa K, Kawahara N, Iwai K, Niiro E, Morioka S, Yamada Y.
    • Free Radic Res. 2017 Oct;51(9-10):755-764. doi: 10.1080/10715762.2017.1383605. Epub 2017 Oct 11.
    • P53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer.
    • Wang X, El-Halaby AA, Zhang H, Yang Q, Laughlin TS, Rothberg PG, Skinner K, Hicks DG.
    • Hum Pathol. 2017 Oct;68:22-25. doi: 10.1016/j.humpath.2017.04.007. Epub 2017 Apr 21.
    • Breast cancer genetics in young women: What do we know?
    • Gómez-Flores-Ramos L, Álvarez-Gómez RM, Villarreal-Garza C, Wegman-Ostrosky T, Mohar A.
    • Mutat Res. 2017 Oct;774:33-45. doi: 10.1016/j.mrrev.2017.08.001. Epub 2017 Aug 25.
    • Review
    • A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
    • Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A, Maruvka YE, Leshchiner I, Lander ES, Golub TR, Zick A, Orthwein A, Lawrence MS, Batra RN, Caldas C, Haber DA, Laird PW, Shen H, Ellisen LW, D'Andrea AD, Chanock SJ, Foulkes WD, Getz G.
    • Nat Genet. 2017 Oct;49(10):1476-1486. doi: 10.1038/ng.3934. Epub 2017 Aug 21.
    • miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.
    • Fkih M'hamed I, Privat M, Trimeche M, Penault-Llorca F, Bignon YJ, Kenani A.
    • Pathol Oncol Res. 2017 Oct;23(4):815-827. doi: 10.1007/s12253-017-0188-4. Epub 2017 Jan 18.
    • Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients.
    • Jeong HM, Kim RN, Kwon MJ, Oh E, Han J, Lee SK, Choi JS, Park S, Nam SJ, Gong GY, Nam JW, Choi DH, Lee H, Nam BH, Choi YL, Shin YK.
    • Oncotarget. 2017 Jun 27;8(37):61538-61550. doi: 10.18632/oncotarget.18618. eCollection 2017 Sep 22.
    • BRCA2 carriers with male breast cancer show elevated tumour methylation.
    • Deb S, Gorringe KL, Pang JB, Byrne DJ, Takano EA, Investigators K, Dobrovic A, Fox SB.
    • BMC Cancer. 2017 Sep 11;17(1):641. doi: 10.1186/s12885-017-3632-7.
    • BRCA1 regulation on β-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.
    • Sengodan SK, Nadhan R, Nair RS, Hemalatha SK, Somasundaram V, Sushama RR, Rajan A, Latha NR, Varghese GR, Thankappan RK, Kumar JM, Chil A, Anilkumar TV, Srinivas P.
    • Oncogenesis. 2017 Sep 4;6(9):e376. doi: 10.1038/oncsis.2017.75.
    • BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays.
    • Mahmoud AM, Macias V, Al-Alem U, Deaton RJ, Kadjaksy-Balla A, Gann PH, Rauscher GH.
    • PLoS One. 2017 Sep 1;12(9):e0184385. doi: 10.1371/journal.pone.0184385. eCollection 2017.
    • Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-grade Ovarian Carcinoma.
    • Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza AM, Sun JX, Robillard L, Maloney L, Bowtell DDL, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin K, Scott CL.
    • Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

    Related:

    Review:

    Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.

    • Elevated Serum Level of CA125 Is a Biomarker That Can Be Used to Alter Prognosis Determined by BRCA Mutation and Family History in Ovarian Cancer.
    • Liu W, Wang Z, Ma J, Hou Y, Zhao J, Dong B, Tu S, Wang L, Guo Y.
    • Genet Test Mol Biomarkers. 2017 Sep;21(9):547-554. doi: 10.1089/gtmb.2017.0104. Epub 2017 Aug 11.
    • High-grade serous carcinoma of tubo-ovarian origin: recent developments.
    • Singh N, McCluggage WG, Gilks CB.
    • Histopathology. 2017 Sep;71(3):339-356. doi: 10.1111/his.13248. Epub 2017 Jul 18.
    • Review
    • LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.
    • Schmoeckel E, Odai-Afotey AA, Schleißheimer M, Rottmann M, Flesken-Nikitin A, Ellenson LH, Kirchner T, Mayr D, Nikitin AY.
    • Mod Pathol. 2017 Sep;30(9):1241-1250. doi: 10.1038/modpathol.2017.53. Epub 2017 Jun 30.
    • TGFbeta and miRNA regulation in familial and sporadic breast cancer.
    • Danza K, Summa S, Pinto R, Pilato B, Palumbo O, Carella M, Popescu O, Digennaro M, Lacalamita R, Tommasi S.
    • Oncotarget. 2017 Jan 30;8(31):50715-50723. doi: 10.18632/oncotarget.14899. eCollection 2017 Aug 1.
    • Telomere Length Is Predictive of Breast Cancer Risk in BRCA2 Mutation Carriers.
    • Thorvaldsdottir B, Aradottir M, Stefansson OA, Bodvarsdottir SK, Eyfjörd JE.
    • Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1248-1254. doi: 10.1158/1055-9965.EPI-16-0946. Epub 2017 Feb 24.
    • A novel Ubc9 -dependent pathway regulates SIRT1- ER-α Axis and BRCA1-associated TNBC lung metastasis.
    • Xu J, Shumate C, Qin Y, Reddy V, Burnam Y, Lopez V, Okoli J, P Reddy ES, Rao VN.
    • Integr Mol Med. 2017 Aug;4(4). doi: 10.15761/IMM.1000298. Epub 2017 Jul 28.
    321. s
    • NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
    • Mangia A, Scarpi E, Partipilo G, Schirosi L, Opinto G, Giotta F, Simone G.
    • Oncotarget. 2017 Jul 22;8(39):65730-65742. doi: 10.18632/oncotarget.19444. eCollection 2017 Sep 12.
    • Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    • Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, Knight JA, Hsu L, Concannon P, Mellemkjær L, Tischkowitz M, Haile RW, Shen R, Malone KE, Woods M, Liang X, Morrow M, Bernstein JL; WECARE Study Collaborative Group.
    • Breast Cancer Res. 2017 Jul 19;19(1):83. doi: 10.1186/s13058-017-0874-x.
    • Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
    • Li B, Ní Chonghaile T, Fan Y, Madden S, Klinger R, O'Connor AE, Walsh L, O'Hurley G, Mallya Udupi G, Joseph J, Tarrant F, Conroy E, Gaber A, Chin SF, Bardwell HA, Provenzano E, Crown J, Dubois T, Linn SC, Jirstrom K, Caldas C, O'Connor D, Gallagher WM.
    • Cancer Res. 2017 Jul 15;77(14):3834-3845. doi: 10.1158/0008-5472.CAN-16-2546. Epub 2017 Apr 28.
    • Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
    • Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M.
    • Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul.
    • Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
    • Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, Yelensky R, Spencer SK, Robertson JD, Ho TW, Fielding A, Ledermann JA, Barrett JC.
    • Oncotarget. 2017 Jul 4;8(27):43653-43661. doi: 10.18632/oncotarget.17613.

    Related:

    Research news:

    Olaparib and somatic BRCA mutations.

    • Targeting reactive nitrogen species suppresses hereditary pancreatic cancer.
    • Li M, Chen Q, Ma T, Yu X.
    • Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7106-7111. doi: 10.1073/pnas.1702156114. Epub 2017 Jun 19.
    • Assessment of Breast Cancer Risk Factors Reveals Subtype Heterogeneity.
    • Holm J, Eriksson L, Ploner A, Eriksson M, Rantalainen M, Li J, Hall P, Czene K.
    • Cancer Res. 2017 Jul 1;77(13):3708-3717. doi: 10.1158/0008-5472.CAN-16-2574. Epub 2017 May 16.
    • The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing.
    • Lang GT, Shi JX, Hu X, Zhang CH, Shan L, Song CG, Zhuang ZG, Cao AY, Ling H, Yu KD, Shan L, Sun MH, Zhou XY, Huang W, Shao ZM.
    • Int J Cancer. 2017 Jul 1;141(1):129-142. doi: 10.1002/ijc.30692. Epub 2017 Apr 25.
    • Single-base LOH can be used as Specific Marker to Classify BRCAx Familial Breast Cancer into More Homogenous Subtypes.
    • Downs B, Xiao F, Kim YC, Chen PX, Huang D, Fleissner EA, Cowan K, Wang SM.
    • Breast J. 2017 Jul;23(4):479-481. doi: 10.1111/tbj.12777. Epub 2017 Jan 24.
    • Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    • Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW.
    • Eur Urol. 2017 Jul;72(1):34-42. doi: 10.1016/j.eururo.2017.02.023. Epub 2017 Mar 1.
    • Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
    • Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Gao J, Chakravarty D, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MTA, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, Taylor BS, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers CL, Schultz N, Scher HI.
    • JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00029. Epub 2017 May 31.
    • MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    • Chen LL, Zhang ZJ, Yi ZB, Li JJ.
    • Br J Cancer. 2017 Jun 27;117(1):78-88. doi: 10.1038/bjc.2017.150. Epub 2017 Jun 1.
    • BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.
    • Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS.
    • Oncotarget. 2017 Jun 20;8(25):39945-39962. doi: 10.18632/oncotarget.18098.

    Related:

    News:

    New perspectives for colorectal cancer.

    • Rotating night work, lifestyle factors, obesity and promoter methylation in BRCA1 and BRCA2 genes among nurses and midwives.
    • Peplonska B, Bukowska A, Wieczorek E, Przybek M, Zienolddiny S, Reszka E.
    • PLoS One. 2017 Jun 8;12(6):e0178792. doi: 10.1371/journal.pone.0178792. eCollection 2017.
    • Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.
    • Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, Dushyanthen S, Mansour M, Pang JB, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Perou CM, Visvader JE, Gray DHD, Loi S, Lindeman GJ.
    • Sci Transl Med. 2017 Jun 7;9(393). pii: eaal4922. doi: 10.1126/scitranslmed.aal4922.
    • DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.
    • De Gregoriis G, Ramos JA, Fernandes PV, Vignal GM, Brianese RC, Carraro DM, Monteiro AN, Struchiner C, Suarez-Kurtz G, Vianna-Jorge R, de Carvalho MA.
    • Cancer Biol Ther. 2017 Jun 3;18(6):439-449. doi: 10.1080/15384047.2017.1323590. Epub 2017 May 5.
    • Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
    • Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, Ferretti V, Grant RC, Lungu IM, Costello E, Greenhalf W, Palmer D, Ghaneh P, Neoptolemos JP, Buchler M, Petersen G, Thayer S, Hollingsworth MA, Sherker A, Durocher D, Dhani N, Hedley D, Serra S, Pollett A, Roehrl MH, Bavi P, Bartlett JM, Cleary S, Wilson JM, Alexandrov LB, Moore M, Wouters BG, McPherson JD, Notta F, Stein LD, Gallinger S.
    • JAMA Oncol. 2017 Jun 1;3(6):774-783. doi: 10.1001/jamaoncol.2016.3916.
    • Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.
    • Mutter RW, Riaz N, Ng CK, Delsite R, Piscuoglio S, Edelweiss M, Martelotto LG, Sakr RA, King TA, Giri DD, Drobnjak M, Brogi E, Bindra R, Bernheim G, Lim RS, Blecua P, Desrichard A, Higginson D, Towers R, Jiang R, Lee W, Weigelt B, Reis-Filho JS, Powell SN.
    • J Pathol. 2017 Jun;242(2):165-177. doi: 10.1002/path.4890. Epub 2017 Apr 27.
    • Non-BRCA familial breast cancer: review of reported pathology and molecular findings.
    • Keeney MG, Couch FJ, Visscher DW, Lindor NM.
    • Pathology. 2017 Jun;49(4):363-370. doi: 10.1016/j.pathol.2017.03.002. Epub 2017 Apr 24.
    • BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    • Vos S, Moelans CB, van Diest PJ.
    • Breast Cancer Res. 2017 May 31;19(1):64. doi: 10.1186/s13058-017-0856-z.
    • BRCA1 controls the cell division axis and governs ploidy and phenotype in human mammary cells.
    • He Z, Kannan N, Nemirovsky O, Chen H, Connell M, Taylor B, Jiang J, Pilarski LM, Fleisch MC, Niederacher D, Pujana MA, Eaves CJ, Maxwell CA.
    • Oncotarget. 2017 May 16;8(20):32461-32475. doi: 10.18632/oncotarget.15688.
    • The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    • Bogan D, Meile L, El Bastawisy A, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM.
    • BMC Cancer. 2017 May 12;17(1):329. doi: 10.1186/s12885-017-3283-8.
    • [Hereditary breast and ovarian cancer].
    • Lax SF.
    • Pathologe. 2017 May;38(3):149-155. doi: 10.1007/s00292-017-0298-5.
    • Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.
    • Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller MD, Ferretti E, Benedetti Panici P.
    • Tumour Biol. 2017 May;39(5):1010428317695525. doi: 10.1177/1010428317695525.
    • Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.
    • Krüger K, Wik E, Knutsvik G, Nalwoga H, Klingen TA, Arnes JB, Chen Y, Mannelqvist M, Dimitrakopoulou K, Stefansson IM, Birkeland E, Aas T, Tobin NP, Jonassen I, Bergh J, Foulkes WD, Akslen LA.
    • Sci Rep. 2017 Apr 24;7(1):1089. doi: 10.1038/s41598-017-00862-w.
    • Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
    • Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL.
    • J Clin Oncol. 2017 Apr 20;35(12):1274-1280. doi: 10.1200/JCO.2016.70.4627. Epub 2017 Feb 13.
    • Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
    • Heublein S, Mayr D, Meindl A, Kircher A, Jeschke U, Ditsch N.
    • J Exp Clin Cancer Res. 2017 Apr 20;36(1):57. doi: 10.1186/s13046-017-0517-1.
    • Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.
    • Begg CB, Rice MS, Zabor EC, Tworoger SS.
    • Br J Cancer. 2017 Apr 11;116(8):1088-1091. doi: 10.1038/bjc.2017.73. Epub 2017 Mar 23.
    • Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
    • Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL.
    • Cancer Prev Res (Phila). 2017 Apr;10(4):255-266. doi: 10.1158/1940-6207.CAPR-16-0281. Epub 2017 Mar 6.
    • BRCA1 allele-specific expression in genetic predisposed breast/ovarian cancer.
    • Jamard E, Volard B, Dugué AE, Legros A, Leconte A, Clarisse B, Davy G, Polycarpe F, Dugast C, Abadie C, Frebourg T, Tinat J, Tennevet I, Layet V, Joly F, Castéra L, Berthet P, Vaur D, Krieger S.
    • Fam Cancer. 2017 Apr;16(2):167-171. doi: 10.1007/s10689-016-9940-2.
    • HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
    • Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S.
    • Nat Med. 2017 Apr;23(4):517-525. doi: 10.1038/nm.4292. Epub 2017 Mar 13.
    • Transactivation of the estrogen receptor promoter by BRCA1.
    • Archey WB, Arrick BA.
    • Cancer Cell Int. 2017 Mar 2;17:33. doi: 10.1186/s12935-017-0401-2. eCollection 2017.
    • Intratumor heterogeneity of homologous recombination deficiency in primary breast cancer.
    • von Wahlde MK, Timms KM, Chagpar AB, Wali VB, Jiang T, Bossuyt V, Saglam O, Reid JE, Gutin A, Neff C, Lanchbury JS, Hatzis C, Hofstatter E, Pustzai L.
    • Clin Cancer Res. 2017 Mar 1;23(5):1193-1199. doi: 10.1158/1078-0432.CCR-16-0889. Epub 2016 Sep 6.
    • BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency.
    • Lips EH, Debipersad R, Scheerman CE, Mulder L, Sonke GS, van der Kolk LE, Wesseling J, Hogervorst FB, Nederlof PM.
    • Clin Cancer Res. 2017 Mar 1;23(5):1236-1241. doi: 10.1158/1078-0432.CCR-16-0198. Epub 2016 Sep 12.
    • The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
    • Hjortkjær M, Waldstrøm M, Jakobsen A, Kanstrup H, Søgaard-Andersen E, Dahl Steffensen K.
    • Int J Gynecol Pathol. 2017 Mar;36(2):180-189. doi: 10.1097/PGP.0000000000000310.
    • Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
    • Heerma van Voss MR, Brilliant JD, Vesuna F, Bol GM, van der Wall E, van Diest PJ, Raman V.
    • Med Oncol. 2017 Mar;34(3):33. doi: 10.1007/s12032-017-0889-2. Epub 2017 Jan 30.
    • Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.
    • Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Van Damme T, De Nobele S, Perletti G, De Leeneer K, Claes KB, Vral A.
    • Oncol Rep. 2017 Mar;37(3):1379-1386. doi: 10.3892/or.2017.5407. Epub 2017 Jan 25.
    • BRCA1 promoter methylation in peripheral blood cells and predisposition to breast cancer.
    • Al-Moghrabi NM.
    • J Taibah Univ Med Sci. 2017 Feb 22;12(3):189-193. doi: 10.1016/j.jtumed.2017.01.004. eCollection 2017 Jun.
    • Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies.
    • Azzollini J, Pesenti C, Ferrari L, Fontana L, Calvello M, Peissel B, Portera G, Tabano S, Carcangiu ML, Riva P, Miozzo M, Manoukian S.
    • PLoS One. 2017 Feb 15;12(2):e0171663. doi: 10.1371/journal.pone.0171663. eCollection 2017.
    • Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    • Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X.
    • J Ovarian Res. 2017 Feb 10;10(1):9. doi: 10.1186/s13048-017-0304-9.
    • DNA Methylation in Breast Tumor from High-risk Women in the Breast Cancer Family Registry.
    • Wu HC, Southey MC, Hibshoosh H, Santella RM, Terry MB.
    • Anticancer Res. 2017 Feb;37(2):659-664.
    • Pathogenesis and heterogeneity of ovarian cancer.
    • Kroeger PT Jr, Drapkin R.
    • Curr Opin Obstet Gynecol. 2017 Feb;29(1):26-34. doi: 10.1097/GCO.0000000000000340.
    • Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
    • Rzepecka IK, Szafron LM, Stys A, Felisiak-Golabek A, Podgorska A, Timorek A, Sobiczewski P, Pienkowska-Grela B, El-Bahrawy M, Kupryjanczyk J.
    • Gynecol Oncol. 2017 Feb;144(2):369-376. doi: 10.1016/j.ygyno.2016.11.028. Epub 2016 Dec 7.
    • Role of Fallopian Tubes in the Development of Ovarian Cancer.
    • Corzo C, Iniesta MD, Patrono MG, Lu KH, Ramirez PT.
    • J Minim Invasive Gynecol. 2017 Feb;24(2):230-234. doi: 10.1016/j.jmig.2016.12.007. Epub 2016 Dec 19.
    • Review
    • Germline large genomic alterations on 7q in patients with multiple primary cancers.
    • Villacis RA, Basso TR, Canto LM, Nóbrega AF, Achatz MI, Rogatto SR.
    • Sci Rep. 2017 Jan 31;7:41677. doi: 10.1038/srep41677.
    • Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer.
    • Felicio PS, Melendez ME, Arantes LM, Kerr LM, Carraro DM, Grasel RS, Campacci N, Scapulatempo-Neto C, Fernandes GC, de Carvalho AC, Palmero EI.
    • Oncotarget. 2017 Jan 10;8(2):2850-2862. doi: 10.18632/oncotarget.13750.
    • Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
    • Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG.
    • Nat Commun. 2017 Jan 9;8:13671. doi: 10.1038/ncomms13671.

    Related:

    Research News:

    Prostate cancer: Genomic drivers of BRCA2-mutant tumours.

    • The fate of BRCA1-related germline mutations in triple-negative breast tumors.
    • Kotoula V, Fostira F, Papadopoulou K, Apostolou P, Tsolaki E, Lazaridis G, Manoussou K, Zagouri F, Pectasides D, Vlachos I, Tikas I, Lakis S, Konstantopoulou I, Pentheroudakis G, Gogas H, Papakostas P, Christodoulou C, Bafaloukos D, Razis E, Karavasilis V, Bamias C, Yannoukakos D, Fountzilas G.
    • Am J Cancer Res. 2017 Jan 1;7(1):98-114. eCollection 2017.
    • Male Breast Cancer.
    • Serdy KM, Leone JP, Dabbs DJ, Bhargava R.
    • Am J Clin Pathol. 2017 Jan 1;147(1):110-119. doi: 10.1093/ajcp/aqw207.
    • Genomic LOH May Predict Rucaparib Response in Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2017 Jan;7(1):OF8. doi: 10.1158/2159-8290.CD-RW2016-230. Epub 2016 Dec 9.
    • Research News
    • Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.
    • Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J.
    • J Hum Genet. 2017 Jan;62(1):15-24. doi: 10.1038/jhg.2016.89. Epub 2016 Jul 21.
    • Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family.
    • Geyer FC, Berman SH, Marchiò C, Burke KA, Guerini-Rocco E, Piscuoglio S, Ng CK, Pareja F, Wen HY, Hodi Z, Schnitt SJ, Rakha EA, Ellis IO, Norton L, Weigelt B, Reis-Filho JS.
    • Mod Pathol. 2017 Jan;30(1):69-84. doi: 10.1038/modpathol.2016.161. Epub 2016 Oct 7.
    • Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.
    • Arora A, Parvathaneni S, Aleskandarany MA, Agarwal D, Ali R, Abdel-Fatah TM, Green AR, Ball GR, Rakha EA, Ellis IO, Sharma S, Madhusudan S.
    • Mol Cancer Ther. 2017 Jan;16(1):239-250. doi: 10.1158/1535-7163.MCT-16-0290. Epub 2016 Nov 11.
    • Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications.
    • Agboola AO, Ebili HO, Iyawe VO, Banjo AA, Salami BA, Rakha EA, Nolan CC, Ellis IO, Green AR.
    • Pathol Res Pract. 2017 Jan;213(1):27-33. doi: 10.1016/j.prp.2016.10.005. Epub 2016 Oct 25.
    • MicroRNA in breast cancer: The association with BRCA1/2.
    • Nina P, Radoslav D, Vladan B, Milan O, Esma IR.
    • Cancer Biomark. 2017;19(2):119-128. doi: 10.3233/CBM-160319.
    • Review
    • CpG methylation of APC promoter 1A in sporadic and familial breast cancer patients.
    • Debouki-Joudi S, Trifa F, Khabir A, Sellami-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R.
    • Cancer Biomark. 2017;18(2):133-141. doi: 10.3233/CBM-160005.
    • Molecular analysis of BRCA1 and BRCA2 genes by next generation sequencing and ultrastructural aspects of breast tumor tissue.
    • Mihalcea CE, Moroşanu AM, Murăraşu D, Puiu L, Cinca SA, Voinea SC, Mirancea N.
    • Rom J Morphol Embryol. 2017;58(2):445-455.
    • Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    • Odén L, Akbari M, Zaman T, Singer CF, Sun P, Narod SA, Salmena L, Kotsopoulos J.
    • Oncotarget. 2016 Dec 27;7(52):86687-86694. doi: 10.18632/oncotarget.13417.
    • Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
    • Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, Győrffy B, Lifton RP, Symmans WF, Pusztai L, Hatzis C.
    • PLoS Med. 2016 Dec 13;13(12):e1002193. doi: 10.1371/journal.pmed.1002193. eCollection 2016.
    • Methylation Analysis of BRCA1 and APC in Breast Cancer and It's Relationship to Clinicopathological Features.
    • Shakeri H, Fakhrjou A, Nikanfar A, Mohaddes-Ardebili SM.
    • Clin Lab. 2016 Dec 1;62(12):2333-2337. doi: 10.7754/Clin.Lab.2016.160418.
    • BRCA1 expression in benign and malignant breast lesions.
    • Fernández Á, Reigosa A.
    • Invest Clin. 2016 Dec;57(4):330-51.
    • Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry.
    • Scott CM, Joo JE, O'Callaghan N, Buchanan DD, Clendenning M, Giles GG, Hopper JL, Wong EM, Southey MC.
    • PLoS One. 2016 Nov 30;11(11):e0165436. doi: 10.1371/journal.pone.0165436. eCollection 2016.
    • Tumor characteristics and prognosis in familial breast cancer.
    • Arpino G, Pensabene M, Condello C, Ruocco R, Cerillo I, Lauria R, Forestieri V, Giuliano M, De Angelis C, Montella M, Crispo A, De Placido S.
    • BMC Cancer. 2016 Nov 29;16(1):924.
    • FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort.
    • Johnson J, Choi M, Dadmanesh F, Han B, Qu Y, Yu-Rice Y, Zhang X, Bagaria S, Taylor C, Giuliano AE, Amersi F, Cui X.
    • Oncotarget. 2016 Nov 15;7(46):75729-75738. doi: 10.18632/oncotarget.12370.
    • Blood-based DNA methylation as biomarker for breast cancer: a systematic review.
    • Tang Q, Cheng J, Cao X, Surowy H, Burwinkel B.
    • Clin Epigenetics. 2016 Nov 14;8:115. eCollection 2016.
    • Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.
    • Rebbeck TR, Friebel TM, Mitra N, Wan F, Chen S, Andrulis IL, Apostolou P, Arnold N, Arun BK, Barrowdale D, Benitez J, Berger R, Berthet P, Borg A, Buys SS, Caldes T, Carter J, Chiquette J, Claes KB, Couch FJ, Cybulski C, Daly MB, de la Hoya M, Diez O, Domchek SM, Nathanson KL, Durda K, Ellis S; EMBRACE, Evans DG, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Glendon G, Godwin AK, Greene MH, Gronwald J, Hahnen E, Hallberg E, Hamann U, Hansen TV; HEBON, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska-Bieniek K, John EM, Karlan BY, Kaufman B, Investigators K, Kwong A, Laitman Y, Lasset C, Lazaro C, Lester J, Loman N, Lubinski J, Manoukian S, Mitchell G, Montagna M, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Offit K, Olah E, Olopade OI, Park SK, Piedmonte M, Radice P, Rappaport-Fuerhauser C, Rookus MA, Seynaeve C, Simard J, Singer CF, Soucy P, Southey M, Stoppa-Lyonnet D, Sukiennicki G, Szabo CI, Tancredi M, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Toland AE, Toloczko-Grabarek A, Tung N, van Rensburg EJ, Villano D, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Zidan J, Zorn KK, McGuffog L, Easton D, Chenevix-Trench G, Antoniou AC, Ramus SJ.
    • Breast Cancer Res. 2016 Nov 11;18(1):112.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: BRCA2 and PALB2 mutation

    • Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers.
    • Rizzolo P, Navazio AS, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Scarnò M, Tommasi S, Palli D, Ottini L.
    • Oncotarget. 2016 Nov 8;7(45):74097-74106. doi: 10.18632/oncotarget.12272.
    • Utilizing fluorescent life time imaging microscopy technology for identify carriers of BRCA2 mutation.
    • Zahavi T, Yahav G, Shimshon Y, Gershanov S, Kaduri L, Sonneblick A, Fixler D, Salmon AY, Salmon-Divon M.
    • Biochem Biophys Res Commun. 2016 Nov 4;480(1):36-41. doi: 10.1016/j.bbrc.2016.10.013. Epub 2016 Oct 6.
    • Disease evolution and heterogeneity in bilateral breast cancer.
    • Fountzilas E, Kotoula V, Zagouri F, Giannoulatou E, Kouvatseas G, Pentheroudakis G, Koletsa T, Bobos M, Papadopoulou K, Samantas E, Demiri E, Miliaras S, Christodoulou C, Chrisafi S, Razis E, Fostira F, Pectasides D, Zografos G, Fountzilas G.
    • Am J Cancer Res. 2016 Nov 1;6(11):2611-2630. eCollection 2016.
    • EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations.
    • Navazio AS, Rizzolo P, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Tommasi S, Palli D, Ottini L.
    • Breast Cancer Res Treat. 2016 Nov;160(1):181-186. doi: 10.1007/s10549-016-3976-8. Epub 2016 Sep 15.
    • A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
    • Dong F, Davineni PK, Howitt BE, Beck AH.
    • Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1511-1516. Epub 2016 Aug 5.
    • Prognostic impact of total and tyrosine phosphorylated GIV/Girdin in breast cancers.
    • Dunkel Y, Diao K, Aznar N, Swanson L, Liu L, Zhu W, Mi X, Ghosh P.
    • FASEB J. 2016 Nov;30(11):3702-3713. Epub 2016 Jul 20.
    • In vitro model for DNA double-strand break repair analysis in breast cancer reveals cell type-specific associations with age and prognosis.
    • Deniz M, Kaufmann J, Stahl A, Gundelach T, Janni W, Hoffmann I, Keimling M, Hampp S, Ihle M, Wiesmüller L.
    • FASEB J. 2016 Nov;30(11):3786-3799. Epub 2016 Aug 5.
    • Analysis of alternative lengthening of telomere markers in BRCA1 defective cells.
    • Kargaran PK, Yasaei H, Anjomani-Virmouni S, Mangiapane G, Slijepcevic P.
    • Genes Chromosomes Cancer. 2016 Nov;55(11):864-76. doi: 10.1002/gcc.22386. Epub 2016 Jul 26.
    • Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma.
    • Morse CB, Norquist BM, Harrell MI, Agnew KJ, Gray HJ, Urban RR, Garcia RL, Goff BA, Swisher EM.
    • Gynecol Oncol. 2016 Nov;143(2):389-392. doi: 10.1016/j.ygyno.2016.08.324. Epub 2016 Aug 27.
    • Non-Neoplastic Conditions of the Ovaries in Grossly Normal Adnexa: A Clinicopathologic Study of 403 Completely Embedded Cases.
    • Seidman JD, Krishnan J.
    • Int J Gynecol Pathol. 2016 Nov;35(6):544-548.
    • Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets.
    • Chen S, Cavazza E, Barlier C, Salleron J, Filhine-Tresarrieu P, Gavoilles C, Merlin JL, Harlé A.
    • Oncol Lett. 2016 Nov;12(5):3264-3272. Epub 2016 Sep 2.
    • Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
    • Domagala P, Hybiak J, Rys J, Byrski T, Cybulski C, Lubinski J.
    • Oncotarget. 2016 Oct 18;7(42):68662-68673. doi: 10.18632/oncotarget.11900.
    • Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis.
    • Lo PK, Zhang Y, Wolfson B, Gernapudi R, Yao Y, Duru N, Zhou Q.
    • Oncotarget. 2016 Oct 4;7(40):65067-65089. doi: 10.18632/oncotarget.11364.
    • Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
    • Muranen TA, Blomqvist C, Dörk T, Jakubowska A, Heikkilä P, Fagerholm R, Greco D, Aittomäki K, Bojesen SE, Shah M, Dunning AM, Rhenius V, Hall P, Czene K, Brand JS, Darabi H, Chang-Claude J, Rudolph A, Nordestgaard BG, Couch FJ, Hart SN, Figueroa J, García-Closas M, Fasching PA, Beckmann MW, Li J, Liu J, Andrulis IL, Winqvist R, Pylkäs K, Mannermaa A, Kataja V, Lindblom A, Margolin S, Lubinski J, Dubrowinskaja N, Bolla MK, Dennis J, Michailidou K, Wang Q, Easton DF, Pharoah PD, Schmidt MK, Nevanlinna H.
    • Breast Cancer Res. 2016 Oct 3;18(1):98. doi: 10.1186/s13058-016-0758-5.
    • BRCA2 Mutations in Prostate Cancer Assort Into Cluster Regions.
    • Patel VL, Busch E, D'Amico AV, Rebbeck TR.
    • Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E569-E570. doi: 10.1016/j.ijrobp.2016.06.2054.
    • Conference abstract
    • Unfurling the Genetic Map of Sarcomas.
    • [No authors listed]
    • Cancer Discov. 2016 Oct;6(10):1073-1074. Epub 2016 Aug 23.
    • News
    • Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients.
    • Jung J, Kang E, Gwak JM, Seo AN, Park SY, Lee AS, Baek H, Chae S, Kim EK, Kim SW.
    • Curr Oncol. 2016 Oct;23(5):298-303. Epub 2016 Oct 25.
    • Genetic landscape of a case of extraovarian peritoneal serous papillary carcinoma.
    • Cheng Z, Yang W, Guo J, Luo N, Chen L, Xie Y, Qu X, Hu L, Dai H, Zuo X.
    • Oncol Lett. 2016 Oct;12(4):2395-2402. Epub 2016 Aug 2.
    • Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.
    • Warmoes M, Lam SW, der Groep PV, Jaspers JE, Smolders YH, de Boer L, Pham TV, Piersma SR, Rottenberg S, Boven E, Jonkers J, van Diest PJ, Jimenez CR.
    • Oncotarget. 2016 Sep 27;7(39):63537-63548. doi: 10.18632/oncotarget.11535.
    • The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review.
    • Lu YM, Cheng F, Teng LS.
    • Sci Rep. 2016 Sep 13;6:32723. doi: 10.1038/srep32723.
    • The association of PTEN hypermethylation and breast cancer: a meta-analysis.
    • Luo S, Chen J, Mo X.
    • An investigation of the association of genetic susceptibility risk with somatic mutation burden in breast cancer.
    • Zhu B, Mukherjee A, Machiela MJ, Song L, Hua X, Shi J, Garcia-Closas M, Chanock SJ, Chatterjee N.
    • Br J Cancer. 2016 Sep 6;115(6):752-60. doi: 10.1038/bjc.2016.223. Epub 2016 Jul 28.
    • Intratumor heterogeneity of homologous recombination deficiency in primary breast cancer.
    • von Wahlde MK, Timms KM, Chagpar AB, Wali VB, Jiang T, Bossuyt V, Saglam O, Reid JE, Gutin A, Neff C, Lanchbury JS, Hatzis C, Hofstatter E, Pustzai L.
    • Clin Cancer Res. 2016 Sep 6. pii: clincanres.0889.2016. [Epub ahead of print]
    • [BRCA1 and BRCA2 - pathologists starting kit].
    • Škapa P.
    • Cesk Patol. 2016 Fall;52(4):193-196.
    • [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    • Škapa P, Dundr P.
    • Cesk Patol. 2016 Fall;52(4):199-204.
    • Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-grade Serous Carcinoma: A Review of the Evidence.
    • Sherman M, Drapkin R, Horowitz NS, Crum CP, Friedman S, Kwon J, Levine DA, Shih IM, Shoupe D, Swisher EM, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, Minasian L.
    • Cancer Prev Res (Phila). 2016 Sep;9(9):713-20. doi: 10.1158/1940-6207.CAPR-15-0384. Epub 2016 May 24.
    • Review
    • Incidental Serous Tubal Intraepithelial Carcinoma and Non-Neoplastic Conditions of the Fallopian Tubes in Grossly Normal Adnexa: A Clinicopathologic Study of 388 Completely Embedded Cases.
    • Seidman JD, Krishnan J, Yemelyanova A, Vang R.
    • Int J Gynecol Pathol. 2016 Sep;35(5):423-429.
    • DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-grade Serous Ovarian Cancer.
    • Klinkebiel D1, Zhang W2, Akers SN3, Odunsi K4, Karpf AR5.
    • Mol Cancer Res. 2016 Sep;14(9):787-94. doi: 10.1158/1541-7786.MCR-16-0097. Epub 2016 Jun 3.
    • Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.
    • Warmoes M, Lam SW, der Groep PV, Jaspers JE, Smolders YH, de Boer L, Pham TV, Piersma SR, Rottenberg S, Boven E, Jonkers J, van Diest PJ, Jimenez CR.
    • Oncotarget. 2016 Aug 23. doi: 10.18632/oncotarget.11535. [Epub ahead of print]
    • Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.
    • Chehade R, Pettapiece-Phillips R, Salmena L, Kotlyar M, Jurisica I, Narod SA, Akbari MR, Kotsopoulos J.
    • Breast Cancer Res. 2016 Aug 17;18(1):87. doi: 10.1186/s13058-016-0739-8.
    • Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: Evidence for metformin-based "starvation" strategies in BRCA1 carriers.
    • Cuyàs E, Fernández-Arroyo S, Alarcón T, Lupu R, Joven J, Menendez JA.
    • Oncotarget. 2016 Aug 16;7(33):52974-52992. doi: 10.18632/oncotarget.9732.
    • BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
    • Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J.
    • J Clin Invest. 2016 Aug 1;126(8):2903-18. doi: 10.1172/JCI70196. Epub 2016 Jul 25.

    Related:

    Editorial / Commentary

    BRCA1 loses the ring but lords over resistance.

    • RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
    • Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N.
    • J Clin Invest. 2016 Aug 1;126(8):3145-57. doi: 10.1172/JCI87033. Epub 2016 Jul 25.

    Related:

    Editorial / Commentary

    BRCA1 loses the ring but lords over resistance.

    • DNA Repair Gene Expression Levels as Indicators of Breast Cancer in the Breast Cancer Family Registry.
    • Kappil MA, Liao Y, Terry MB, Santella RM.
    • Anticancer Res. 2016 Aug;36(8):4039-44.
    • Molecular Testing in Breast Cancer: A Guide to Current Practices.
    • Hagemann IS.
    • Arch Pathol Lab Med. 2016 Aug;140(8):815-24. doi: 10.5858/arpa.2016-0051-RA.
    • Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
    • Alshareeda AT, Negm OH, Aleskandarany MA, Green AR, Nolan C, TigHhe PJ, Madhusudan S, Ellis IO, Rakha EA.
    • Breast Cancer Res Treat. 2016 Aug;159(1):41-53. doi: 10.1007/s10549-016-3915-8. Epub 2016 Jul 27.
    • Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.
    • Hellner K, Miranda F, Fotso Chedom D, Herrero-Gonzalez S, Hayden DM, Tearle R, Artibani M, KaramiNejadRanjbar M, Williams R, Gaitskell K, Elorbany S, Xu R, Laios A, Buiga P, Ahmed K, Dhar S, Zhang RY, Campo L, Myers KA, Lozano M, Ruiz-Miró M, Gatius S, Mota A, Moreno-Bueno G, Matias-Guiu X, Benítez J, Witty L, McVean G, Leedham S, Tomlinson I, Drmanac R, Cazier JB, Klein R, Dunne K, Bast RC Jr, Kennedy SH, Hassan B, Lise S, Garcia MJ, Peters BA, Yau C, Sauka-Spengler T, Ahmed AA.
    • EBioMedicine. 2016 Aug;10:137-49. doi: 10.1016/j.ebiom.2016.06.048. Epub 2016 Jul 2.
    • Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
    • Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM.
    • Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):893-905. doi: 10.1586/17474124.2016.1153424. Epub 2016 Feb 26.
    • Review
    • Tumour cell membrane laminin expression is associated with basal-like phenotype and poor survival in Nigerian breast cancer.
    • Agboola AO, Ebili HO, Iyawe VO, Banjo AA, Salami BS, Rakha EA, Nolan C, Ellis IO, Green AR.
    • Malays J Pathol. 2016 Aug;38(2):83-92.
    • Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.
    • Ritterhouse LL, Nowak JA, Strickland KC, Garcia EP, Jia Y, Lindeman NI, Macconaill LE, Konstantinopoulos PA, Matulonis UA, Liu J, Berkowitz RS, Nucci MR, Crum CP, Sholl LM, Howitt BE.
    • Mod Pathol. 2016 Aug;29(8):893-903. doi: 10.1038/modpathol.2016.82. Epub 2016 May 6.
    • Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.
    • Daniels SL, Burghel GJ, Chambers P, Al-Baba S, Connley DD, Brock IW, Cramp HE, Dotsenko O, Wilks O, Wyld L, Cross SS, Cox A
    • PLoS One. 2016 Jul 27;11(7):e0160174. doi: 10.1371/journal.pone.0160174.
    • Synchronous Onset of Breast and Pancreatic Cancers: Results of Germline and Somatic Genetic Analysis.
    • Castro M, Vierkoetter K, Prager D, Montgomery S, Sedgwick K.
    • Case Rep Oncol. 2016 Jul 21;9(2):387-394.
    • Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients.
    • Obermeier K, Sachsenweger J, Friedl TW, Pospiech H, Winqvist R, Wiesmüller L.
    • Oncogene. 2016 Jul 21;35(29):3796-806. doi: 10.1038/onc.2015.448. Epub 2015 Dec 7.
    • Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer Patients.
    • Zimmermann MT, Jiang G, Wang C.
    • AMIA Jt Summits Transl Sci Proc. 2016 Jul 20;2016:94-100. eCollection 2016.
    • Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
    • Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, Le Guillou M, Perrault de Jotemps M, Chauvet MP, Chaouat M, Pujol P, Feunteun J, Delaloge S, Forgez P, Gompel A.
    • Oncotarget. 2016 Jul 19;7(29):45317-45330. doi: 10.18632/oncotarget.9638.
    • Persistent Activation of NF-κB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage.
    • Sau A, Lau R, Cabrita MA, Nolan E, Crooks PA, Visvader JE, Pratt MA.
    • Cell Stem Cell. 2016 Jul 7;19(1):52-65. doi: 10.1016/j.stem.2016.05.003. Epub 2016 Jun 9.
    • Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice.
    • Dong A, Lu Y, Lu B.
    • J Cancer. 2016 Jul 5;7(11):1441-51. doi: 10.7150/jca.15556. eCollection 2016.
    • Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.
    • Gargiulo P, Pensabene M, Milano M, Arpino G, Giuliano M, Forestieri V, Condello C, Lauria R, De Placido S.
    • BMC Cancer. 2016 Jul 4;16(1):375.
    • RANKL/RANK control Brca1 mutation-driven mammary tumors.
    • Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, Kozieradzki I, Schramek D, Edokobi N, Hersl J, Sampson A, Odai-Afotey A, Lazaro C, Gonzalez-Suarez E, Pujana MA, Cimba F, Heyn H, Vidal E, Cruickshank J, Berman H, Sarao R, Ticevic M, Uribesalgo I, Tortola L, Rao S, Tan Y, Pfeiler G, Lee EY, Bago-Horvath Z, Kenner L, Popper H, Singer C, Khokha R, Jones LP, Penninger JM.
    • Cell Res. 2016 Jul;26(7):761-74. doi: 10.1038/cr.2016.69. Epub 2016 May 31.

    Related:

    Prevention of breast cancer by RANKL/RANK blockade.

    • Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.
    • Casey MJ, Colanta AB.
    • Fam Cancer. 2016 Jul;15(3):371-84. doi: 10.1007/s10689-016-9878-4.
    • Review
    • Assessing the genetic architecture of epithelial ovarian cancer histological subtypes.
    • Cuellar-Partida G, Lu Y, Dixon SC; Australian Ovarian Cancer Study, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty JA, Rossing MA, Chang-Claude J, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Høgdall E, Høgdall C, Jensen A, Giles GG, Bruinsma F, Kjaer SK, Hildebrandt MA, Liang D, Lu KH, Wu X, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Stampfer M, Missmer S, Bjorge L, Salvesen HB, Kopperud RK, Bischof K, Aben KK, Kiemeney LA, Massuger LF, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Blake Gilks C, Gronwald J, Jakubowska A, Lubiński J, Kluz T, Song H, Tyrer JP, Wentzensen N, Brinton L, Trabert B, Lissowska J, McLaughlin JR, Narod SA, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Campbell I, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Wu AH, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham JM, Fridley BL, Winham SJ, Bandera EV, Poole EM, Morgan TK, Goode EL, Schildkraut JM, Pearce CL, Berchuck A, Pharoah PD, Webb PM, Chenevix-Trench G, Risch HA, MacGregor S.
    • Hum Genet. 2016 Jul;135(7):741-56. doi: 10.1007/s00439-016-1663-9. Epub 2016 Apr 13.
    • Association Between BRCA Status and P53 Status in Breast Cancer: A Meta-Analysis.
    • Peng L, Xu T, Long T, Zuo H.
    • Med Sci Monit. 2016 Jun 8;22:1939-45.
    • When Genome Maintenance Goes Badly Awry.
    • Kass EM, Moynahan ME, Jasin M.
    • Mol Cell. 2016 Jun 2;62(5):777-87. doi: 10.1016/j.molcel.2016.05.021.
    • Review
    • BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.
    • Xu J, Footman A, Qin Y, Aysola K, Black S, Reddy V, Singh K, Grizzle W, You S, Moellering D, Reddy ES, Fu Y, Rao VN.
    • Int J Chronic Dis Ther. [2016 Jun;]2(3):31-38. Epub 2016 Jun 23.
    • Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development.
    • Malmberg K, Klynning C, Flöter-Rådestad A, Carlson JW.
    • Virchows Arch. 2016 Jun;468(6):707-13. doi: 10.1007/s00428-016-1928-7. Epub 2016 Mar 22.
    • Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
    • Wen WX, Soo JS, Kwan PY, Hong E, Khang TF, Mariapun S, Lee CS, Hasan SN, Rajadurai P, Yip CH, Mohd Taib NA, Teo SH.
    • Breast Cancer Res. 2016 May 27;18(1):56. doi: 10.1186/s13058-016-0717-1.
    • Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
    • Somasundaram V, Hemalatha SK, Pal K, Sinha S, Nair AS, Mukhopadhyay D, Srinivas P.
    • BMC Cancer. 2016 May 26;16(1):336. doi: 10.1186/s12885-016-2372-4.
    • Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution.
    • Bartlett TE, Chindera K, McDermott J, Breeze CE, Cooke WR, Jones A, Reisel D, Karegodar ST, Arora R, Beck S, Menon U, Dubeau L, Widschwendter M.
    • Nat Commun. 2016 May 24;7:11620. doi: 10.1038/ncomms11620.
    • Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.
    • Pellegrino B, Bella M, Michiara M, Zanelli P, Naldi N, Porzio R, Bortesi B, Boggiani D, Zanoni D, Camisa R, Neri TM, Pinto C, Musolino A.
    • Acta Biomed. 2016 May 6;87(1):54-63.
    • Profiling of Cross-Functional Peptidases Regulated Circulating Peptides in BRCA1 Mutant Breast Cancer.
    • Fan J, Tea MK, Yang C, Ma L, Meng QH, Hu TY, Singer CF, Ferrari M.
    • J Proteome Res. 2016 May 6;15(5):1534-45. doi: 10.1021/acs.jproteome.6b00010. Epub 2016 Apr 26.
    • Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.
    • Decker B, Karyadi DM, Davis BW, Karlins E, Tillmans LS, Stanford JL, Thibodeau SN, Ostrander EA.
    • Am J Hum Genet. 2016 May 5;98(5):818-829. doi: 10.1016/j.ajhg.2016.03.003. Epub 2016 Apr 14.
    • Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression.
    • Templeton AJ, Gonzalez LD, Vera-Badillo FE, Tibau A, Goldstein R, Šeruga B, Srikanthan A, Pandiella A, Amir E, Ocana A.
    • PLoS One. 2016 May 5;11(5):e0154789. doi: 10.1371/journal.pone.0154789. eCollection 2016.
    • Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers.
    • Benitez-Buelga C, Vaclová T, Ferreira S, Urioste M, Inglada-Perez L, Soberón N, Blasco MA, Osorio A, Benitez J.
    • Oncotarget. 2016 May 3;7(18):25815-25. doi: 10.18632/oncotarget.8272.
    • Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention.
    • George SH, Garcia R, Slomovitz BM.
    • Front Oncol. 2016 May 2;6:108. doi: 10.3389/fonc.2016.00108. eCollection 2016.
    • The topography of mutational processes in breast cancer genomes.
    • Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H, Staaf J, Sieuwerts AM, Brinkman AB, Martin S, Ramakrishna M, Butler A, Kim HY, Borg Å, Sotiriou C, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Sale J, Rada C, Stratton MR, Birney E, Nik-Zainal S.
    • Nat Commun. 2016 May 2;7:11383. doi: 10.1038/ncomms11383.
    • Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
    • Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.
    • Nature. 2016 May 2;534(7605):47-54. doi: 10.1038/nature17676.

    Related:

    News: Breast cancer mutation map could aid personalised treatment (PHG Foundation)

    Press: Scientists say they now have a near-perfect picture of the genetic events that cause breast cancer. (BBC.com)

    Press: Personalized Breast Cancer Treatment Gets Closer to Reality (Time.com)

    • Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
    • De Picciotto N, Cacheux W, Roth A, Chappuis PO, Labidi-Galy SI.
    • Crit Rev Oncol Hematol. 2016 May;101:50-9. doi: 10.1016/j.critrevonc.2016.02.014. Epub 2016 Feb 27.
    • Male breast cancer is not congruent with the female disease.
    • Fentiman IS.
    • Crit Rev Oncol Hematol. 2016 May;101:119-24. doi: 10.1016/j.critrevonc.2016.02.017. Epub 2016 Feb 27.
    • PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    • Webb JR, Milne K, Kroeger DR, Nelson BH.
    • Gynecol Oncol. 2016 May;141(2):293-302. doi: 10.1016/j.ygyno.2016.03.008. Epub 2016 Mar 16.
    • Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients.
    • Jouhadi H, Tazzite A, Azeddoug H, Naim A, Nadifi S, Benider A.
    • BMC Res Notes. 2016 Apr 29;9(1):248. doi: 10.1186/s13104-016-2057-8.
    • Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.
    • Korlimarla A, Prabhu JS, Remacle J, Rajarajan S, Raja U, C E A, Srinath BS, Manjunath S, K S G, Correa M, M S N P, Sridhar TS.
    • PLoS One. 2016 Apr 14;11(4):e0153113. doi: 10.1371/journal.pone.0153113. eCollection 2016.
    • A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.
    • Buckley NE, Haddock P, De Matos Simoes R, Parkes E, Irwin G, Emmert-Streib F, McQuaid S, Kennedy R, Mullan P.
    • Oncotarget. 2016 Apr 12;7(15):19884-96. doi: 10.18632/oncotarget.7865.
    • MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
    • Matamala N, Vargas MT, González-Cámpora R, Arias JI, Menéndez P, Andrés-León E, Yanowsky K, Llaneza-Folgueras A, Miñambres R, Martínez-Delgado B, Benítez J.
    • Oncotarget. 2016 Apr 12;7(15):20068-79. doi: 10.18632/oncotarget.7705.
    • Small RNA sequencing reveals a comprehensive miRNA signature of BRCA1-associated high-grade serous ovarian cancer.
    • Brouwer J, Kluiver J, de Almeida RC, Modderman R, Terpstra MM, Kok K, Withoff S, Hollema H, Reitsma W, de Bock GH, Mourits MJ, van den Berg A.
    • J Clin Pathol. 2016 Apr 5. pii: jclinpath-2016-203679. doi: 10.1136/jclinpath-2016-203679. [Epub ahead of print]
    • The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications.
    • Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J.
    • Arch Gynecol Obstet. 2016 Apr;293(4):695-700. doi: 10.1007/s00404-016-4035-8. Epub 2016 Feb 19.
    • Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer.
    • Murria Estal R, Palanca Suela S, de Juan Jiménez I, Alenda Gonzalez C, Egoavil Rojas C, García-Casado Z, López Guerrero JA, Juan Fita MJ, Sánchez Heras AB, Segura Huerta Á, Santaballa Bertrán A, Chirivella González I, Llop García M, Pérez Simó G, Barragán González E, Bolufer Gilabert P.
    • Fam Cancer. 2016 Apr;15(2):193-200. doi: 10.1007/s10689-015-9864-2.
    • Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
    • Thike AA, Tan PH, Ikeda M, Iqbal J.
    • Histopathology. 2016 Apr;68(5):702-12. doi: 10.1111/his.12801. Epub 2015 Nov 2.
    • Relationship between Caffeine and Levels of DNA Repair and Oxidative Stress in Women with and without a BRCA1 Mutation.
    • Nikitina D, Chen Z, Vallis K, Poll A, Ainsworth P, Narod SA, Kotsopoulos J.
    • J Nutrigenet Nutrigenomics. 2015 [2016 Apr;]8(4-6):174-84. doi: 10.1159/000439110. Epub 2015 Dec 16.
    • Genomic profiling of male breast cancer.
    • Burki TK.
    • Lancet Oncol. 2016 Apr;17(4):e141. doi: 10.1016/S1470-2045(16)00179-0. Epub 2016 Mar 18.
    • News
    • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    • Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA.
    • Oncotarget. 2016 Mar 22;7(12):13587-98. doi: 10.18632/oncotarget.7277.
    • Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer.
    • Li D, Wu QJ, Bi FF, Chen SL, Zhou YM, Zhao Y, Yang Q.
    • Am J Transl Res. 2016 Mar 15;8(3):1601-8. eCollection 2016.
    • Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
    • Alvarez C, Aravena A, Tapia T, Rozenblum E, Solís L, Corvalán A, Camus M, Alvarez M, Munroe D, Maass A, Carvallo P.
    • BMC Cancer. 2016 Mar 15;16(1):219. doi: 10.1186/s12885-016-2261-x.
    • Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility.
    • Piccolo SR, Hoffman LM, Conner T, Shrestha G, Cohen AL, Marks JR, Neumayer LA, Agarwal CA, Beckerle MC, Andrulis IL, Spira AE, Moos PJ, Buys SS, Johnson WE, Bild AH.
    • Mol Syst Biol. 2016 Mar 10;12(3):860. doi: 10.15252/msb.20156506.
    • BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer.
    • Sedic M, Kuperwasser C.
    • Cell Cycle. 2016 Mar 3;15(5):621-7. doi: 10.1080/15384101.2016.1141841.
    • Mutation Screening of BRCA Genes in 10 Iranian Males with Breast Cancer.
    • Zorrieh Zahra A, Kadkhoda S, Behjati F, Aghakhani Moghaddam F, Badiei A, Sirati F, Afshin Alavi H, Atri M, Omranipour R, Keyhani E.
    • Int J Mol Cell Med. 2016 Spring;5(2):114-22. Epub 2016 May 9.
    • Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.
    • Hussein YR, Ducie JA, Arnold AG, Kauff ND, Vargas-Alvarez HA, Sala E, Levine DA, Soslow RA.
    • Am J Surg Pathol. 2016 Mar;40(3):404-9. doi: 10.1097/PAS.0000000000000556.
    • Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
    • Chay WY, McCluggage WG, Lee CH, Köbel M, Irving J, Millar J, Gilks CB, Tinker AV.
    • Int J Gynecol Cancer. 2016 Mar;26(3):431-6. doi: 10.1097/IGC.0000000000000639.
    • Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.
    • Tung N, Garber JE, Hacker MR, Torous V, Freeman GJ, Poles E, Rodig S, Alexander B, Lee L, Collins LC, Schnitt SJ.
    • NPJ Breast Cancer. 2016 Feb 24;2:16002. doi: 10.1038/npjbcancer.2016.2. eCollection 2016.
    • PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.
    • Pharoah PD, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, Alsop K; Australian Ovarian Cancer Study Group, Bogdanova N, Cicek MS, Cunningham JM, Fridley BL, Gentry-Maharaj A, Hillemanns P, Lele S, Lester J, McGuire V, Moysich KB, Poblete S, Sieh W, Sucheston-Campbell L, Widschwendter M; Ovarian Cancer Association Consortium, Whittemore AS, Dörk T, Menon U, Odunsi K, Goode EL, Karlan BY, Bowtell DD, Gayther SA, Ramus SJ.
    • J Natl Cancer Inst. 2016 Jan 27;108(3). pii: djv347. doi: 10.1093/jnci/djv347. Print 2016 Mar.
    • BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.
    • Madaras L, Balint N, Gyorffy B, Tokes AM, Barshack I, Yosepovich A, Friedman E, Paluch-Shimon S, Zippel D, Baghy K, Timar J, Kovalszky I, Kulka J, Szasz AM.
    • Pathobiology. [2016 Mar;]83(1):1-12. doi: 10.1159/000439135. Epub 2015 Nov 14.
    • Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.
    • Tung N, Garber JE, Hacker MR, Torous V, Freeman GJ, Poles E, Rodig S, Alexander B, Lee L, Collins LC, Schnitt SJ.
    • NPJ Breast Cancer. 2016 Feb 24;2:16002. doi: 10.1038/npjbcancer.2016.2. eCollection 2016.
    • Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    • Podo F, Santoro F, Di Leo G, Manoukian S, de Giacomi C, Corcione S, Cortesi L, Carbonaro LA, Trimboli RM, Cilotti A, Preda L, Bonanni B, Pensabene M, Martincich L, Savarese A, Contegiacomo A, Sardanelli F.
    • Clin Cancer Res. 2016 Feb 15;22(4):895-904. doi: 10.1158/1078-0432.CCR-15-0459. Epub 2015 Oct 26.
    • Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas.
    • Manié E, Popova T, Battistella A, Tarabeux J, Caux-Moncoutier V, Golmard L, Smith NK, Mueller CR, Mariani O, Sigal-Zafrani B, Dubois T, Vincent-Salomon A, Houdayer C, Stoppa-Lyonnet D, Stern MH.
    • Int J Cancer. 2016 Feb 15;138(4):891-900. doi: 10.1002/ijc.29829. Epub 2015 Sep 24.
    • Autoantibodies directed to centromere protein F in a patient with BRCA1 gene mutation.
    • Moghaddas F, Joshua F, Taylor R, Fritzler MJ, Toh BH.
    • BMC Res Notes. 2016 Feb 11;9(1):84. doi: 10.1186/s13104-016-1908-7.
    • Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
    • Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim SW; kConFab Investigators, Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, Balmaña J, Diez O, Ivady G, Papp J, Olah E, Kwong A; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Nevanlinna H, Aittomäki K, Perez Segura P, Caldes T, Van Maerken T, Poppe B, Claes KB, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, Eeles R, Ellis S; EMBRACE, Hamann U, Garber J, Fostira F, Fountzilas G, Pasini B, Giannini G, Rizzolo P, Russo A, Cortesi L, Papi L, Varesco L, Palli D, Zanna I, Savarese A, Radice P, Manoukian S, Peissel B, Barile M, Bonanni B, Viel A, Pensotti V, Tommasi S, Peterlongo P, Weitzel JN, Osorio A, Benitez J, McGuffog L, Healey S, Gerdes AM, Ejlertsen B, Hansen TV, Steele L, Ding YC, Tung N, Janavicius R, Goldgar DE, Buys SS, Daly MB, Bane A, Terry MB, John EM, Southey M, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L.
    • Breast Cancer Res. 2016 Feb 9;18(1):15. doi: 10.1186/s13058-016-0671-y.

    Related:

    Blog post: New insights into the role of gender in breast cancer development. (Oh Medicine)

    • Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.
    • Evans DG, Lalloo F, Howell S, Verhoef S, Woodward ER, Howell A.
    • Breast Cancer Res Treat. 2016 Feb;155(3):597-601. doi: 10.1007/s10549-016-3697-z. Epub 2016 Feb 18.
    • CAF-like state in primary skin fibroblasts with constitutional BRCA1 epimutation sheds new light on tumor suppressor deficiency-related changes in healthy tissue.
    • Etzold A, Galetzka D, Weis E, Bartsch O, Haaf T, Spix C, Itzel T, Schweiger S, Strand D, Strand S, Zechner U.
    • Epigenetics. 2016 Feb;11(2):120-31. doi: 10.1080/15592294.2016.1140295. Epub 2016 Mar 7.
    • BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities in vitro and in vivo.
    • Uziel O, Yerushalmi R, Zuriano L, Naser S, Beery E, Nordenberg J, Lubin I, Adel Y, Shepshelovich D, Yavin H, Ben Aharon I, Pery S, Rizel S, Pasmanik-Chor M, Frumkin D, Lahav M.
    • Oncotarget. 2016 Jan 19;7(3):2433-54. doi: 10.18632/oncotarget.5693.
    • miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
    • Zavala V, Pérez-Moreno E, Tapia T, Camus M, Carvallo P.
    • Cancer Biomark. 2016 Jan 18;16(1):99-107. doi: 10.3233/CBM-150545.
    • Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
    • Nomura H, Kataoka F, Aoki D, Jinno H, Kitagawa Y, Sato Y, Womack C, Wombwell H, Hodgson D, O'Connor M, Harbron C, Yin X.
    • Cancer Biomark. 2016 Jan 18;16(1):145-52. doi: 10.3233/CBM-150550.
    • DNA Methylation and microRNA patterns are in association with the expression of BRCA1 in ovarian cancer.
    • Shariati-Kohbanani M, Zare-Bidaki M, Taghavi MM, Taghipour Z, Shabanizadeh A, Kennedy D, Dahim H, Salahshoor MR, Jalili C, Kazemi Arababadi M.
    • Cell Mol Biol (Noisy-le-grand). 2016 Jan 11;62(1):16-23.
    • Review
    • It's Totally Tubular…Riding The New Wave of Ovarian Cancer Research.
    • Perets R, Drapkin R.
    • Cancer Res. 2016 Jan 1;76(1):10-7. doi: 10.1158/0008-5472.CAN-15-1382. Epub 2015 Dec 15.
    • Review
    • Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients.
    • Partipilo G, Simone G, Scattone A, Scarpi E, Azzariti A, Mangia A.
    • Int J Cancer. 2016 Jan 1;138(1):110-20. doi: 10.1002/ijc.29699. Epub 2015 Aug 6.
    • Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
    • Branham MT, Campoy E, Laurito S, Branham R, Urrutia G, Orozco J, Gago F, Urrutia R, Roqué M.
    • Breast Cancer Res Treat. 2016 Jan;155(1):13-23. doi: 10.1007/s10549-015-3648-0. Epub 2015 Nov 27.
    • Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression.
    • Pettapiece-Phillips R, Kotlyar M, Chehade R, Salmena L, Narod SA, Akbari M, Jurisica I, Kotsopoulos J.
    • Cancer Prev Res (Phila). 2016 Jan;9(1):83-8. doi: 10.1158/1940-6207.CAPR-15-0291. Epub 2015 Nov 2.
    • The cancer genetics and pathology of male breast cancer.
    • Deb S, Lakhani SR, Ottini L, Fox SB.
    • Histopathology. 2016 Jan;68(1):110-8. doi: 10.1111/his.12862.
    • BRCA2 gene mutations and coagulation-associated biomarkers.
    • Perez-Segura P, Zamorano-León JJ, Acosta D, Santos-Sancho JM, Modrego J, Caldés T, de la Hoya M, Díaz-Rubio E, Díaz-Millán I, de Las Heras N, Rico Zalba LA, Lahera V, Melander O, López Farré A.
    • Thromb Haemost. 2016 Jan;115(2):415-23. doi: 10.1160/TH15-06-0520. Epub 2015 Oct 8.
    • BRCA1 Gene Mutations and Influence of Chemotherapy on Autophagy and Apoptotic Mechanisms in Egyptian Breast Cancer Patients.
    • Abdel-Mohsen MA, Ahmed OA, El-Kerm YM.
    • Asian Pac J Cancer Prev. 2016;17(3):1285-92.
    • Evaluation of expression profiles of microRNAs and two target genes, FOXO3a and RUNX2, effectively supports diagnostics and therapy predictions in breast cancer.
    • Jurkovicova D, Magyerkova M, Sestakova Z, Copakova L, Bella V, Konecny M, Krivjanska M, Kulcsar L, Chovanec M.
    • Neoplasma. 2016;63(6):941-951.
    • 3'UTR shortening and EGF signaling: implications for breast cancer.
    • Akman HB, Oyken M, Tuncer T, Can T, Erson-Bensan AE.
    • Hum Mol Genet. 2015 Dec 15;24(24):6910-20. doi: 10.1093/hmg/ddv391. Epub 2015 Sep 22.
    • Meta-Analysis
    • Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency.
    • Kovac M, Blattmann C, Ribi S, Smida J, Mueller NS, Engert F, Castro-Giner F, Weischenfeldt J, Kovacova M, Krieg A, Andreou D, Tunn PU, Dürr HR, Rechl H, Schaser KD, Melcher I, Burdach S, Kulozik A, Specht K, Heinimann K, Fulda S, Bielack S, Jundt G, Tomlinson I, Korbel JO, Nathrath M, Baumhoer D.
    • Nat Commun. 2015 Dec 3;6:8940. doi: 10.1038/ncomms9940.
    • Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    • Yamashita N, Tokunaga E, Kitao H, Hitchins M, Inoue Y, Tanaka K, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Oda Y, Saeki H, Oki E, Maehara Y.
    • Clin Breast Cancer. 2015 Dec;15(6):498-504. doi: 10.1016/j.clbc.2015.06.009. Epub 2015 Jun 18.
    • BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    • de Juan I, Palanca S, Domenech A, Feliubadaló L, Segura Á, Osorio A, Chirivella I, de la Hoya M, Sánchez AB, Infante M, Tena I, Díez O, Garcia-Casado Z, Vega A, Teulé À, Barroso A, Pérez P, Durán M, Carrasco E, Juan-Fita MJ, Murria R, Llop M, Barragan E, Izquierdo Á, Benítez J, Caldés T, Salas D, Bolufer P.
    • Fam Cancer. 2015 Dec;14(4):505-13. doi: 10.1007/s10689-015-9814-z.
    • Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer.
    • Biesma HD, Schouten PC, Lacle MM, Sanders J, Brugman W, Kerkhoven R, Mandjes I, van der Groep P, van Diest PJ, Linn SC.
    • Genes Chromosomes Cancer. 2015 Dec;54(12):734-44. doi: 10.1002/gcc.22284. Epub 2015 Sep 10.
    • Decreased Expression of BRCA2 Accelerates Sporadic Breast Cancer Progression.
    • Saha S, Mandal P, Ganguly S, Jana D, Ayaz A, Banerjee A, Chouhan R, Sarkar DK.
    • Indian J Surg Oncol. 2015 Dec;6(4):378-83. doi: 10.1007/s13193-015-0449-1. Epub 2015 Aug 21.
    • Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
    • Massink MP, Kooi IE, Martens JW, Waisfisz Q, Meijers-Heijboer H.
    • BMC Cancer. 2015 Nov 9;15:877. doi: 10.1186/s12885-015-1880-y.
    • First description of a sporadic breast cancer in a woman with BRCA1 germline mutation.
    • Curtit E, Benhamo V, Gruel N, Popova T, Manie E, Cottu P, Mariani O, Stoppa-Lyonnet D, Pivot X, Stern MH, Vincent-Salomon A.
    • Oncotarget. 2015 Nov 3;6(34):35616-24. doi: 10.18632/oncotarget.5348.
    • Next-Generation Sequencing of Tubal Intraepithelial Carcinomas.
    • McDaniel AS, Stall JN, Hovelson DH, Cani AK, Liu CJ, Tomlins SA, Cho KR.
    • JAMA Oncol. 2015 Nov 1;1(8):1128-1132. doi: 10.1001/jamaoncol.2015.1618.
    • BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.
    • Mohanty SK, Lai JP, Gordon OK, Pradhan D, Bose S, Dadmanesh F.
    • Breast J. 2015 Nov;21(6):596-603. doi: 10.1111/tbj.12494. Epub 2015 Sep 22.
    • Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer: A meta-analysis.
    • Guo T, Ren Y, Wang B, Huang Y, Jia S, Tang W, Luo Y.
    • Mol Clin Oncol. 2015 Nov;3(6):1353-1360. Epub 2015 Aug 11.
    • Lipid and Metabolite Deregulation in BRCA1 and BRCA2 Genetic Mutations.
    • Stanwell P, Gluch L.
    • Radiology. 2015 Nov;277(2):614-5. doi: 10.1148/radiol.2015151153.
    • Comment, Letter

    Related:

    Lipid and Metabolite Deregulation in the Breast Tissue of Women Carrying BRCA1 and BRCA2 Genetic Mutations.

    • DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.
    • Yang RL, Mick R, Lee K, Graves HL, Nathanson KL, Domchek SM, Kelz RR, Zhang PJ, Czerniecki BJ.
    • J Transl Med. 2015 Oct 24;13(1):335. doi: 10.1186/s12967-015-0698-3.
    • miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
    • Vos S, Vesuna F, Raman V, van Diest PJ, van der Groep P.
    • Oncotarget. 2015 Oct 13;6(31):32115-37. doi: 10.18632/oncotarget.5617.
    • High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.
    • Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B.
    • Cancer. 2015 Oct 1;121(19):3422-3427. doi: 10.1002/cncr.29572. Epub 2015 Aug 17.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: HR-low-positive tumors. Treat as TNBC?

    • BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression.
    • Wiener D, Gajardo-Meneses P, Ortega-Hernández V, Herrera-Cares C, Díaz S, Fernández W, Cornejo V, Gamboa J, Tapia T, Alvarez C, Carvallo P.
    • Breast Cancer Res Treat. 2015 Oct;153(3):669-78. doi: 10.1007/s10549-015-3575-0. Epub 2015 Sep 22.
    • MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers.
    • Maresca L, Spugnesi L, Lodovichi S, Cozzani C, Naccarato AG, Tancredi M, Collavoli A, Falaschi E, Rossetti E, Aretini P, Cervelli T, Galli A, Caligo MA.
    • Eur J Med Genet. 2015 Oct;58(10):531-9. doi: 10.1016/j.ejmg.2015.09.005. Epub 2015 Sep 14.
    • BRCAness in endometrial cancer.
    • Stephan JM, Cohen E, Gonzalez J.
    • Gynecologic Oncology. 2015 Oct;139(1):188. 2015 WAGO ABSTRACTS. doi: 10.1016/j.ygyno.2015.07.044.
    • Conference abstract
    • Loss of heterozygosity in non-traditional cancers occurring in BRCA1 and BRCA2 mutation carriers.
    • McIlwain C, Norquist B, Bernards S, Agnew K, Swisher E.
    • Gynecologic Oncology. 2015 Oct;139(1):200. 2015 WAGO ABSTRACTS. doi: 10.1016/j.ygyno.2015.07.075.
    • Conference abstract
    • BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
    • Severson TM, Peeters J, Majewski I, Michaut M, Bosma A, Schouten PC, Chin SF, Pereira B, Goldgraben MA, Bismeijer T, Kluin RJ, Muris JJ, Jirström K, Kerkhoven RM, Wessels L, Caldas C, Bernards R, Simon IM, Linn S.
    • Mol Oncol. 2015 Oct;9(8):1528-38. doi: 10.1016/j.molonc.2015.04.011. Epub 2015 May 7.
    • A network-based approach to identify disease-associated gene modules through integrating DNA methylation and gene expression.
    • Zhang Y, Zhang J, Liu Z, Liu Y, Tuo S.
    • Biochem Biophys Res Commun. 2015 Sep 25;465(3):437-42. doi: 10.1016/j.bbrc.2015.08.033. Epub 2015 Aug 14.
    • Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes.
    • Cochran RL, Cidado J, Kim M, Zabransky DJ, Croessmann S, Chu D, Wong HY, Beaver JA, Cravero K, Erlanger B, Parsons H, Heaphy CM, Meeker AK, Lauring J, Park BH.
    • Oncotarget. 2015 Sep 22;6(28):25240-51. doi: 10.18632/oncotarget.4595.
    • Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
    • Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, Dubeau L, Cline M, Pan Y, Yi PC, Gareth Evans D, Jacobs IJ, Menon U, Wood CE, Dougall WC.
    • EBioMedicine. 2015 Sep 9;2(10):1331-9. doi: 10.1016/j.ebiom.2015.08.037. eCollection 2015.

    Related:

    Commentary

    RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers.

    • New insights in the pathophysiology of ovarian cancer and implications for screening and prevention.
    • Nezhat FR, Apostol R, Nezhat C, Pejovic T.
    • Am J Obstet Gynecol. 2015 Sep;213(3):262-7. doi: 10.1016/j.ajog.2015.03.044. Epub 2015 Mar 25.
    • BRCA1 mislocalization associated with breast carcinogenesis and poor prognosis in Taiwanese women.
    • Ho JY, Hsu RJ, Wu CL, Chen SH, Wu MY, Yu JC, Gao HW, Yen AM, Chen HH, Yu CP.
    • Eur J Cancer Prev. 2015 Sep;24(5):407-15. doi: 10.1097/CEJ.0000000000000114.
    • Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.
    • Fleury H, Communal L, Carmona E, Portelance L, Arcand SL, Rahimi K, Tonin PN, Provencher D, Mes-Masson AM.
    • Genes Cancer. 2015 Sep;6(9-10):378-398.
    • Ethnicity-Dependent and -Independent Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization.
    • Nakshatri H, Anjanappa M, Bhat-Nakshatri P.
    • Sci Rep. 2015 Aug 27;5:13526. doi: 10.1038/srep13526.
    • Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.
    • Bayraktar S, Qiu H, Liu D, Shen Y, Gutierrez-Barrera AM, Arun BK, Sahin AA.
    • Biomark Cancer. 2015 Aug 18;7:39-49. doi: 10.4137/BIC.S29716. eCollection 2015.
    • Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing.
    • Alkner S, Tang MH, Brueffer C, Dahlgren M, Chen Y, Olsson E, Winter C, Baker S, Ehinger A, Rydén L, Saal LH, Fernö M, Gruvberger-Saal SK.
    • Breast Cancer Res. 2015 Aug 5;17(1):102. doi: 10.1186/s13058-015-0608-x.
    • Prospective multicenter cohort study of estrogen and insulin-like growth factor system in BRCA mutation carriers.
    • Kim J, Johnson L, Skrzynia C, Buchanan A, Gracia C, Mersereau JE.
    • Cancer Causes Control. 2015 Aug;26(8):1087-92. doi: 10.1007/s10552-015-0601-9. Epub 2015 May 26.
    • The secondary Müllerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters.
    • Singh N, Gilks CB, Wilkinson N, McCluggage WG.
    • Pathology. 2015 Aug;47(5):423-31. doi: 10.1097/PAT.0000000000000291.
    • Review
    • Mitochondrial DNA Copy Number in Peripheral Blood Cells and Risk of Developing Breast Cancer.
    • Lemnrau A, Brook MN, Fletcher O, Coulson P, Tomczyk K, Jones M, Ashworth A, Swerdlow A, Orr N, Garcia-Closas M.
    • Cancer Res. 2015 Jul 15;75(14):2844-50. doi: 10.1158/0008-5472.CAN-14-1692. Epub 2015 May 14.
    • Mammographic density and breast cancer in women from high risk families.
    • Ramón Y Cajal T, Chirivella I, Miranda J, Teule A, Izquierdo Á, Balmaña J, Sánchez-Heras AB, Llort G, Fisas D, Lope V, Hernández-Agudo E, Juan-Fita MJ, Tena I, Robles L, Guillén-Ponce C, Pérez-Segura P, Luque-Molina MS, Hernando-Polo S, Salinas M, Brunet J, Salas-Trejo MD, Barnadas A, Pollán M.
    • Breast Cancer Res. 2015 Jul 11;17:93. doi: 10.1186/s13058-015-0604-1.
    • Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
    • Yan M, Shield-Artin K, Byrne D, Deb S, Waddell N; kConFab Investigators, kConFab, Haviv I, Fox SB.
    • BMC Cancer. 2015 Jul 8;15:506. doi: 10.1186/s12885-015-1522-4.
    • Epidemiological and clinicopathological characteristics of BRCA-positive and BRCA-negative breast cancer patients in Greece.
    • Triantafyllidou O, Vlachos IS, Apostolou P, Konstantopoulou I, Grivas A, Panopoulos C, Dimitrakakis C, Kassanos D, Loghis C, Bramis I, Vlahos N, Yannoukakos D, Fostira F.
    • J BUON. 2015 Jul-Aug;20(4):978-84.
    • DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers.
    • Vaclová T, Gómez-López G, Setién F, Bueno JM, Macías JA, Barroso A, Urioste M, Esteller M, Benítez J, Osorio A.
    • Breast Cancer Res Treat. 2015 Jul;152(2):271-82. doi: 10.1007/s10549-015-3459-3. Epub 2015 Jun 14.
    • Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography.
    • Møller P, Tharmaratnam K, Howell A, Stavrinos P, Sampson S, Wallace A, Maxwell AJ, Hagen AI, Evans DG.
    • Breast Cancer Res Treat. 2015 Jul;152(1):87-94. doi: 10.1007/s10549-015-3448-6. Epub 2015 Jun 3.
    • Family history and outcome of young patients with breast cancer in the UK (POSH study).
    • Eccles BK, Copson ER, Cutress RI, Maishman T, Altman DG, Simmonds P, Gerty SM, Durcan L, Stanton L, Eccles DM; POSH Study Steering Group.
    • Br J Surg. 2015 Jul;102(8):924-35. doi: 10.1002/bjs.9816. Epub 2015 May 20.
    • Discordant pattern of BRCA1 gene epimutation in blood between mothers and daughters.
    • Wojdacz TK, Harari F, Vahter M, Broberg K.
    • J Clin Pathol. 2015 Jul;68(7):575-7. doi: 10.1136/jclinpath-2015-202982. Epub 2015 Apr 15.
    • Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine.
    • Murria R, Palanca S, de Juan I, Alenda C, Egoavil C, Seguí FJ, García-Casado Z, Juan MJ, Sánchez AB, Segura Á, Santaballa A, Chirivella I, Llop M, Pérez G, Barragán E, Salas D, Bolufer P.
    • Am J Cancer Res. 2015 Jun 15;5(7):2330-43. eCollection 2015.
    • Plasma Proteomic Profiling in Hereditary Breast Cancer Reveals a BRCA1-Specific Signature: Diagnostic and Functional Implications.
    • Scumaci D, Tammè L, Fiumara CV, Pappaianni G, Concolino A, Leone E, Faniello MC, Quaresima B, Ricevuto E, Costanzo FS, Cuda G.
    • PLoS One. 2015 Jun 10;10(6):e0129762. doi: 10.1371/journal.pone.0129762.
    • Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers.
    • Chiang HC, Elledge R, Larson P, Jatoi I, Li R, Hu Y.
    • Breast Cancer (Auckl). 2015 Jun 2;9:25-9. doi: 10.4137/BCBCR.S26774. eCollection 2015.
    • Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways.
    • Heublein S, Mayr D, Meindl A, Angele M, Gallwas J, Jeschke U, Ditsch N.
    • PLoS One. 2015 Jun 1;10(6):e0127072. doi: 10.1371/journal.pone.0127072. eCollection 2015.
    • BRCA1 mutation site may be linked with nuclear DNA ploidy in BRCA1-mutated ovarian carcinomas.
    • Aghmesheh M, Saxena A, Niknam F.
    • Asia Pac J Clin Oncol. 2015 Jun;11(2):135-41. doi: 10.1111/ajco.12310. Epub 2014 Nov 27.
    • The effect of oral 3,3'-diindolylmethane supplementation on the 2:16α-OHE ratio in BRCA1 mutation carriers.
    • Nikitina D, Llacuachaqui M, Sepkovic D, Bradlow HL, Narod SA, Kotsopoulos J.
    • Fam Cancer. 2015 Jun;14(2):281-6. doi: 10.1007/s10689-015-9783-2.
    • Lipid and Metabolite Deregulation in the Breast Tissue of Women Carrying BRCA1 and BRCA2 Genetic Mutations.
    • Ramadan S, Arm J, Silcock J, Santamaria G, Buck J, Roy M, Leong KM, Lau P, Clark D, Malycha P, Mountford C.
    • Radiology. 2015 Jun;275(3):675-82. doi: 10.1148/radiol.15140967. Epub 2015 Mar 3.

    Related:

    Comment / Letter

    Lipid and Metabolite Deregulation in BRCA1 and BRCA2 Genetic Mutations.

    • Whole-genome characterization of chemoresistant ovarian cancer.
    • Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.
    • Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410.
    • Pathologic findings at risk-reducing surgery.
    • Mourits MJ, de Bock GH, Hollema H.
    • J Clin Oncol. 2015 May 1;33(13):1514. doi: 10.1200/JCO.2014.59.3376. Epub 2015 Mar 2.

    Related:

    Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199.

    Letter

    Reply to m.j. Mourits et Al.

    • Epigenetic changes in BRCA1-mutated familial breast cancer.
    • Downs B, Wang SM.
    • Cancer Genet. 2015 May;208(5):237-40. doi: 10.1016/j.cancergen.2015.02.001. Epub 2015 Feb 13.
    • Salpingectomy as a means to reduce ovarian cancer risk.
    • Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, Lu KH.
    • Cancer Prev Res (Phila). 2015 May;8(5):342-8. doi: 10.1158/1940-6207.CAPR-14-0293. Epub 2015 Jan 13.

    Related:

    Comment

    The fallopian tube: from back stage to center stage.

    • Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.
    • Veskimäe K, Staff S, Tabaro F, Nykter M, Isola J, Mäenpää J.
    • Genes Chromosomes Cancer. 2015 May;54(5):276-87. doi: 10.1002/gcc.22241. Epub 2015 Feb 23.
    • Ovarian cancer survival by tumor dominance, a surrogate for site of origin.
    • Ivanova A, Loo A, Tworoger S, Crum CP, Fan I, McLaughlin JR, Rosen B, Risch H, Narod SA, Kotsopoulos J.
    • Cancer Causes Control. 2015 Apr;26(4):601-8. doi: 10.1007/s10552-015-0547-y. Epub 2015 Mar 13.
    • Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.
    • Massink MP, Kooi IE, van Mil SE, Jordanova ES, Ameziane N, Dorsman JC, van Beek DM, van der Voorn JP, Sie D, Ylstra B, van Deurzen CH, Martens JW, Smid M, Sieuwerts AM, de Weerd V, Foekens JA, van den Ouweland AM, van Dyk E, Nederlof PM, Waisfisz Q, Meijers-Heijboer H.
    • Mol Oncol. 2015 Apr;9(4):877-88. doi: 10.1016/j.molonc.2014.12.012. Epub 2015 Jan 13.
    • Low grade serious carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a "low-grade serous tubal intra-epithelial carcinoma" (STIC) on risk reducing surgery.
    • Chay WY, Horlings HM, Tinker AV, Gelmon KA, Gilks CB.
    • Gynecol Oncol Rep. 2015 Mar 28;12:72-4. doi: 10.1016/j.gore.2015.03.007. eCollection 2015.
    • Evidence for a Dualistic Model of High-grade Serous Carcinoma: BRCA Mutation Status, Histology, and Tubal Intraepithelial Carcinoma.
    • Howitt BE, Hanamornroongruang S, Lin DI, Conner JE, Schulte S, Horowitz N, Crum CP, Meserve EE.
    • Am J Surg Pathol. 2015 Mar;39(3):287-93. doi: 10.1097/PAS.0000000000000369.
    • Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases: Further Evidence for the Tubal Origin of High-grade Serous Carcinomas.
    • Gilks CB, Irving J, Köbel M, Lee C, Singh N, Wilkinson N, McCluggage WG.
    • Am J Surg Pathol. 2015 Mar;39(3):357-64. doi: 10.1097/PAS.0000000000000353.
    • Serous Tubal Intraepithelial Carcinoma Localizes to the Tubal-peritoneal Junction: A Pivotal Clue to the Site of Origin of Extrauterine High-grade Serous Carcinoma (Ovarian Cancer).
    • Seidman JD.
    • Int J Gynecol Pathol. 2015 Mar;34(2):112-20. doi: 10.1097/PGP.0000000000000123.
    • Low-level constitutional mosaicism of a de novoBRCA1 gene mutation.
    • Friedman E, Efrat N, Soussan-Gutman L, Dvir A, Kaplan Y, Ekstein T, Nykamp K, Powers M, Rabideau M, Sorenson J, Topper S.
    • Br J Cancer. 2015 Feb 17;112(4):765-768. doi: 10.1038/bjc.2015.14. Epub 2015 Jan 29.
    • MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors.
    • Tanic M, Yanowski K, Gómez-López G, Socorro Rodriguez-Pinilla M, Marquez-Rodas I, Osorio A, Pisano DG, Martinez-Delgado B, Benítez J.
    • Int J Cancer. 2015 Feb 15;136(3):593-602. doi: 10.1002/ijc.29021. Epub 2014 Jun 19.
    • Ultrasonographic characteristics and BI-RADS-US classification of BRCA1 mutation-associated breast cancer in Guangxi, China.
    • Li C, Liu J, Wang S, Chen Y, Yuan Z, Zeng J, Li Z.
    • Int J Clin Exp Med. 2015 Feb 15;8(2):2411-6. eCollection 2015.
    • BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
    • Erturk E, Cecener G, Tezcan G, Egeli U, Tunca B, Gokgoz S, Tolunay S, Tasdelen I.
    • Gene. 2015 Feb 10;556(2):163-9. doi: 10.1016/j.gene.2014.11.047. Epub 2014 Nov 22.
    • The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.
    • Gu Y, Zhang M, Peng F, Fang L, Zhang Y, Liang H, Zhou W, Ao L, Guo Z.
    • Oncotarget. 2015 Feb 10;6(4):2397-406.
    • High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients.
    • Kalniete D, Nakazawa-Miklaševiča M, Štrumfa I, Āboliņš A, Irmejs A, Gardovskis J, Miklaševičs E.
    • Hered Cancer Clin Pract. 2015 Feb 8;13(1):7. doi: 10.1186/s13053-015-0028-z. eCollection 2015.
    • DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
    • Aleskandarany M, Caracappa D, Nolan CC, Macmillan RD, Ellis IO, Rakha EA, Green AR.
    • Breast Cancer Res Treat. 2015 Feb;150(1):81-90. doi: 10.1007/s10549-015-3306-6. Epub 2015 Feb 19.
    • Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer.
    • van Verschuer VM, Hooning MJ, van Baare-Georgieva RD, Hollestelle A, Timmermans AM, Koppert LB, Verhoog LC, Martens JW, Seynaeve C, van Deurzen CH.
    • Hum Pathol. 2015 Feb;46(2):182-90. doi: 10.1016/j.humpath.2014.10.020. Epub 2014 Nov 15.
    • Ovarian cancer risk after salpingectomy: a nationwide population-based study.
    • Falconer H, Yin L, Grönberg H, Altman D.
    • J Natl Cancer Inst. 2015 Jan 27 [2015 Feb;];107(2). pii: dju410. doi: 10.1093/jnci/dju410. Print 2015 Feb.

    Related:

    Comment / Editorial

    Salpingectomy as a potential ovarian cancer risk-reducing procedure.

    Research snippets.

    News

    • Salpingectomy as a potential ovarian cancer risk-reducing procedure.
    • Poole EM, Rice MS, Crum CP, Tworoger SS.
    • J Natl Cancer Inst. 2015 Jan 27 [2015 Feb;];107(2). pii: dju490. doi: 10.1093/jnci/dju490. Print 2015 Feb.

    Related:

    Ovarian cancer risk after salpingectomy: a nationwide population-based study.

    • Sister chromatid exchange: A possible approach to characterize familial breast cancer patients.
    • De Pascalis I, Pilato B, Mazzotta A, Dell'Endice TS, Rubini V, Simone G, Paradiso A, Aiello V, Mangia A.
    • Oncol Rep. 2015 Feb;33(2):930-4. doi: 10.3892/or.2014.3628. Epub 2014 Nov 26.
    • Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications.
    • Dubeau L.
    • Transl Cancer Res. 2015 Feb;4(1):3-13.
    • Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked.
    • Niravath P, Eble T, Contreras A, Li M, Franco LM, Rimawi M.
    • Exp Hematol Oncol. 2015 Jan 6;4(1):1. doi: 10.1186/2162-3619-4-1. eCollection 2015.
    • Subtyping of triple-negative breast cancer: Implications for therapy.
    • Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA.
    • Cancer. 2015 Jan 1;121(1):8-16. doi: 10.1002/cncr.28914. Epub 2014 Jul 16.
    • MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis.
    • Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Merla G, Simone G, Tommasi S.
    • Oncotarget. 2015 Jan 1;6(1):471-83.
    • Biological and clinical significance of PARP1 protein expression in breast cancer.
    • Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, Madhusudan S, Ellis IO, Rakha EA.
    • Breast Cancer Res Treat. 2015 Jan;149(2):353-62. doi: 10.1007/s10549-014-3230-1. Epub 2014 Dec 21.
    • Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients.
    • Benitez-Buelga C, Sanchez-Barroso L, Gallardo M, Apellániz-Ruiz M, Inglada-Pérez L, Yanowski K, Carrillo J, Garcia-Estevez L, Calvo I, Perona R, Urioste M, Osorio A, Blasco MA, Rodriguez-Antona C, Benitez J.
    • Breast Cancer Res Treat. 2015 Jan;149(2):385-94. doi: 10.1007/s10549-014-3246-6. Epub 2014 Dec 21.
    • Metastatic patterns of breast cancer subtypes: What radiologists should know in the era of personalized cancer medicine.
    • Chikarmane SA, Tirumani SH, Howard SA, Jagannathan JP, DiPiro PJ.
    • Clin Radiol. 2015 Jan;70(1):1-10. doi: 10.1016/j.crad.2014.08.015. Epub 2014 Oct 7.
    • Review
    • Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update.
    • Zeppernick F, Meinhold-Heerlein I, Shih IeM.
    • J Obstet Gynaecol Res. 2015 Jan;41(1):6-11. doi: 10.1111/jog.12550. Epub 2014 Oct 20.
    • Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
    • Duffy MJ, Walsh S, McDermott EW, Crown J.
    • Adv Clin Chem. 2015;71:1-23. doi: 10.1016/bs.acc.2015.05.001. Epub 2015 Jun 23.
    • Review

    Related:

    Comment / Introductory Journal Article

    Preface.

    • BRCA1 185delAG Mutation Enhances Interleukin-1β Expression in Ovarian Surface Epithelial Cells.
    • Woolery KT, Mohamed M, Linger RJ, Dobrinski KP, Roman J, Kruk PA.
    • Biomed Res Int. 2015;2015:652017. doi: 10.1155/2015/652017. Epub 2015 Aug 19.
    • Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
    • Desai A, Xu J, Aysola K, Akinbobuyi O, White M, Reddy VE, Okoli J, Clark C, Partridge EE, Childs E, Beech DJ, Rice MV, Reddy E, Rao VN.
    • J Gynecol Res. 2015;1(1). pii: 103. Epub 2015 Apr 24.
    • Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
    • Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB, Schmidt MK, Schmutzler RK, Engel C, Wappenschmidt B, Nevanlinna H, Thomassen M, Southey M, Radice P, Ramus SJ, Domchek SM, Nathanson KL, Lee A, Healey S, Nussbaum RL, Rebbeck TR, Arun BK, James P, Karlan BY, Lester J, Cass I; Breast Cancer Family Registry, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, v O Hansen T, Ejlertsen B, Gerdes AM, Nielsen FC, Dennis J, Cunningham J, Hart S, Slager S, Osorio A, Benitez J, Duran M, Weitzel JN, Tafur I, Hander M, Peterlongo P, Manoukian S, Peissel B, Roversi G, Scuvera G, Bonanni B, Mariani P, Volorio S, Dolcetti R, Varesco L, Papi L, Tibiletti MG, Giannini G, Fostira F, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D; EMBRACE Study, Douglas F, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Ong KR, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Ellis S, Godwin AK, Rhiem K, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Steinemann D, Bogdanova-Markov N, Kast K, Varon-Mateeva R, Wang-Gohrke S, Gehrig A, Markiefka B, Buecher B, Lefol C, Stoppa-Lyonnet D, Rouleau E, Prieur F, Damiola F; GEMO Study Collaborators, Barjhoux L, Faivre L, Longy M, Sevenet N, Sinilnikova OM, Mazoyer S, Bonadona V, Caux-Moncoutier V, Isaacs C, Van Maerken T, Claes K, Piedmonte M, Andrews L, Hays J, Rodriguez GC, Caldes T, de la Hoya M, Khan S, Hogervorst FB, Aalfs CM, de Lange JL, Meijers-Heijboer HE, van der Hout AH, Wijnen JT, van Roozendaal KE, Mensenkamp AR, van den Ouweland AM, van Deurzen CH, van der Luijt RB; HEBON, Olah E, Diez O, Lazaro C, Blanco I, Teulé A, Menendez M, Jakubowska A, Lubinski J, Cybulski C, Gronwald J, Jaworska-Bieniek K, Durda K, Arason A, Maugard C, Soucy P, Montagna M, Agata S, Teixeira MR; KConFab Investigators, Olswold C, Lindor N, Pankratz VS, Hallberg E, Wang X, Szabo CI, Vijai J, Jacobs L, Corines M, Lincoln A, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Phelan CM, Mai PL, Greene MH, Rennert G, Imyanitov EN, Glendon G, Toland AE, Bojesen A, Pedersen IS, Jensen UB, Caligo MA, Friedman E, Berger R, Laitman Y, Rantala J, Arver B, Loman N, Borg A, Ehrencrona H, Olopade OI, Simard J, Easton DF, Chenevix-Trench G, Offit K, Couch FJ, Antoniou AC; CIMBA.
    • Breast Cancer Res. 2014 Dec 31;16(6):3416. doi: 10.1186/s13058-014-0492-9.
    • Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
    • Spurdle AB, Couch FJ, Parsons MT, McGuffog L, Barrowdale D, Bolla MK, Wang Q, Healey S, Schmutzler R, Wappenschmidt B, Rhiem K, Hahnen E, Engel C, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Ellis S, Frost D, Platte R, Perkins J, Evans D, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Scuvera G, Manoukian S, Bonanni B, Mariette F, Fortuzzi S, Viel A, Pasini B, Papi L, Varesco L, Balleine R, Nathanson KL, Domchek SM, Offitt K, Jakubowska A, Lindor N, Thomassen M, Jensen U, Rantala J, Borg Å, Andrulis IL, Miron A, Hansen T, Caldes T, Neuhausen SL, Toland AE, Nevanlinna H, Montagna M, Garber J, Godwin AK, Osorio A, Factor RE, Terry MB, Rebbeck TR, Karlan BY, Southey M, Rashid M, Tung N, Pharoah P, Blows FM, Dunning AM, Provenzano E, Hall P, Czene K, Schmidt MK, Broeks A, Cornelissen S, Verhoef S, Fasching PA, Beckmann MW, Ekici AB, Slamon DJ, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Chang-Claude J, Flesch-Janys D, Rudolph A, Seibold P, Aittomäki K, Muranen TA, Heikkilä P, Blomqvist C, Figueroa J, Chanock SJ, Brinton L, Lissowska J, Olson JE, Pankratz VS, John EM, Whittemore AS, West DW, Hamann U, Torres D, Ulmer H, Rüdiger T, Devilee P, Tollenaar R, Seynaeve C, Van Asperen CJ, Eccles DM, Tapper WJ, Durcan L, Jones L, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Dwek M, Swann R, Bane AL, Glendon G, Mulligan AM, Giles GG, Milne RL, Baglietto L, McLean C, Carpenter J, Clarke C, Scott R, Brauch H, Brüning T, Ko YD, Cox A, Cross SS, Reed M, Lubinski J, Jaworska-Bieniek K, Durda K, Gronwald J, Dörk T, Bogdanova N, Park-Simon TW, Hillemanns P, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Burwinkel B, Marme F, Surovy H, Yang R, Anton-Culver H, Ziogas A, Hooning MJ, Collée J, Martens J, Tilanus-Linthorst M, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Lindblom A, Margolin S, Joseph V, Robson M, Rau-Murthy R, González-Neira A, Arias J, Zamora P, Benítez J, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Peterlongo P, Zaffaroni D, Barile M, Capra F, Radice P, Teo SH, Easton DF, Antoniou AC, Chenevix-Trench G, Goldgar DE; ABCTB Investigators; EMBRACE Group; GENICA Network; HEBON Group; kConFab Investigators.
    • Breast Cancer Res. 2014 Dec 23;16(6):3419. doi: 10.1186/s13058-014-0474-y.
    • Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.
    • Deb S, Wong SQ, Li J, Do H, Weiss J, Byrne D, Chakrabarti A, Bosma T; kConFab Investigators, Fellowes A, Dobrovic A, Fox SB.
    • Br J Cancer. 2014 Dec 9;111(12):2351-2360. doi: 10.1038/bjc.2014.511.
    • MicroRNA expression profiling in male and female familial breast cancer.
    • Pinto R, De Summa S, Danza K, Popescu O, Paradiso A, Micale L, Merla G, Palumbo O, Carella M, Tommasi S.
    • Br J Cancer. 2014 Dec 9;111(12):2361-2368. doi: 10.1038/bjc.2014.535. Epub 2014 Nov 13.
    • Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    • Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS.
    • Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.
    • Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
    • Niskakoski A, Kaur S, Staff S, Renkonen-Sinisalo L, Lassus H, Järvinen HJ, Mecklin JP, Bützow R, Peltomäki P.
    • Epigenetics. 2014 Dec 2;9(12):1577-87. doi: 10.4161/15592294.2014.983374.
    • The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
    • Meisel JL, Hyman DM, Garg K, Zhou Q, Dao F, Bisogna M, Gao J, Schultz ND, Grisham RN, Phillips M, Iasonos A, Kauff ND, Levine DA, Soslow RA, Spriggs DR.
    • Ann Oncol. 2014 Dec;25(12):2372-8. doi: 10.1093/annonc/mdu461. Epub 2014 Oct 3.
    • Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.
    • Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS, Amos C, Gambello M, Ready KJ, Arun B.
    • Breast. 2014 Dec;23(6):770-4. doi: 10.1016/j.breast.2014.08.010. Epub 2014 Sep 16.
    • Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
    • Gupta S, Jaworska-Bieniek K, Narod SA, Lubinski J, Wojdacz TK, Jakubowska A.
    • Breast Cancer Res Treat. 2014 Dec;148(3):615-22. doi: 10.1007/s10549-014-3179-0. Epub 2014 Nov 7.
    • Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.
    • Loud JT.
    • Breast Cancer Res Treat. 2014 Dec;148(3):691-2. doi: 10.1007/s10549-014-3186-1.
    • Letter, Comment

    Related:

    Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.

    Letter, Comment:

    Concerns about methods for determination of estrogens in body fluids.

    • Morphological and immunohistochemical pattern of tubo-ovarian dysplasia and serous tubal intraepithelial carcinoma.
    • Chene G, Cayre A, Raoelfils I, Lagarde N, Dauplat J, Penault-Llorca F.
    • Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:89-95. doi: 10.1016/j.ejogrb.2014.10.003. Epub 2014 Oct 14.
    • Distinct claudin expression characterizes BRCA1-related breast cancer.
    • Heerma van Voss MR, van Diest PJ, Smolders YH, Bart J, van der Wall E, van der Groep P.
    • Histopathology. 2014 Dec;65(6):814-27. doi: 10.1111/his.12490. Epub 2014 Aug 26.
    • Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
    • Toffoli S, Bar I, Abdel-Sater F, Delrée P, Hilbert P, Cavallin F, Moreau F, Van Criekinge W, Lacroix-Triki M, Campone M, Martin AL, Roché H, Machiels JP, Carrasco J, Canon JL.
    • Breast Cancer Res. 2014 Nov 22;16(6):466. doi: 10.1186/s13058-014-0466-y.
    • miRNA expression profiling of formalin-fixed paraffin-embedded (FFPE) hereditary breast tumors.
    • Tanić M, Yanowski K, Andrés E, Gómez-López G, Socorro MR, Pisano DG, Martinez-Delgado B, Benítez J.
    • Genom Data. 2014 Nov 22;3:75-9. doi: 10.1016/j.gdata.2014.11.008. eCollection 2015.
    • Clinical application of micronucleus test: a case-control study on the prediction of breast cancer risk/susceptibility.
    • Bolognesi C, Bruzzi P, Gismondi V, Volpi S, Viassolo V, Pedemonte S, Varesco L.
    • PLoS One. 2014 Nov 21;9(11):e112354. doi: 10.1371/journal.pone.0112354. eCollection 2014.
    • Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.
    • Danza K, De Summa S, Pilato B, Carella M, Palumbo O, Popescu O, Paradiso A, Pinto R, Tommasi S.
    • J Transl Med. 2014 Nov 19;12(1):319. doi: 10.1186/s12967-014-0319-6.
    • The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females.
    • Al-Moghrabi N, Nofel A, Al-Yousef N, Madkhali S, Bin Amer SM, Alaiya A, Shinwari Z, Al-Tweigeri T, Karakas B, Tulbah A, Aboussekhra A.
    • BMC Cancer. 2014 Nov 17;14:830. doi: 10.1186/1471-2407-14-830.
    • Clinicopathological features of young patients (<35 years of age) with breast cancer in a Japanese Breast Cancer Society supported study.
    • Kataoka A, Tokunaga E, Masuda N, Shien T, Kawabata K, Miyashita M.
    • Breast Cancer. 2014 Nov;21(6):643-50. doi: 10.1007/s12282-013-0466-2. Epub 2013 Apr 16.
    • TGFβ Induces "BRCAness" and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes.
    • Liu L, Zhou W, Cheng CT, Ren X, Somlo G, Fong MY, Chin AR, Li H, Yu Y, Xu Y, O'Connor ST, O'Connor TR, Ann DK, Stark JM, Wang SE.
    • Mol Cancer Res. 2014 Nov;12(11):1597-609. doi: 10.1158/1541-7786.MCR-14-0201. Epub 2014 Aug 7.
    • Single Nucleotide Polymorphisms in Noncoding Regions of Rad51C Do Not Change the Risk of Unselected Breast Cancer but They Modulate the Level of Oxidative Stress and the DNA Damage Characteristics: A Case-Control Study.
    • Gresner P, Gromadzinska J, Jablonska E, Stepnik M, Zambrano Quispe O, Twardowska E, Wasowicz W.
    • PLoS One. 2014 Oct 24;9(10):e110696. doi: 10.1371/journal.pone.0110696. eCollection 2014.
    • Hereditary breast cancer: clinical, pathological and molecular characteristics.
    • Larsen MJ, Thomassen M, Gerdes AM, Kruse TA.
    • Breast Cancer (Auckl). 2014 Oct 15;8:145-55. doi: 10.4137/BCBCR.S18715. eCollection 2014.
    • Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199.
    • Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH.
    • J Clin Oncol. 2014 Oct 10;32(29):3275-83. doi: 10.1200/JCO.2013.54.1987. Epub 2014 Sep 8.

    Related:

    Letter, Comment:

    Pathologic findings at risk-reducing surgery.

    Letter, Reply:

    Reply to m.j. Mourits et Al.

    • Retraction: Relation between HPV genotypes and BRCA mutation in familial breast cancer.
    • Rassi H, Mohammadian T, Salmanpor S, Gholami Roudmajani E.
    • J Microbiol Biotechnol. 2014 Oct 8. doi: 10.4014/jmb.1407.07011. [Epub ahead of print]
    • Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
    • Park JY, Singh TR, Nassar N, Zhang F, Freund M, Hanenberg H, Meetei AR, Andreassen PR.
    • Oncogene. 2014 Oct 2;33(40):4803-12. doi: 10.1038/onc.2013.421. Epub 2013 Oct 21.
    • Terminal duct lobular unit involution of the normal breast: implications for breast cancer etiology.
    • Figueroa JD, Pfeiffer RM, Patel DA, Linville L, Brinton LA, Gierach GL, Yang XR, Papathomas D, Visscher D, Mies C, Degnim AC, Anderson WF, Hewitt S, Khodr ZG, Clare SE, Storniolo AM, Sherman ME.
    • J Natl Cancer Inst. 2014 Oct 1;106(10). pii: dju286. doi: 10.1093/jnci/dju286. Print 2014 Oct.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: No pregnancy and risk of cancer

    • Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
    • Noori SF, Gangi A, Nelson ME, Choi M, Mirzadehgan P, Bonk AK, Mirocha J, Amersi F, Giuliano AE.
    • Ann Surg Oncol. 2014 Oct;21(10):3324-9. doi: 10.1245/s10434-014-3904-2. Epub 2014 Jul 22.
    • Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
    • Reyes MC, Arnold AG, Kauff ND, Levine DA, Soslow RA.
    • Mod Pathol. 2014 Oct;27(10):1405-11. doi: 10.1038/modpathol.2013.237. Epub 2014 Feb 28.
    • Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations.
    • Erturk E, Cecener G, Egeli U, Tunca B, Tezcan G, Gokgoz S, Tolunay S, Tasdelen I.
    • Mol Cell Biochem. 2014 Oct;395(1-2):77-88. doi: 10.1007/s11010-014-2113-4. Epub 2014 Jun 19.
    • BRCA1 pathway function in basal-like breast cancer cells.
    • Hill SJ, Clark AP, Silver DP, Livingston DM.
    • Mol Cell Biol. 2014 Oct;34(20):3828-42. doi: 10.1128/MCB.01646-13. Epub 2014 Aug 4.
    • Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment.
    • Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens JW, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter JP, Vreeswijk MP, Jager A, van Gent DC.
    • Clin Cancer Res. 2014 Sep 15;20(18):4816-26. doi: 10.1158/1078-0432.CCR-14-0571. Epub 2014 Jun 24.
    • Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.
    • Gruessner C, Gruessner A, Glaser K, AbuShahin N, Zhou Y, Laughren C, Wright H, Pinkerton S, Yi X, Stoffer J, Azodi M, Zheng W, Chambers SK.
    • Cancer Prev Res (Phila). 2014 Sep;7(9):896-905. doi: 10.1158/1940-6207.CAPR-13-0408. Epub 2014 Jun 20.
    • Reproductive and hormonal factors, family history, and breast cancer according to the hormonal receptor status.
    • Rosato V, Bosetti C, Negri E, Talamini R, Dal Maso L, Malvezzi M, Falcini F, Montella M, La Vecchia C.
    • Eur J Cancer Prev. 2014 Sep;23(5):412-7. doi: 10.1097/CEJ.0b013e3283639f7a.
    • A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    • Cass I, Walts AE, Barbuto D, Lester J, Karlan B.
    • Gynecol Oncol. 2014 Sep;134(3):492-7. doi: 10.1016/j.ygyno.2014.07.084. Epub 2014 Jul 12.
    • Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer.
    • Deb S, Johansson I, Byrne D, Nilsson C, Investigators k, Constable L, Fjällskog ML, Dobrovic A, Hedenfalk I, Fox SB.
    • Mod Pathol. 2014 Sep;27(9):1223-30. doi: 10.1038/modpathol.2013.231. Epub 2014 Jan 24.
    • Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers.
    • Gevensleben H, Bossung V, Meindl A, Wappenschmidt B, de Gregorio N, Osorio A, Romero A, Buettner R, Markiefka B, Schmutzler RK.
    • Virchows Arch. 2014 Sep;465(3):365-9. doi: 10.1007/s00428-014-1619-1. Epub 2014 Jul 4.
    • Letter
    • Biology of breast cancer in young women.
    • Azim HA, Partridge AH.
    • Breast Cancer Res. 2014 Aug 27;16(4):427. doi: 10.1186/s13058-014-0427-5.
    • Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study.
    • Gierach GL, Li H, Loud JT, Greene MH, Chow CK, Lan L, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Olopade OI, Gail MH, Giger ML.
    • Breast Cancer Res. 2014;16(4):424. doi: 10.1186/PREACCEPT-1744229618121391. Epub 2014 Aug 23.
    • Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
    • Prat A, Cruz C, Hoadley KA, Díez O, Perou CM, Balmaña J.
    • Breast Cancer Res Treat. 2014 Aug;147(1):185-91. doi: 10.1007/s10549-014-3056-x. Epub 2014 Jul 22.
    • VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer.
    • Castilla MÁ, López-García MÁ, Atienza MR, Rosa-Rosa JM, Díaz-Martín J, Pecero ML, Vieites B, Romero-Pérez L, Benítez J, Calcabrini A, Palacios J.
    • Endocr Relat Cancer. 2014 Aug;21(4):587-99. doi: 10.1530/ERC-13-0485. Epub 2014 Jun 2.
    • BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    • Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.
    • Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001. Epub 2014 Jun 2.
    • MicroRNAs Discriminate Familial from Sporadic Non-BRCA1/2 Breast Carcinoma Arising in Patients ≤35 Years.
    • Bastos EP, Brentani H, Pasini FS, Silva AR, Torres CH, Puga RD, Olivieri EH, Piovezani AR, Pereira CA, Machado-Lima A, Carraro DM, Brentani MM.
    • PLoS One. 2014 Jul 9;9(7):e101656. doi: 10.1371/journal.pone.0101656. eCollection 2014.
    • A small organ takes center stage: selected topics in fallopian tube pathology.
    • Rutgers JK, Lawrence WD.
    • Int J Gynecol Pathol. 2014 Jul;33(4):385-92. doi: 10.1097/PGP.0000000000000143.
    • Displaced Granulosa Cells Within the Ovarian Stroma in a BRCA1 Mutation Carrier.
    • Chui MH, Chapman WB, Clarke BA.
    • Int J Gynecol Pathol. 2014 Jul;33(4):423-4. doi: 10.1097/PGP.0b013e3182a3cd2c.
    • Letter, Comment

    Related:

    Case report:

    Displaced granulosa cells in the fallopian tube mistaken for metastatic granulosa cell tumor.

    • Family history of cancer associated with breast tumor clinicopathological features.
    • Ricks LJ, Ewing A, Thompson N, Harrison B, Wilson B, Richardson F, Carter-Nolan P, Spencer C, Laiyemo A, Williams C.
    • J Community Genet. 2014 Jul;5(3):233-40. doi: 10.1007/s12687-013-0180-y. Epub 2014 Jan 15.
    • A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival.
    • Anjum S, Fourkala EO, Zikan M, Wong A, Gentry-Maharaj A, Jones A, Hardy R, Cibula D, Kuh D, Jacobs IJ, Teschendorff AE, Menon U, Widschwendter M.
    • Genome Med. 2014 Jun 27;6(6):47. doi: 10.1186/gm567. eCollection 2014.

    Related:

    Press: Prospects for blood test to predict breast cancer risk. (PHG Foundation)

    • Clinicopathological features and prognostic factors of young breast cancers in Eastern Guangdong of China.
    • Wei JT, Huang WH, Du CW, Qiu SQ, Wei XL, Liu J, Zhang GJ.
    • Sci Rep. 2014 Jun 19;4:5360. doi: 10.1038/srep05360.
    • Genomic Aberrations of BRCA1-Mutated Fallopian Tube Carcinomas.
    • Hunter SM, Ryland GL, Moss P; kConFab Investigators, Gorringe KL, Campbell IG.
    • Am J Pathol. 2014 Jun;184(6):1871-6. doi: 10.1016/j.ajpath.2014.02.013. Epub 2014 Apr 13.
    • Early Detection of High-grade Tubal Serous Carcinoma in Women at Low Risk for Hereditary Breast and Ovarian Cancer Syndrome by Systematic Examination of Fallopian Tubes Incidentally Removed During Benign Surgery.
    • Rabban JT, Garg K, Crawford B, Chen LM, Zaloudek CJ.
    • Am J Surg Pathol. 2014 Jun;38(6):729-42. doi: 10.1097/PAS.0000000000000199.
    • Lymphocyte Telomere Length Is Long in BRCA1 and BRCA2 Mutation Carriers Regardless of Cancer-Affected Status.
    • Pooley KA, McGuffog L, Barrowdale D, Frost D, Ellis SD, Fineberg E, Platte R, Izatt L, Adlard J, Bardwell J, Brewer C, Cole T, Cook J, Davidson R, Donaldson A, Dorkins H, Douglas F, Eason J, Houghton C, Kennedy MJ, McCann E, Miedzybrodzka Z, Murray A, Porteous ME, Rogers MT, Side LE, Tischkowitz M, Walker L, Hodgson S, Eccles DM, Morrison PJ, Evans DG, Eeles RA, Antoniou AC, Easton DF, Dunning AM; EMBRACE;.
    • Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1018-24. doi: 10.1158/1055-9965.EPI-13-0635-T. Epub 2014 Mar 18.
    • Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.
    • Chen Y, Bancroft E, Ashley S, Arden-Jones A, Thomas S, Shanley S, Saya S; Carrier Clinic Collaborators, Wakeling E, Eeles R.
    • Fam Cancer. 2014 Jun;13(2):197-203. doi: 10.1007/s10689-013-9697-9.
    • Characteristics of BRCA1/2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry.
    • Yu JH, Lee JW, Son BH, Kim SW, Park SK, Lee MH, Kim LS, Noh WC, Kim EK, Yoon DS, Lee J, Jung JH, Jung SS, Gong G, Ahn SH.
    • J Breast Cancer. 2014 Jun;17(2):129-35. doi: 10.4048/jbc.2014.17.2.129. Epub 2014 Jun 27.
    • Genome instability in blood cells of a BRCA1+ breast cancer family.
    • Xiao F, Kim YC, Snyder C, Wen H, Chen PX, Luo J, Becirovic D, Downs B, Cowan KH, Lynch H, Wang SM.
    • BMC Cancer. 2014 May 19;14:342. doi: 10.1186/1471-2407-14-342.
    • Systemic treatment strategies for triple-negative breast cancer.
    • Yadav BS, Sharma SC, Chanana P, Jhamb S.
    • World J Clin Oncol. 2014 May 10;5(2):125-33. doi: 10.5306/wjco.v5.i2.125.
    • Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk.
    • Anton A, Schott S, Kaip G, Rath M, Heil J, Aulmann S, Sinn HP.
    • Arch Gynecol Obstet. 2014 May;289(5):1079-85. doi: 10.1007/s00404-013-3062-y. Epub 2013 Nov 7.
    • Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    • Aloraifi F, Alshehhi M, McDevitt T, Cody N, Meany M, O'Doherty A, Quinn CM, Green AJ, Bracken A, Geraghty JG.
    • Eur J Surg Oncol. 2015 May;41(5):641-6. doi: 10.1016/j.ejso.2015.01.021. Epub 2015 Feb 17.
    • Risk factors for ovarian cancers with and without microsatellite instability.
    • Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Sun P, Narod SA, Schildkraut J.
    • Int J Gynecol Cancer. 2014 May;24(4):664-9. doi: 10.1097/IGC.0000000000000134.
    • Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    • Staff S, Tolonen T, Laasanen SL, Mecklin JP, Isola J, Mäenpää J.
    • Int J Gynecol Pathol. 2014 May;33(3):309-16. doi: 10.1097/PGP.0b013e31829c673b.
    • BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis.
    • Tang MK, Kwong A, Tam KF, Cheung AN, Ngan HY, Xia W, Wong A.
    • Cancer Lett. 2014 Apr 28;346(1):139-47. doi: 10.1016/j.canlet.2013.12.026. Epub 2013 Dec 28.
    • Comparison of breast cancers diagnosed in screening patients in their 40s with and without family history of breast cancer in a community outpatient facility.
    • Destounis SV, Arieno AL, Morgan RC, Cavanaugh D, Seifert PJ, Murphy PF, Somerville PA.
    • AJR Am J Roentgenol. 2014 Apr;202(4):928-32. doi: 10.2214/AJR.13.11194.
    • SUMOylation proteins in breast cancer.
    • Alshareeda AT, Negm OH, Green AR, Nolan C, Tighe P, Albarakati N, Sultana R, Madhusudan S, Ellis IO, Rakha EA.
    • Breast Cancer Res Treat. 2014 Apr;144(3):519-30. doi: 10.1007/s10549-014-2897-7. Epub 2014 Mar 1.
    • Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy.
    • van Verschuer VM, Heemskerk-Gerritsen BA, van Deurzen CH, Obdeijn IM, Tilanus-Linthorst MM, Verhoef C, Schmidt MK, Koppert LB, Hooning MJ, Seynaeve C.
    • Cancer Biol Ther. 2014 Apr;15(4):371-9. doi: 10.4161/cbt.27628. Epub 2014 Jan 14.
    • Hereditary risk evaluation for borderline ovarian tumors based on immunohistochemistry.
    • Park JM, Kim MK.
    • J Menopausal Med. 2014 Apr;20(1):14-20. doi: 10.6118/jmm.2014.20.1.14. Epub 2014 Apr 28.
    • Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS.
    • Saito M, Matsuzaki M, Sakuma T, Katagata N, Watanabe F, Yamaguchi Y, Schetter AJ, Takenoshita S, Nomizu T.
    • Breast Cancer. 2014 Mar;21(2):140-5. doi: 10.1007/s12282-012-0389-3. Epub 2012 Aug 9.
    • BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.
    • Burgess M, Puhalla S.
    • Front Oncol. 2014 Feb 27;4:19. eCollection 2014.
    • Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer.
    • De Summa S, Pinto R, Pilato B, Sambiasi D, Porcelli L, Guida G, Mattioli E, Paradiso A, Merla G, Micale L, De Nittis P, Tommasi S.
    • Cell Death Dis. 2014 Feb 20;5:e1076. doi: 10.1038/cddis.2014.30.
    • Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis.
    • Li HX, Lu ZH, Shen K, Cheng WJ, Malpica A, Zhang J, Wei JJ, Zhang ZH, Liu J.
    • Int J Clin Exp Pathol. 2014 Feb 15;7(3):848-57. eCollection 2014.
    • Regulation of DNA methyltransferase 1 transcription in BRCA1-mutated breast cancer: a novel crosstalk between E2F1 motif hypermethylation and loss of histone H3 lysine 9 acetylation.
    • Li D, Bi FF, Cao JM, Cao C, Liu B, Yang Q.
    • Mol Cancer. 2014 Feb 6;13:26. doi: 10.1186/1476-4598-13-26.
    • Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube.
    • Dietl J.
    • Arch Gynecol Obstet. 2014 Feb;289(2):241-6. doi: 10.1007/s00404-013-3041-3. Epub 2013 Oct 8.
    • Review
    643. s
    • Clinical significance of CYLD downregulation in breast cancer.
    • Hayashi M, Jono H, Shinriki S, Nakamura T, Guo J, Sueta A, Tomiguchi M, Fujiwara S, Yamamoto-Ibusuki M, Murakami K, Yamashita S, Yamamoto Y, Li JD, Iwase H, Ando Y.
    • Breast Cancer Res Treat. 2014 Feb;143(3):447-57. doi: 10.1007/s10549-013-2824-3. Epub 2014 Jan 8.
    • Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.
    • Loud JT, Gierach GL, Veenstra TD, Falk RT, Nichols K, Guttmann A, Xu X, Greene MH, Gail MH.
    • Breast Cancer Res Treat. 2014 Feb;143(3):517-29. doi: 10.1007/s10549-013-2821-6. Epub 2014 Jan 18.

    Related:

    Letter, Comment:

    Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.

    Letter, Comment:

    Concerns about methods for determination of estrogens in body fluids.

    • Triple-negative breast cancer: molecular subtypes and targeted therapy.
    • Hirshfield KM, Ganesan S.
    • Curr Opin Obstet Gynecol. 2014 Feb;26(1):34-40. doi: 10.1097/GCO.0000000000000038.
    • Review
    • Differences in DNA methylation by extent of breast cancer family history in unaffected women.
    • Delgado-Cruzata L, Wu HC, Liao Y, Santella RM, Terry MB.
    • Epigenetics. 2014 Feb;9(2):243-8. doi: 10.4161/epi.26880. Epub 2013 Oct 29.
    • BRCA1/2 mutations and FMR1 alleles are randomly distributed: a case control study.
    • Dagan E, Cohen Y, Mory A, Adir V, Borochowitz Z, Raanani H, Kurolap A, Melikhan-Revzin S, Meirow D, Gershoni-Baruch R.
    • Eur J Hum Genet. 2014 Feb;22(2):277-9. doi: 10.1038/ejhg.2013.281. Epub 2013 Nov 27.
    • The FMR1 CGG repeat test is not a candidate prescreening tool for identifying women with a high probability of being carriers of BRCA mutations.
    • Ricci MT, Pennese L, Gismondi V, Perfumo C, Grasso M, Gennaro E, Bruzzi P, Varesco L.
    • Eur J Hum Genet. 2014 Feb;22(2):280-2. doi: 10.1038/ejhg.2013.193. Epub 2013 Sep 25.

    Related:

    Comment:

    Do BRCA1/2 mutations and low FMR1 alleles interact or not?

    • The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
    • Reade CJ, McVey RM, Tone AA, Finlayson SJ, McAlpine JN, Fung-Kee-Fung M, Ferguson SE.
    • J Obstet Gynaecol Can. 2014 Feb;36(2):133-40.
    • Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.
    • Suspitsin EN, Yanus GA, Sokolenko AP, Yatsuk OS, Zaitseva OA, Bessonov AA, Ivantsov AO, Heinstein VA, Klimashevskiy VF, Togo AV, Imyanitov EN.
    • Med Oncol. 2014 Feb;31(2):828. doi: 10.1007/s12032-013-0828-9. Epub 2014 Jan 12.
    • Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.
    • De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF, Seoane J, Reis-Filho JS.
    • Mol Oncol. 2014 Feb;8(1):150-8. doi: 10.1016/j.molonc.2013.10.006. Epub 2013 Oct 31.
    • RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.
    • Larsen MJ, Thomassen M, Tan Q, Lænkholm AV, Bak M, Sørensen KP, Andersen MK, Kruse TA, Gerdes AM.
    • BMC Med Genomics. 2014 Jan 31;7(1):9. doi: 10.1186/1755-8794-7-9.
    • Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Status.
    • Killick E, Tymrakiewicz M, Cieza-Borrella C, Smith P, Thompson DJ, Pooley KA, Easton DF, Bancroft E, Page E, Leongamornlert D; IMPACT collaborators, Kote-Jarai Z, Eeles RA.
    • PLoS One. 2014 Jan 29;9(1):e86659. doi: 10.1371/journal.pone.0086659. eCollection 2014.
    • Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.
    • Sama AR, Schilder RJ.
    • Int J Womens Health. 2014 Jan 28;6:149-57. doi: 10.2147/IJWH.S40889. eCollection 2014.
    • BRCA and Early Events in the Development of Serous Ovarian Cancer.
    • George SH, Shaw P.
    • Front Oncol. 2014 Jan 23;4:5. doi: 10.3389/fonc.2014.00005. eCollection 2014.
    • Integrated analysis of germline and somatic variants in ovarian cancer.
    • Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, Zhang Q, Koboldt DC, Xie M, Kandoth C, McMichael JF, Wyczalkowski MA, Larson DE, Schmidt HK, Miller CA, Fulton RS, Spellman PT, Mardis ER, Druley TE, Graubert TA, Goodfellow PJ, Raphael BJ, Wilson RK, Ding L.
    • Nat Commun. 2014 Jan 22;5:3156. doi: 10.1038/ncomms4156.
    • Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma.
    • Gruessner C, Gruessner A, Glaser K, Abushahin N, Laughren C, Zheng W, Chambers SK.
    • Am J Cancer Res. 2014 Jan 15;4(1):61-72. eCollection 2014.
    • Triple-negative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome.
    • Sullivan HC, Oprea-Ilies G, Adams AL, Page AJ, Kim S, Wang J, Cohen C.
    • Appl Immunohistochem Mol Morphol. 2014 Jan;22(1):17-23. doi: 10.1097/PAI.0b013e318281148e.
    • Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.
    • Engel JB, Honig A, Kapp M, Hahne JC, Meyer SR, Dietl J, Segerer SE.
    • Arch Gynecol Obstet. 2014 Jan;289(1):141-7. doi: 10.1007/s00404-013-2922-9. Epub 2013 Jul 5.
    • Breast cancer subtypes and previously established genetic risk factors: a bayesian approach.
    • O'Brien KM, Cole SR, Engel LS, Bensen JT, Poole C, Herring AH, Millikan RC.
    • Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):84-97. doi: 10.1158/1055-9965.EPI-13-0463. Epub 2013 Oct 31.
    • BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.
    • Foulkes W.
    • Clin Genet. 2014 Jan;85(1):1-4. doi: 10.1111/cge.12291. Epub 2013 Oct 25.
    • Editorial / Commentary
    • The impact of bilateral salpingo-oophorectomy on breast MRI background parenchymal enhancement and fibroglandular tissue.
    • Price ER, Brooks JD, Watson EJ, Brennan SB, Comen EA, Morris EA.
    • Eur Radiol. 2014 Jan;24(1):162-8. doi: 10.1007/s00330-013-2993-9. Epub 2013 Aug 28.
    • Lobulitis in nonneoplastic breast tissue from breast cancer patients: association with phenotypes that are common in hereditary breast cancer.
    • Gulbahce HE, Vanderwerf S, Blair C, Sweeney C.
    • Hum Pathol. 2014 Jan;45(1):78-84. doi: 10.1016/j.humpath.2013.08.008. Epub 2013 Oct 21.
    • Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.
    • Hirasawa A, Masuda K, Akahane T, Ueki A, Yokota M, Tsuruta T, Nomura H, Kataoka F, Tominaga E, Banno K, Makita K, Susumu N, Sugano K, Kosaki K, Kameyama K, Aoki D.
    • Jpn J Clin Oncol. 2014 Jan;44(1):49-56. doi: 10.1093/jjco/hyt171. Epub 2013 Nov 11.
    • Influence of estrogen and variations at the BRCA1 promoter region on transcription and translation.
    • Fernandes LR, Costa EC, Vargas FR, Moreira MA.
    • Mol Biol Rep. 2014 Jan;41(1):489-95. doi: 10.1007/s11033-013-2884-9. Epub 2013 Dec 1.
    • Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer.
    • Maksimenko J, Irmejs A, Nakazawa-Miklasevica M, Melbarde-Gorkusa I, Trofimovics G, Gardovskis J, Miklasevics E.
    • Oncol Lett. 2014 Jan;7(1):278-284. Epub 2013 Nov 14.
    • [Morphologically qnd immunohistochemically based screening criteria for selection of patients with possible mutation of BRCA1 gene in primary ovarian cancer].
    • Popovska S, Ivanov I, Dineva T, Jordanov A, Kovacheva K, Kamburova Z, Tomov S, Ivanova V, Boneva I, Mateva S.
    • Akush Ginekol (Sofiia). 2014;53(4):21-8.
    • [Article in Bulgarian]
    • BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.
    • Li D, Chen NN, Cao JM, Sun WP, Zhou YM, Li CY, Wang XX.
    • Cell Cycle. 2014;13(16):2564-71. doi: 10.4161/15384101.2015.942208.
    • Hormone responsive breast cancer and BRCA1 mutation: mechanism, regulation and iron-mediated effects.
    • Zghair AN, Sharma R, Sharma AK.
    • Curr Pharm Biotechnol. 2014;15(12):1113-24.
    • Review
    • Network-based analysis of omics with multi-objective optimization.
    • Mosca E, Milanesi L.
    • Mol Biosyst. 2013 Dec 29;9(12):2971-80. doi: 10.1039/c3mb70327d. Epub 2013 Oct 14.
    • Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas.
    • Pécuchet N, Popova T, Manié E, Lucchesi C, Battistella A, Vincent-Salomon A, Caux-Moncoutier V, Bollet M, Sigal-Zafrani B, Sastre-Garau X, Stoppa-Lyonnet D, Stern MH.
    • Int J Cancer. 2013 Dec 15;133(12):2834-2842. doi: 10.1002/ijc.28315. Epub 2013 Jul 10.
    • Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.
    • Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R.
    • Cancer Cell. 2013 Dec 9;24(6):751-65. doi: 10.1016/j.ccr.2013.10.013.

    Related:

    Research news:

    Ovarian cancer: A better mimic.

    • Tackling the diversity of triple-negative breast cancer.
    • Turner NC, Reis-Filho JS.
    • Clin Cancer Res. 2013 Dec 1;19(23):6380-8. doi: 10.1158/1078-0432.CCR-13-0915.
    • Clinical implications of using molecular diagnostics for ovarian cancers.
    • Kohn EC, Romano S, Lee JM.
    • Ann Oncol. 2013 Dec;24 Suppl 10:x22-26. doi: 10.1093/annonc/mdt464.
    • Explaining variance in the cumulus mammographic measures that predict breast cancer risk: a twins and sisters study.
    • Nguyen TL, Schmidt DF, Makalic E, Dite GS, Stone J, Apicella C, Bui M, Macinnis RJ, Odefrey F, Cawson JN, Treloar SA, Southey MC, Giles GG, Hopper JL.
    • Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2395-403. doi: 10.1158/1055-9965.EPI-13-0481. Epub 2013 Oct 15.
    • Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer.
    • Crum CP, Herfs M, Ning G, Bijron JG, Howitt BE, Jimenez CA, Hanamornroongruang S, McKeon FD, Xian W.
    • J Pathol. 2013 Dec;231(4):402-12. doi: 10.1002/path.4263.
    • MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
    • Ren J, Jin F, Yu Z, Zhao L, Wang L, Bai X, Zhao H, Yao W, Mi X, Wang E, Olopade OI, Wei M.
    • Tumour Biol. 2013 Dec;34(6):3945-58. doi: 10.1007/s13277-013-0983-9. Epub 2013 Jul 17.
    • MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours.
    • Tanic M, Andrés E, M Rodriguez-Pinilla S, Marquez-Rodas I, Cebollero-Presmanes M, Fernandez V, Osorio A, Benítez J, Martinez-Delgado B.
    • Br J Cancer. 2013 Nov 12;109(10):2724-34. doi: 10.1038/bjc.2013.612. Epub 2013 Oct 8.
    • Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.
    • PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.
    • Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules.
    • Isfoss BL, Holmqvist B, Jernström H, Alm P, Olsson H.
    • BMC Clin Pathol. 2013 Nov 4;13(1):28. doi: 10.1186/1472-6890-13-28.
    • The role of the fallopian tube in the origin of ovarian cancer.
    • Erickson BK, Conner MG, Landen CN Jr.
    • Am J Obstet Gynecol. 2013 Nov;209(5):409-14. doi: 10.1016/j.ajog.2013.04.019. Epub 2013 Apr 10.

    Related:

    Letter, Comment:

    Risk-reducing salpingectomy as a new and safe strategy to prevent ovarian cancer.

    Letter, Reply:

    Reply: To PMID 23583217.

    • Biology of hereditary breast and ovarian cancers.
    • Tommasi S.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii7. doi: 10.1093/annonc/mdt309.
    • Breast cancer risk in BRCA1 mutation carriers: insight from mouse models.
    • Barcellos-Hoff MH, Kleinberg DL.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii8-viii12. doi: 10.1093/annonc/mdt305.
    • Coming into focus: the nonovarian origins of ovarian cancer.
    • Dubeau L, Drapkin R.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii28-viii35. doi: 10.1093/annonc/mdt308.
    • Male breast cancer: genetics, epigenetics, and ethical aspects.
    • Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, Gulino M, Frati P, Ottini L.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii75-viii82. doi: 10.1093/annonc/mdt316.
    • Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
    • Vilasco M, Communal L, Hugon-Rodin J, Penault-Llorca F, Mourra N, Wu Z, Forgez P, Gompel A; BRACAPS.
    • Breast Cancer Res Treat. 2013 Nov;142(2):283-96. doi: 10.1007/s10549-013-2722-8. Epub 2013 Oct 29.
    • MicroRNA signatures in hereditary breast cancer.
    • Murria Estal R, Palanca Suela S, de Juan Jiménez I, Egoavil Rojas C, García-Casado Z, Juan Fita MJ, Sánchez Heras AB, Segura Huerta A, Chirivella González I, Sánchez-Izquierdo D, Llop García M, Barragán González E, Bolufer Gilabert P.
    • Breast Cancer Res Treat. 2013 Nov;142(1):19-30. doi: 10.1007/s10549-013-2723-7. Epub 2013 Oct 16.
    • Increased Proliferative Background in Healthy Women with BRCA1/2 Haploinsufficiency Is Associated with High Risk for Breast Cancer.
    • Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Gronowitz S, Peretz T.
    • Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2110-5. doi: 10.1158/1055-9965.EPI-13-0193. Epub 2013 Aug 21.
    • BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.
    • Buckley NE, Nic An Tsaoir CB, Blayney JK, Oram LC, Crawford NT, D'Costa ZC, Quinn JE, Kennedy RD, Harkin DP, Mullan PB.
    • Nucleic Acids Res. 2013 Oct 1;41(18):8601-14. doi: 10.1093/nar/gkt626. Epub 2013 Jul 17.
    • The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy.
    • Markowska J, Bar J, Mądry R, Słomska I, Mardas M, Grabowski JP.
    • Arch Gynecol Obstet. 2013 Oct;288(4):839-44. doi: 10.1007/s00404-013-2825-9. Epub 2013 Apr 4.
    • Pyrimidine base damage is increased in women with BRCA mutations.
    • Budzinski EE, Patrzyc HB, Dawidzik JB, Freund HG, Frederick P, Godoy HE, Voian NC, Odunsi K, Box HC.
    • Cancer Lett. 2013 Sep 28;338(2):267-70. doi: 10.1016/j.canlet.2013.04.001. Epub 2013 Apr 11.
    • Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade.
    • Martinez-Delgado B, Gallardo M, Tanic M, Yanowsky K, Inglada-Perez L, Barroso A, Rodriguez-Pinilla M, Cañamero M, Blasco MA, Benitez J.
    • Breast Cancer Res Treat. 2013 Sep;141(2):231-42. doi: 10.1007/s10549-013-2696-6. Epub 2013 Sep 15.
    • Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients.
    • Pedersen BS, Konstantinopoulos PA, Spillman MA, De S.
    • Genes Chromosomes Cancer. 2013 Sep;52(9):794-801. doi: 10.1002/gcc.22075. Epub 2013 May 28.
    • Cytogenetic finding of breast cancer cases and in their first-degree relatives.
    • Celik DA, Koşar PA, Ozçelik N, Eroğlu E.
    • J Breast Cancer. 2013 Sep;16(3):285-90. doi: 10.4048/jbc.2013.16.3.285. Epub 2013 Sep 30.
    • Association between BRCA Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation.
    • Noh JM, Han BK, Choi DH, Rhee SJ, Cho EY, Huh SJ, Park W, Park H, Nam SJ, Lee JE, Kil WH.
    • J Breast Cancer. 2013 Sep;16(3):308-14. doi: 10.4048/jbc.2013.16.3.308. Epub 2013 Sep 30.
    • Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
    • Yi YW, Kang HJ, Kim HJ, Hwang JS, Wang A, Bae
    • Mol Carcinog. 2013 Sep;52(9):667-75. doi: 10.1002/mc.21905. Epub 2012 Apr 4.
    • BRCA1 and p53 regulate critical prostate cancer pathways.
    • De Luca P, Moiola CP, Zalazar F, Gardner K, Vazquez ES, De Siervi A.
    • Prostate Cancer Prostatic Dis. 2013 Sep;16(3):233-8. doi: 10.1038/pcan.2013.12. Epub 2013 May 14.
    • Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
    • Bijron JG, Seldenrijk CA, Zweemer RP, Lange JG, Verheijen RH, van Diest PJ.
    • Am J Surg Pathol. 2013 Aug;37(8):1123-30. doi: 10.1097/PAS.0b013e318282da7f.
    • Case report

    Related:

    Letter, Comment:

    Fallopian tube intraluminal tumor spread.

    Letter, Comment:

    Serous carcinogenesis: a classic causality dilemma or which came first... ?

    • Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype.
    • Senkus E, Szade J, Pieczyńska B, Żaczek A, Brożek I, Radecka B, Kowalczyk A, Wełnicka-Jaśkiewicz M, Jassem J.
    • Breast. 2013 Aug;22(4):425-30. doi: 10.1016/j.breast.2013.04.005. Epub 2013 May 1.
    • Autophagy Opposes p53-Mediated Tumor Barrier to Facilitate Tumorigenesis in a Model of PALB2-Associated Hereditary Breast Cancer.
    • Huo Y, Cai H, Teplova I, Bowman-Colin C, Chen G, Price S, Barnard N, Ganesan S, Karantza V, White E, Xia B.
    • Cancer Discov. 2013 Aug;3(8):894-907. doi: 10.1158/2159-8290.CD-13-0011. Epub 2013 May 6.
    • Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer.
    • Danza K, Pilato B, Lacalamita R, Addati T, Giotta F, Bruno A, Paradiso A, Tommasi S.
    • Eur J Hum Genet. 2013 Aug;21(8):824-30. doi: 10.1038/ejhg.2012.273. Epub 2012 Dec 12.
    • The complex genetic landscape of familial breast cancer.
    • Melchor L, Benítez J.
    • Hum Genet. 2013 Aug;132(8):845-63. doi: 10.1007/s00439-013-1299-y. Epub 2013 Apr 5.
    • Review
    • Tuberin and p27 expression in breast cancer patients with or without BRCA germline mutations.
    • Dressler AC, Hudelist G, Fink-Retter A, Gschwantler-Kaulich D, Pfeiler G, Rosner M, Hengstschläger M, Singer CF.
    • J Cancer Res Clin Oncol. 2013 Aug;139(8):1349-55. doi: 10.1007/s00432-013-1443-z. Epub 2013 May 21.
    • Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations.
    • Tulchin N, Ornstein L, Dikman S, Strauchen J, Jaffer S, Nagi C, Bleiweiss I, Kornreich R, Edelmann L, Brown K, Bodian C, Nair VD, Chambon M, Woods NT, Monteiro AN.
    • Cancer Cell Int. 2013 Jul 15;13(1):70. doi: 10.1186/1475-2867-13-70.
    • Tumour morphology predicts PALB2 germline mutation status.
    • Teo ZL, Provenzano E, Dite GS, Park DJ, Apicella C, Sawyer SD, James PA, Mitchell G, Trainer AH, Lindeman GJ, Shackleton K, Cicciarelli L; kConFab, Buys SS, Andrulis IL, Mulligan AM, Glendon G, John EM, Terry MB, Daly M, Odefrey FA, Nguyen-Dumont T, Giles GG, Dowty JG, Winship I, Goldgar DE, Hopper JL, Southey MC.
    • Br J Cancer. 2013 Jul 9;109(1):154-63. doi: 10.1038/bjc.2013.295. Epub 2013 Jun 20.
    • Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
    • George J, Alsop K, Etemadmoghadam D, Hondow H, Mikeska T, Dobrovic A, deFazio A; Australian Ovarian Cancer Study Group, Smyth GK, Levine DA, Mitchell G, Bowtell DD.
    • Clin Cancer Res. 2013 Jul 1;19(13):3474-84. doi: 10.1158/1078-0432.CCR-13-0066. Epub 2013 Apr 30.

    Related:

    Research news:

    Genomic signatures of BRCA1 but not BRCA2 associated high-grade serous carcinoma resemble basal-like breast cancer.

    • Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
    • Tryggvadottir L, Olafsdottir EJ, Olafsdottir GH, Sigurdsson H, Johannsson OT, Bjorgvinsson E, Alexiusdottir K, Stefansson OA, Agnarsson BA, Narod SA, Eyfjord JE, Jonasson JG.
    • Breast Cancer Res Treat. 2013 Jul;140(2):375-84. doi: 10.1007/s10549-013-2637-4. Epub 2013 Jul 16.
    • Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    • Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.
    • Breast Cancer Res Treat. 2013 Jul;140(1):195-205. doi: 10.1007/s10549-013-2591-1. Epub 2013 Jun 28.
    • Relationship between family history of breast cancer and clinicopathological features in moroccan patients.
    • Tazzite A, Jouhadi H, Saiss K, Benider A, Nadifi S.
    • Ethiop J Health Sci. 2013 Jul;23(2):150-7.
    • Ovarian surface epithelium as a source of ovarian cancers: Unwarranted speculation or evidence-based hypothesis?
    • Auersperg N.
    • Gynecol Oncol. 2013 Jul;130(1):246-51. doi: 10.1016/j.ygyno.2013.03.021. Epub 2013 Apr 2.
    • Review
    • Risk factors for ovarian cancers with and without microsatellite instability.
    • Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Ping S, Narod SA, Schildkraut J.
    • Int J Gynecol Cancer. 2013 Jul;23(6):1010-5. doi: 10.1097/IGC.0b013e31829a5527.

    Related:

    Retraction:

    Retraction.

    • BRCA1-Dependent Translational Regulation in Breast Cancer Cells.
    • Dacheux E, Vincent A, Nazaret N, Combet C, Wierinckx A, Mazoyer S, Diaz JJ, Lachuer J, Venezia ND.
    • PLoS One. 2013 Jun 21;8(6):e67313. Print 2013.
    • Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions.
    • Chene G, Tchirkov A, Pierre-Eymard E, Dauplat J, Raoelfils I, Cayre A, Watkin E, Vago P, Penault-Llorca F.
    • Clin Cancer Res. 2013 Jun 1;19(11):2873-82. doi: 10.1158/1078-0432.CCR-12-3947. Epub 2013 Apr 15.

    Related:

    Letter, Comment:

    Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions--letter.

    Letter, Reply:

    Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions--response.

    • Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.
    • Alshareeda AT, Negm OH, Albarakati N, Green AR, Nolan C, Sultana R, Madhusudan S, Benhasouna A, Tighe P, Ellis IO, Rakha EA.
    • Breast Cancer Res Treat. 2013 Jun;139(2):301-10. doi: 10.1007/s10549-013-2542-x. Epub 2013 Apr 28.
    • Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.
    • Schouten PC, van Dyk E, Braaf LM, Mulder L, Lips EH, de Ronde JJ, Holtman L, Wesseling J, Hauptmann M, Wessels LF, Linn SC, Nederlof PM.
    • Breast Cancer Res Treat. 2013 Jun;139(2):317-27. doi: 10.1007/s10549-013-2558-2. Epub 2013 May 14.
    • Different methylation and microRNA expression pattern in male and female familial breast cancer.
    • Pinto R, Pilato B, Ottini L, Lambo R, Simone G, Paradiso A, Tommasi S.
    • J Cell Physiol. 2013 Jun;228(6):1264-9. doi: 10.1002/jcp.24281.
    • Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer.
    • Alvarez C, Tapia T, Cornejo V, Fernandez W, Muñoz A, Camus M, Alvarez M, Devoto L, Carvallo P.
    • Mol Carcinog. 2013 Jun;52(6):475-87. doi: 10.1002/mc.21881. Epub 2012 Feb 7.
    • Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67.
    • Hassanein M, Huiart L, Bourdon V, Rabayrol L, Geneix J, Nogues C, Peyrat JP, Gesta P, Meynard P, Dreyfus H, Petrot D, Lidereau R, Noguchi T, Eisinger F, Extra JM, Viens P, Jacquemier J, Sobol H.
    • Pathobiology. [2013 Jun;]80(5):219-27. doi: 10.1159/000339432. Epub 2013 Apr 23.
    • BRCA1 mutations and luminal-basal transformation.
    • Ng T, Irshad S, Stebbing J.
    • Oncogene. 2013 May 30;32(22):2712-4. doi: 10.1038/onc.2012.379. Epub 2012 Aug 27.
    • Comment

    Related:

    Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.

    • Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.
    • Bai F, Smith MD, Chan HL, Pei XH.
    • Oncogene. 2013 May 30;32(22):2715-25. doi: 10.1038/onc.2012.293. Epub 2012 Jul 9.

    Related:

    Comment:

    BRCA1 mutations and luminal-basal transformation.

    • Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
    • Larsen MJ, Kruse TA, Tan Q, Lænkholm AV, Bak M, Lykkesfeldt AE, Sørensen KP, Hansen TV, Ejlertsen B, Gerdes AM, Thomassen M.
    • PLoS One. 2013 May 21;8(5):e64268. doi: 10.1371/journal.pone.0064268. Print 2013.
    • Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
    • Bowman-Colin C, Xia B, Bunting S, Klijn C, Drost R, Bouwman P, Fineman L, Chen X, Culhane AC, Cai H, Rodig SJ, Bronson RT, Jonkers J, Nussenzweig A, Kanellopoulou C, Livingston DM.
    • Proc Natl Acad Sci U S A. 2013 May 21;110(21):8632-7. doi: 10.1073/pnas.1305362110. Epub 2013 May 8.
    • Male breast cancer according to tumor subtype and race : A population-based study.
    • Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH.
    • Cancer. 2013 May 1;119(9):1611-7. doi: 10.1002/cncr.27905. Epub 2013 Jan 22.
    • TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.
    • Shan J, Dsouza SP, Bakhru S, Al-Azwani EK, Ascierto ML, Sastry KS, Bedri S, Kizhakayil D, Aigha II, Malek J, Al-Bozom I, Gehani S, Furtado S, Mathiowitz E, Wang E, Marincola FM, Chouchane L.
    • Cancer Res. 2013 May 1;73(9):2840-9. doi: 10.1158/0008-5472.CAN-12-4313. Epub 2013 Feb 27.
    • Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines.
    • Wark L, Novak D, Sabbaghian N, Amrein L, Jangamreddy JR, Cheang M, Pouchet C, Aloyz R, Foulkes WD, Mai S, Tischkowitz M.
    • Genes Chromosomes Cancer. 2013 May;52(5):480-94. doi: 10.1002/gcc.22045. Epub 2013 Jan 23.
    • SULT1A1 gene deletion in BRCA2-associated male breast cancer: a link between genes and environmental exposures?
    • Palli D, Rizzolo P, Zanna I, Silvestri V, Saieva C, Falchetti M, Navazio AS, Graziano V, Masala G, Bianchi S, Russo A, Tommasi S, Ottini L.
    • J Cell Mol Med. 2013 May;17(5):605-7. doi: 10.1111/jcmm.12043.
    • DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.
    • Kamieniak MM, Muñoz-Repeto I, Rico D, Osorio A, Urioste M, García-Donas J, Hernando S, Robles-Díaz L, Ramón Y Cajal T, Cazorla A, Sáez R, García-Bueno JM, Domingo S, Borrego S, Palacios J, van de Wiel MA, Ylstra B, Benítez J, García MJ.
    • Br J Cancer. 2013 Apr 30;108(8):1732-42. doi: 10.1038/bjc.2013.141. Epub 2013 Apr 4.
    • No evidence for PALB2 methylation in high-grade serous ovarian cancer.
    • Mikeska T, Alsop K; Australian Ovarian Cancer Study Group, Mitchell G, Bowtell DD, Dobrovic A.
    • J Ovarian Res. 2013 Apr 12;6(1):26. doi: 10.1186/1757-2215-6-26.
    • Salpingectomy: Can removing the fallopian tubes lower ovarian cancer risk?
    • Ilana Cass, Doug Levine
    • FORCE. Be Empowered Webinars. 2013 Apr 11.
    • Lipid metabolism genes in contralateral unaffected breast and estrogen receptor status of breast cancer.
    • Wang J, Scholtens D, Holko M, Ivancic D, Lee O, Hu H, Chatterton RT Jr, Sullivan ME, Hansen N, Bethke K, Zalles CM, Khan SA.
    • Cancer Prev Res (Phila). 2013 Apr;6(4):321-30. doi: 10.1158/1940-6207.CAPR-12-0304. Epub 2013 Mar 19.

    Related:

    Press: Breast cancer gene test could allow preventive treatment. (The Telegraph)

    • Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
    • Reitsma W, Mourits MJ, de Bock GH, Hollema H.
    • Mod Pathol. 2013 Apr;26(4):572-8. doi: 10.1038/modpathol.2012.169. Epub 2012 Oct 19.
    • Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient.
    • Zhang J, Shi Y, Lalonde E, Li L, Cavallone L, Ferenczy A, Gotlieb WH, Foulkes WD, Majewski J.
    • BMC Cancer. 2013 Mar 22;13:146. doi: 10.1186/1471-2407-13-146.
    • Male breast cancer, age and sex chromosome aneuploidy.
    • Jacobs PA, Maloney V, Cooke R, Crolla JA, Ashworth A, Swerdlow AJ.
    • Br J Cancer. 2013 Mar 5;108(4):959-63. doi: 10.1038/bjc.2012.577. Epub 2013 Jan 8.
    • Surgical implications of the potential new tubal pathway for ovarian carcinogenesis.
    • Chene G, Rahimi K, Mes-Masson AM, Provencher D.
    • J Minim Invasive Gynecol. 2013 Mar-Apr;20(2):153-9. doi: 10.1016/j.jmig.2012.11.010. Epub 2013 Jan 16.
    • Review
    • Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier.
    • Alanee S, Shah S, Murali R, Rau-Murthy R, Schrader KA, Offit K.
    • Fam Cancer. 2013 Mar;12(1):125-7. doi: 10.1007/s10689-012-9572-0.
    • Case report, Letter

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Should I test for Cowden?

    • 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.
    • Pennington KP, Wickramanayake A, Norquist BM, Pennil CC, Garcia RL, Agnew KJ, Taniguchi T, Welcsh P, Swisher EM.
    • Gynecol Oncol. 2013 Mar;128(3):493-9. doi: 10.1016/j.ygyno.2012.12.007. Epub 2012 Dec 12.
    • Re: "A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1," Int J Gyn Pathol 2012 May;31: 264-271.
    • Köbel M, Ghatage P.
    • Int J Gynecol Pathol. 2013 Mar;32(2):176. doi: 10.1097/PGP.0b013e31826b4ea1.
    • Comment, Letter

    Related:

    Case report:

    A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1.

    Letter, Reply:

    In reply.

    • HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
    • van der Groep P, van Diest PJ, Smolders YH, Ausems MG, van der Luijt RB, Menko FH, Bart J, de Vries EG, van der Wall E.
    • PLoS One. 2013;8(2):e56055. doi: 10.1371/journal.pone.0056055. Epub 2013 Feb 8.
    • Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
    • Hsu NC, Huang YF, Yokoyama KK, Chu PY, Chen FM, Hou MF.
    • PLoS One. 2013;8(2):e56256. doi: 10.1371/journal.pone.0056256. Epub 2013 Feb 6.
    • BRCA2 Dysfunction Promotes Malignant Transformation of Pancreatic Intraepithelial Neoplasia.
    • Wang Q, Liu H, Liu T, Shu S, Jiang H, Cheng S, Yuan Y, Yang W, Wang L.
    • Anticancer Agents Med Chem. 2013 Feb 1;13(2):261-9.
    • Determination of Molecular Markers for BRCA1 and BRCA2 Heterozygosity Using Gene Expression Profiling.
    • Salmon AY, Salmon-Divon M, Zahavi T, Barash Y, Levy-Drummer RS, Jacob-Hirsch J, Peretz T.
    • Cancer Prev Res (Phila). 2013 Feb;6(2):82-90. doi: 10.1158/1940-6207.CAPR-12-0105. Epub 2013 Jan 22.

    Related:

    Research News:

    New test predicts BRCA1 and BRCA2 mutations.

    Press: The Future of BRCA1/BRCA2 Testing. (OncLive)

    • Genetics of Susceptibility to Sporadic Ovarian Cancer.
    • Katabathina VS, Prasad SR.
    • eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net. doi: 10.1002/9780470015902.a0023853. 2013 Feb.
    • Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
    • Wang YQ, Yan Q, Zhang JR, Li SD, Yang YX, Wan XP.
    • J Obstet Gynaecol Res. 2013 Feb;39(2):549-54. doi: 10.1111/j.1447-0756.2012.01979.x. Epub 2012 Sep 25.
    • Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry.
    • Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, Ohashi PS, Andrulis IL.
    • Clin Cancer Res. 2013 Jan 15;19(2):336-46. doi: 10.1158/1078-0432.CCR-11-3314. Epub 2012 Dec 4.
    • VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer.
    • http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053070Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A, Mangia A.
    • PLoS One. 2013;8(1):e53070. doi: 10.1371/journal.pone.0053070. Epub 2013 Jan 11.
    • BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    • Garg K, Levine DA, Olvera N, Dao F, Bisogna M, Secord AA, Berchuck A, Cerami E, Schultz N, Soslow RA.
    • Am J Surg Pathol. 2013 Jan;37(1):138-46. doi: 10.1097/PAS.0b013e31826cabbd.
    • Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    • Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.
    • Eur J Cancer. 2013 Jan;49(1):132-41. doi: 10.1016/j.ejca.2012.07.021. Epub 2012 Aug 21.
    • Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study.
    • Muñoz-Repeto I, García MJ, Kamieniak M, Ramón Y Cajal T, Domingo S, Cazorla A, García Donas J, Hernando Polo S, García Sagredo JM, Hernández E, Lacambra C, Saez R, Robles L, Borrego S, Prat J, Palacios J, Benítez J.
    • Histol Histopathol. 2013 Jan;28(1):133-44.
    • HOX gene methylation status analysis in patients with hereditary breast cancer.
    • Pilato B, Pinto R, De Summa S, Lambo R, Paradiso A, Tommasi S.
    • J Hum Genet. 2013 Jan;58(1):51-3. doi: 10.1038/jhg.2012.118. Epub 2012 Oct 11.
    • PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.
    • Deb S, Do H, Byrne D, Jene N; kConFab Investigators, Dobrovic A, Fox SB.
    • Breast Cancer Res. 2013;15(4):R69.
    • The ectopic expression of BRCA1 is associated with genesis, progression, and prognosis of breast cancer in young patients.
    • Zhang Q, Zhang Q, Cong H, Zhang X.
    • Diagn Pathol. 2012 Dec 31;7:181. doi: 10.1186/1746-1596-7-181.
    • Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations.
    • Rouault A, Banneau G, Macgrogan G, Jones N, Elarouci N, Barouk-Simonet E, Venat L, Coupier I, Letouzé E, de Reyniès A, Bonnet F, Iggo R, Sévenet N, Longy M.
    • PLoS One. 2012;7(12):e52079. doi: 10.1371/journal.pone.0052079. Epub 2012 Dec 21.
    • Mitochondrial DNA mutation in serous ovarian cancer: implications for mitochondria-coded genes in chemoresistance.
    • Guerra F, Perrone AM, Kurelac I, Santini D, Ceccarelli C, Cricca M, Zamagni C, De Iaco P, Gasparre G.
    • J Clin Oncol. 2012 Dec 20;30(36):e373-8. doi: 10.1200/JCO.2012.43.5933. Epub 2012 Nov 13.
    • Ovarian cancer molecular pathology.
    • Longuespée R, Boyon C, Desmons A, Vinatier D, Leblanc E, Farré I, Wisztorski M, Ly K, D'Anjou F, Day R, Fournier I, Salzet M.
    • Cancer Metastasis Rev. 2012 Dec;31(3-4):713-32. doi: 10.1007/s10555-012-9383-7.
    • Review
    • IGF-1 and BRCA1 signalling pathways in familial cancer.
    • Werner H, Bruchim I.
    • Lancet Oncol. 2012 Dec;13(12):E537-44. doi: 10.1016/S1470-2045(12)70362-5.
    • Review
    • BRCA2 promoter hypermethylation in sporadic breast cancer.
    • Bosviel R, Durif J, Guo J, Mebrek M, Kwiatkowski F, Bignon YJ, Bernard-Gallon DJ.
    • OMICS. 2012 Dec;16(12):707-10. doi: 10.1089/omi.2012.0060.
    • Hereditary ovarian cancer and two-compartment tumor metabolism: Epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma.
    • Martinez-Outschoorn UE, Balliet RM, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP.
    • Cell Cycle. 2012 Nov 15;11(22):4152-66. doi: 10.4161/cc.22226. Epub 2012 Oct 9.
    • Proliferation in the Normal FTE Is a Hallmark of the Follicular Phase, Not BRCA Mutation Status.
    • George SH, Milea A, Shaw PA.
    • Clin Cancer Res. 2012 Nov 15;18(22):6199-207. doi: 10.1158/1078-0432.CCR-12-2155. Epub 2012 Sep 11.
    • Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation.
    • Popova T, Manié E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, Delattre O, Sigal-Zafrani B, Bollet M, Longy M, Houdayer C, Sastre-Garau X, Vincent-Salomon A, Stoppa-Lyonnet D, Stern MH.
    • Cancer Res. 2012 Nov 1;72(21):5454-62. doi: 10.1158/0008-5472.CAN-12-1470. Epub 2012 Aug 29.
    • Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer.
    • Coppola D, Nicosia SV, Doty A, Sellers TA, Lee JH, Fulp J, Thompson Z, Galeb S, McLaughlin J, Narod SA, Schildkraut J, Pal T.
    • Anticancer Res. 2012 Nov;32(11):4963-9.
    • E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium.
    • Smith NL, Welcsh P, Press JZ, Agnew KJ, Garcia R, Swisher EM.
    • Genes Chromosomes Cancer. 2012 Nov;51(11):1054-62. doi: 10.1002/gcc.21990. Epub 2012 Aug 9.
    • Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
    • de la Cruz J, Andre F, Harrell RK, Bassett RL Jr, Arun B, Mathieu MC, Delaloge S, Gilcrease MZ.
    • Hum Pathol. 2012 Nov;43(11):1932-9. doi: 10.1016/j.humpath.2012.02.002. Epub 2012 May 14.
    • Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors.
    • Lu FI, Gilks CB, Mulligan AM, Ryan P, Allo G, Sy K, Shaw PA, Pollett A, Clarke BA.
    • Int J Gynecol Pathol. 2012 Nov;31(6):524-31. doi: 10.1097/PGP.0b013e31824fe2aa.
    • Comprehensive molecular portraits of human breast tumours.
    • Cancer Genome Atlas Network.
    • Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.

    Related:

    Press: Study Divides Breast Cancer Into Four Distinct Types (New York Times)

    • Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers.
    • Kaplan JS, Schnitt SJ, Collins LC, Wang Y, Garber JE, Montgomery K, West RB, Krag K, Fetten K, Lincoln A, Tung NM.
    • Am J Surg Pathol. 2012 Oct;36(10):1483-8. doi: 10.1097/PAS.0b013e31825789ed.
    • Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
    • Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, Bulten J, Bol M.
    • Gynecol Oncol. 2012 Oct;127(1):88-93. doi: 10.1016/j.ygyno.2012.06.015. Epub 2012 Jun 16.
    • Peritoneal cytology in risk-reducing salpingo-oophorectomy: Implications for cancer outcomes.
    • Chen L, McAlhaney S, Fehniger J, Powell C, Crawford B, Mak J, Rabban J.
    • Gynecol Oncol. 2012 Oct;127(1 Suppl):S17. doi: 10.1016/j.ygyno.2012.07.047.
    • Conference abstract
    • Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
    • Oonk AM, van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, Wesseling J, Rodenhuis S, Imholz AL, Lips EH.
    • Ann Oncol. 2012 Sep;23(9):2301-5. doi: 10.1093/annonc/mdr621. Epub 2012 Feb 21.

    Related:

    Free text: Clinical Correlates of 'BRCAness' in Triple-Negative Breast Cancer of Patients Receiving Adjuvant Chemotherapy. (Medscape)

    • BRCA1 immunohistochemistry assay: can it play a role in assessing sporadic early-onset breast cancer?
    • Roehe AV, Boff AL, Damin A.
    • Breast J. 2012 Sep;18(5):500-1. doi: 10.1111/j.1524-4741.2012.01292.x. Epub 2012 Aug 16.
    • Letter
    • Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese.
    • Pang D, Zhao Y, Xue W, Shan M, Chen Y, Zhang Y, Zhang G, Liu F, Li D, Yang Y.
    • Med Oncol. 2012 Sep;29(3):1561-8. doi: 10.1007/s12032-011-0100-0. Epub 2011 Nov 11.
    • BRCA1--conductor of the breast stem cell orchestra: the role of BRCA1 in mammary gland development and identification of cell of origin of BRCA1 mutant breast cancer.
    • Buckley NE, Mullan PB.
    • Stem Cell Rev. 2012 Sep;8(3):982-93. doi: 10.1007/s12015-012-9354-y.
    • Review
    • BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.
    • Bal A, Verma S, Joshi K, Singla A, Thakur R, Arora S, Singh G.
    • Virchows Arch. 2012 Sep;461(3):305-12. doi: 10.1007/s00428-012-1286-z. Epub 2012 Jul 21.
    • Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry.
    • Dite GS, Makalic E, Schmidt DF, Giles GG, Hopper JL, Southey MC.
    • Breast Cancer Res. 2012 Aug 28;14(4):R122. doi: 10.1186/bcr3248.
    • The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
    • Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Gruvberger-Saal SK, Saal LH, Holm K, Hegardt C, Arason A, Fagerholm R, Persson C, Grabau D, Johnsson E, Lövgren K, Magnusson L, Heikkilä P, Agnarsson BA, Johannsson OT, Malmström P, Fernö M, Olsson H, Loman N, Nevanlinna H, Barkardottir RB, Borg Å.
    • Cancer Res. 2012 Aug 15;72(16):4028-36. Epub 2012 Jun 15.
    • Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis.
    • Tone AA, Virtanen C, Shaw P, Brown TJ.
    • Clin Cancer Res. 2012 Aug 15;18(16):4334-44. doi: 10.1158/1078-0432.CCR-12-0199. Epub 2012 Jul 2.
    • Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.
    • Fujiwara M, McGuire VA, Felberg A, Sieh W, Whittemore AS, Longacre TA.
    • Am J Surg Pathol. 2012 Aug;36(8):1170-7. doi: 10.1097/PAS.0b013e31825d9b8d.
    • BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer.
    • Tammaro C, Raponi M, Wilson DI, Baralle D.
    • Biochem Soc Trans. 2012 Aug;40(4):768-72. doi: 10.1042/BST20120140.
    • Germline copy number variants are not associated with globally acquired copy number changes in familial breast tumours.
    • Walker LC, Krause L; kConFab Investigators, Spurdle AB, Waddell N.
    • Breast Cancer Res Treat. 2012 Aug;134(3):1005-11. Epub 2012 Mar 21.
    • Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification.
    • Kornegoor R, Moelans CB, Verschuur-Maes AH, Hogenes MCh, de Bruin PC, Oudejans JJ, van Diest PJ.
    • Breast Cancer Res. 2012 Jul 5;14(4):R101. doi: 10.1186/bcr3220.
    • Molecular insights on basal-like breast cancer.
    • Valentin MD, da Silva SD, Privat M, Alaoui-Jamali M, Bignon YJ.
    • Breast Cancer Res Treat. 2012 Jul;134(1):21-30. doi: 10.1007/s10549-011-1934-z. Epub 2012 Jan 11.
    • Review
    • Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.
    • Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, Viale G, Barberis M.
    • Breast Cancer Res Treat. 2012 Jul;134(1):131-7. doi: 10.1007/s10549-011-1945-9. Epub 2012 Jan 8.
    • What drives breast cancer heterogeneity: oncogenic events or cell of origin?
    • Ginestier C, Charafe-Jauffret E, Birnbaum D.
    • J Pathol. 2012 Jul;227(3):267-9. doi: 10.1002/path.4028. Epub 2012 May 8.

    Related:

    A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.

    • Expression of TopBP1 in hereditary breast cancer.
    • Forma E, Krzeslak A, Bernaciak M, Romanowicz-Makowska H, Brys M.
    • Mol Biol Rep. 2012 Jul;39(7):7795-804. doi: 10.1007/s11033-012-1622-z. Epub 2012 Apr 28.
    • Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.
    • Warmoes M, Jaspers JE, Pham TV, Piersma SR, Oudgenoeg G, Massink MP, Waisfisz Q, Rottenberg S, Boven E, Jonkers J, Jimenez CR.
    • Mol Cell Proteomics. 2012 Jul;11(7):M111.013334. doi: 10.1074/mcp.M111.013334. Epub 2012 Feb 24.
    • Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene.
    • Tanic M, Yanowsky K, Rodriguez-Antona C, Andrés R, Márquez-Rodas I, Osorio A, Benitez J, Martinez-Delgado B.
    • PLoS One. 2012;7(6):e38847. doi: 10.1371/journal.pone.0038847. Epub 2012 Jun 11.
    • Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells.
    • Yu VM, Marion CM, Austria TM, Yeh J, Schönthal AH, Dubeau L.
    • Int J Cancer. 2012 Jun 1;130(11):2495-504. doi: 10.1002/ijc.26309. Epub 2011 Aug 29.
    • Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.
    • Holm K, Staaf J, Jönsson G, Vallon-Christersson J, Gunnarsson H, Arason A, Magnusson L, Barkardottir RB, Hegardt C, Ringnér M, Borg A.
    • Breast Cancer Res Treat. 2012 Jun;133(2):583-94. doi: 10.1007/s10549-011-1817-3. Epub 2011 Oct 16.
    • Evolutionary pathways in BRCA1-associated breast tumors.
    • Martins FC, De S, Almendro V, Gönen M, Park SY, Blum JL, Herlihy W, Ethington G, Schnitt SJ, Tung N, Garber JE, Fetten K, Michor F, Polyak K.
    • Cancer Discov. 2012 Jun;2(6):503-11. doi: 10.1158/2159-8290.CD-11-0325. Epub 2012 Apr 10.

    Related:

    Comment:

    Tracking evolution of BRCA1-associated breast cancer.

    • Can a simple blood test really predict breast cancer?
    • McCartney M.
    • BMJ. 2012 May 15;344:e3374. doi: 10.1136/bmj.e3374.
    • News
    • Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk.
    • Brennan K, Garcia-Closas M, Orr N, Fletcher O, Jones M, Ashworth A, Swerdlow A, Thorne H; KConFab Investigators, Riboli E, Vineis P, Dorronsoro M, Clavel-Chapelon F, Panico S, Onland-Moret NC, Trichopoulos D, Kaaks R, Khaw KT, Brown R, Flanagan JM.
    • Cancer Res. 2012 May 1;72(9):2304-13. Epub 2012 Feb 28.

    Related:

    News: Epigenetic test could inform breast cancer risk prediction. (PHG Foundation)

    • Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
    • Okada S, Tokunaga E, Kitao H, Akiyoshi S, Yamashita N, Saeki H, Oki E, Morita M, Kakeji Y, Maehara Y.
    • Ann Surg Oncol. 2012 May;19(5):1499-507. doi: 10.1245/s10434-011-2166-5. Epub 2011 Dec 17.
    • Allelic transcripts dosage effect in morphologically normal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian founder mutation.
    • Abd-Rabbo D, Abaji C, Cardin GB, Filali-Mouhim A, Arous C, Portelance L, Escobar E, Cloutier S, Tonin PN, Provencher DM, Mes-Masson AM, Maugard CM.
    • Cancer Prev Res (Phila). 2012 May;5(5):765-77. doi: 10.1158/1940-6207.CAPR-11-0547. Epub 2012 Mar 8.
    • The role of the fallopian tube in ovarian cancer.
    • Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, Cohen T, Ehlen T, Lee M, Carey MS, Heywood M, Pike J, Hoskins PJ, Stuart GC, Swenerton KD, Huntsman DG, Gilks CB, Miller DM, McAlpine JN.
    • Clin Adv Hematol Oncol. 2012 May;10(5):296-306.
    • The power of DNA double-strand break (DSB) repair testing to predict breast cancer susceptibility.
    • Keimling M, Deniz M, Varga D, Stahl A, Schrezenmeier H, Kreienberg R, Hoffmann I, König J, Wiesmüller L.
    • FASEB J. 2012 May;26(5):2094-104. doi: 10.1096/fj.11-200790. Epub 2012 Jan 25.
    • BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis.
    • Crum CP, McKeon FD, Xian W.
    • Int J Gynecol Cancer. 2012 May;22 Suppl 1:S29-34. doi: 10.1097/IGC.0b013e31824d7269.
    • A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1.
    • Maurac I, Sabol M, Musani V, Car D, Ozretic P, Kalafatic D, Oreskovic S, Babic D, Levanat S.
    • Int J Gynecol Pathol. 2012 May;31(3):264-71. doi: 10.1097/PGP.0b013e31823b6f0f.
    • Case Report

    Related:

    Comment, Letter:

    Re: "A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1," Int J Gyn Pathol 2012 May;31: 264-271.

    • Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.
    • Custodio A, López-Farré AJ, Zamorano-León JJ, Mateos-Cáceres PJ, Macaya C, Caldés T, de la Hoya M, Olivera E, Puente J, Díaz-Rubio E, Pérez-Segura P.
    • J Cancer Res Clin Oncol. 2012 May;138(5):867-75. doi: 10.1007/s00432-012-1161-y. Epub 2012 Feb 7.
    • Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases.
    • Martinez-Delgado B, Yanowsky K, Inglada-Perez L, de la Hoya M, Caldes T, Vega A, Blanco A, Martin T, Gonzalez-Sarmiento R, Blasco M, Robledo M, Urioste M, Song H, Pharoah P, Benitez J.
    • J Med Genet. 2012 May;49(5):341-4. Epub 2012 Apr 6.

    Related:

    Free Full Text: Shorter Telomere Length Is Associated With Increased Ovarian Cancer Risk in Both Familial and Sporadic Cases. (Medscape Oncology)

    • BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
    • McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB.
    • Mod Pathol. 2012 May;25(5):740-50. doi: 10.1038/modpathol.2011.211. Epub 2012 Jan 27.
    • Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
    • Yan M, Xu H, Waddell N, Shield-Artin K, Haviv I; kConFab authors, McKay MJ, Fox SB.
    • Breast Cancer Res. 2012 Apr 26;14(2):R69.
    • The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
    • Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S; METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C, Aparicio S.
    • Nature. 2012 Apr 18;486(7403):346-52. doi: 10.1038/nature10983.

    Related:

    Comment:

    Copy number aberrations define breast cancer subgroups.

    Comment:

    Who's driving anyway? Herculean efforts to identify the drivers of breast cancer.

    Comment:

    Genomics: the breast cancer landscape.

    Comment:

    The breast cancer genome and the complexity of different subgroups: what does it all mean?

    News: Genetic map leads to new thinking on breast cancer. (PHG Foundation)

    • Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    • Joosse SA, Brandwijk KI, Devilee P, Wesseling J, Hogervorst FB, Verhoef S, Nederlof PM.
    • Breast Cancer Res Treat. 2012 Apr;132(2):379-89. doi: 10.1007/s10549-010-1016-7. Epub 2010 Jul 8.
    • Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
    • Alford SH, Toy K, Merajver SD, Kleer CG.
    • Breast Cancer Res Treat. 2012 Apr;132(2):429-37. doi: 10.1007/s10549-011-1591-2. Epub 2011 May 26.
    • Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.
    • Nagel JH, Peeters JK, Smid M, Sieuwerts AM, Wasielewski M, de Weerd V, Trapman-Jansen AM, van den Ouweland A, Brüggenwirth H, van Ijcken WF, Klijn JG, van der Spek PJ, Foekens JA, Martens JW, Schutte M, Meijers-Heijboer H.
    • Breast Cancer Res Treat. 2012 Apr;132(2):439-48. doi: 10.1007/s10549-011-1588-x. Epub 2011 May 26.
    • Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
    • Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, Kauff ND, Levine DA.
    • Mod Pathol. 2012 Apr;25(4):625-36. doi: 10.1038/modpathol.2011.183. Epub 2011 Dec 23.
    • Promoter methylation status and expression of estrogen receptor alpha in familial breast cancer patients.
    • Wei J, Han B, Mao XY, Wei MJ, Yao F, Jin F.
    • Tumour Biol. 2012 Apr;33(2):413-20. doi: 10.1007/s13277-011-0234-x. Epub 2011 Sep 16.
    • APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.
    • Brough R, Bajrami I, Vatcheva R, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A.
    • EMBO J. 2012 Mar 7;31(5):1160-76. doi: 10.1038/emboj.2011.490. Epub 2012 Jan 31.
    • High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
    • Rzepecka IK, Szafron L, Stys A, Bujko M, Plisiecka-Halasa J, Madry R, Osuch B, Markowska J, Bidzinski M, Kupryjanczyk J.
    • Cancer Genet. 2012 Mar;205(3):94-100. doi: 10.1016/j.cancergen.2011.12.005.
    • Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers.
    • Primas H, Kroiss R, Kalteis K, Rappaport C, Muhr D, Primas C, Kubista E, Horvat R, Oefner P, Singer C, Wagner And The Austrian Hereditary Breast And Ovarian Cancer Group T.
    • Eur J Cancer Prev. 2012 Mar;21(2):199-204. doi: 10.1097/CEJ.0b013e32834c9b22.
    • Clinical implications for BRCA gene mutation in breast cancer.
    • Xu J, Wang B, Zhang Y, Li R, Wang Y, Zhang S.
    • Mol Biol Rep. 2012 Mar;39(3):3097-102. doi: 10.1007/s11033-011-1073-y. Epub 2011 Jun 21.
    • BRCA1 haploinsufficiency: consequences for breast cancer.
    • Salmena L, Narod S.
    • Womens Health (Lond Engl). 2012 Mar;8(2):127-9. doi: 10.2217/whe.12.2.
    • Commentary

    Related:

    Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.

    • c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
    • Regan JL, Kendrick H, Magnay FA, Vafaizadeh V, Groner B, Smalley MJ.
    • Oncogene. 2012 Feb 16;31(7):869-83. doi: 10.1038/onc.2011.289. Epub 2011 Jul 18.
    • Role of micronucleus test in predicting breast cancer susceptibility: a systematic review and meta-analysis.
    • Cardinale F, Bruzzi P, Bolognesi C.
    • Br J Cancer. 2012 Feb 14;106(4):780-90. doi: 10.1038/bjc.2011.567. Epub 2011 Dec 20.
    • Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.
    • Bijron JG, van der Groep P, van Dorst EB, Seeber LM, Sie-Go DM, Verheijen RH, van Diest PJ.
    • Endocr Relat Cancer. 2012 Feb 13;19(1):69-81. doi: 10.1530/ERC-11-0338. Print 2012 Feb.

    Related:

    Comment:

    Epigenetic modification and cancer: mark or stamp?

    • The breast cancer susceptibility gene BRCA2 is required for the maintenance of telomere homeostasis.
    • Min J, Choi ES, Hwang K, Kim J, Sampath S, Venkitaraman AR, Lee H.
    • J Biol Chem. 2012 Feb 10;287(7):5091-101. doi: 10.1074/jbc.M111.278994. Epub 2011 Dec 20.
    • Functional differences among BRCA1 missense mutations in the control of centrosome duplication.
    • Kais Z, Chiba N, Ishioka C, Parvin JD.
    • Oncogene. 2012 Feb 9;31(6):799-804. doi: 10.1038/onc.2011.271. Epub 2011 Jul 4.
    • Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    • Aysal A, Karnezis A, Medhi I, Grenert JP, Zaloudek CJ, Rabban JT.
    • Am J Surg Pathol. 2012 Feb;36(2):163-72. doi: 10.1097/PAS.0b013e31823bc434.
    • Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.
    • Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH.
    • Breast Cancer Res Treat. 2012 Feb;131(3):1061-6. doi: 10.1007/s10549-011-1872-9. Epub 2011 Nov 13.
    • TLE3 Expression Is Associated with Sensitivity to Taxane Treatment in Ovarian Carcinoma.
    • Samimi G, Ring BZ, Ross DT, Seitz RS, Sutherland RL, O'Brien PM, Hacker NF, Huh WK.
    • Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):273-9. doi: 10.1158/1055-9965.EPI-11-0917. Epub 2011 Dec 22.
    • Tetraploidy in BRCA2 breast tumours.
    • Jonsdottir AB, Stefansson OA, Bjornsson J, Jonasson JG, Ogmundsdottir HM, Eyfjord JE.
    • Eur J Cancer. 2012 Feb;48(3):305-10. doi: 10.1016/j.ejca.2011.11.008. Epub 2011 Nov 29.
    • Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers.
    • Hopper JL, Jenkins MA, Dowty JG, Dite GS, Apicella C, Keogh L, Win AK, Young JP, Buchanan D, Walsh MD, Rosty C, Baglietto L, Severi G, Phillips KA, Wong EM, Dobrovic A, Waring P, Winship I, Ramus SJ, Giles GG, Southey MC.
    • Pathology. 2012 Feb;44(2):89-98. doi: 10.1097/PAT.0b013e32834e8e5b.
    • Review
    • Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.
    • Heravi-Moussavi A, Anglesio MS, Cheng SW, Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE, Hamel N, Roth A, Ha G, Wan AN, Maines-Bandiera S, Salamanca C, Pasini B, Clarke BA, Lee AF, Lee CH, Zhao C, Young RH, Aparicio SA, Sorensen PH, Woo MM, Boyd N, Jones SJ, Hirst M, Marra MA, Gilks B, Shah SP, Foulkes WD, Morin GB, Huntsman DG.
    • N Engl J Med. 2012 Jan 19;366(3):234-42. doi: 10.1056/NEJMoa1102903. Epub 2011 Dec 21.

    Related:

    Press: Gene Links Rare And Unrelated Cancers. (Medical News Today)

    • BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
    • Wysham WZ, Mhawech-Fauceglia P, Li H, Hays L, Syriac S, Skrepnik T, Wright J, Pande N, Hoatlin M, Pejovic T.
    • PLoS One. 2012;7(1):e30042. doi: 10.1371/journal.pone.0030042. Epub 2012 Jan 11.
    • Dysfunctional telomeres in human BRCA2 mutated breast tumors and cell lines.
    • Bodvarsdottir SK, Steinarsdottir M, Bjarnason H, Eyfjord JE.
    • Mutat Res. 2012 Jan 3;729(1-2):90-9. doi: 10.1016/j.mrfmmm.2011.10.002. Epub 2011 Oct 12.
    • Monozygotic twins discordant for constitutive BRCA1 promoter methylation, childhood cancer and secondary cancer.
    • Galetzka D, Hansmann T, El Hajj N, Weis E, Irmscher B, Ludwig M, Schneider-Rätzke B, Kohlschmidt N, Beyer V, Bartsch O, Zechner U, Spix C, Haaf T.
    • Epigenetics. 2012 Jan 1;7(1):47-54. doi: 10.4161/epi.7.1.18814. Epub 2012 Jan 1.
    • Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
    • Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Nielsen FC, Osorio A, Stavropoulou A, Benítez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB; HEBON, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C; EMBRACE, Weaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schönbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L; GEMO Study Collaborators, Isaacs C, Peshkin BN, Caldes T, de la Hoya M, Cañadas C, Heikkinen T, Heikkilä P, Aittomäki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox S; kConFab Investigators, Rebbeck TR, Rubinstein W, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson K; SWE-BRCA Collaborators, Steele L, Neuhausen SL, Nussbaum R, Beattie M, Odunsi K, Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2.
    • Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47. doi: 10.1158/1055-9965.EPI-11-0775. Epub 2011 Dec 5.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Article Request

    • Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
    • Vollebergh MA, Jonkers J, Linn SC.
    • Cell Mol Life Sci. 2012 Jan;69(2):223-45. doi: 10.1007/s00018-011-0809-0. Epub 2011 Sep 16.
    • Review
    • Presence of intratumoral stem cells in breast cancer patients with or without BRCA germline mutations.
    • Singer CF, Zabkova P, Rappaport C, Muhr D, Pfeiler G, Gschwantler-Kaulich D, Fink-Retter A, Staudigl C, Walter I, Hudelist G, Spiess AC, Kubista E.
    • Curr Cancer Drug Targets. 2012 Jan;12(1):44-50.
    • [Morphologic and immunohistochemical features of Fallopian tubes and ovaries in women with genetic predisposition to ovarian cancer].
    • Bilyk EA, Buchanskaia LG, Polishchuk LZ, Peëvich T.
    • Vopr Onkol. 2012;58(4):507-13.
    • [Article in Russian]